Biophysical characterization of branched amphiphilic peptide capsules and their potential applications in radiotherapy by Sukthankar, Pinakin Ramchandra
  
 
 
BIOPHYSICAL CHARACTERIZATION OF BRANCHED AMPHIPHILIC PEPTIDE 
CAPSULES AND THEIR POTENTIAL APPLICATIONS IN RADIOTHERAPY  
 
 
by 
 
 
PINAKIN RAMCHANDRA SUKTHANKAR 
 
 
 
M.Sc., University of Mumbai, India 2006 
 
 
 
AN ABSTRACT OF A DISSERTATION 
 
 
submitted in partial fulfillment of the requirements for the degree 
 
 
 
DOCTOR OF PHILOSOPHY 
 
 
 
Graduate Biochemistry and Molecular Biophysics Group 
College of Arts and Sciences 
 
 
 
KANSAS STATE UNIVERSITY 
Manhattan, Kansas 
 
 
2014 
 
 
  
 
Abstract 
Branched Amphiphilic Peptide Capsules (BAPCs) are peptide nano-spheres comprised of 
equimolar proportions of two branched peptide sequences bis(FLIVI)-K-KKKK and 
bis(FLIVIGSII)-K-KKKK that self-assemble in water to form bilayer delimited poly-cationic 
capsules capable of trapping solutes. We examined the lipid-like properties of this system 
including assembly, fusion, solute encapsulation, and resizing by membrane extrusion as well as 
their capability to be maintained at a specific size by storage at 4˚C. These studies along with 
earlier work from the lab (Gudlur et al. (2012) PLOS ONE 7(9): e45374) demonstrated that the 
capsules, while sharing many properties with lipid vesicles, were much more robust. We next 
investigated the stability, size limitations of encapsulation, cellular localization, retention and, 
bio-distribution of the BAPCs. We demonstrated that the BAPCs are readily taken up by 
epithelial cells in culture, escape or evade the endocytotic pathway, and accumulate in the peri-
nuclear region where they persist without any apparent degradation. The stability and persistence 
of the capsules suggested they might be useful in delivering radionuclides. The BAPCs 
encapsulated alpha particle emitting radionuclides without any apparent leakage, were taken up 
by cells and were retained for extended periods of time. Their potential in this clinical 
application is being currently pursued.  Lastly we studied the temperature dependence of capsule 
formation by examining the biophysical characteristics of temperature induced conformational 
changes in BAPCs and examined the structural parameters within the sequences that contribute 
to their remarkable stability. A region in the nine-residue sequence was identified as the critical 
element in this process. The ability to prepare stable uniform nano-scale capsules of desired sizes 
makes BAPCs potentially attractive as delivery vehicles for various solutes/drugs. 
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Chapter 1 - Introduction 
The prefix ‘nano’ in nanotechnology is derived from the Greek word ‘νάνος’, meaning 
dwarf. One nanometer (nm) is equal to a billionth of a meter; the width of six carbon atoms or 
ten molecules of water.  In 1959, Richard Feynman delivered a talk at the American Physical 
Society entitled ‘There's Plenty of Room at the Bottom’, in which he first laid out the conceptual 
underpinnings of nanotechnology as he explored the possibility of directly manipulating matter 
on the atomic and molecular scale.
1
 Nanotechnology today, is a multi-disciplinary field 
pertaining to the development, design, characterization and applications of materials with a 
functional organization on the nanometer scale.
2,3
 Perhaps a stricter definition comes from the 
National Nanotechnology Initiative (NNI), which refers to nanotechnology as science, 
engineering, and technology conducted at the nanoscale, which is roughly in the size range of 1-
100 nm. At this quantum-realm scale, the quantum mechanical effects gain significance and the 
macroscopic properties of the material become secondary to that of the individual and interacting 
groups of molecules.
4
 More commonly, nanotechnology now refers to structures that are 
engineered from individual components by top-down or bottom-up modalities that can be several 
hundred nanometers in size.
5
 While the earliest developments in nanotechnology were driven by 
the electronics industry in a bid to develop micro-circuitry,
 6
 today nanotechnology offers 
opportunities and insights in diverse areas of investigation such as engineering, physics, 
chemistry, biology and medicine. The enormous scientific and commercial importance of 
nanotechnology is reflected in the National Nanotechnology Initiative, a multiagency umbrella 
program established by President Clinton in 2000 in order to build, characterize and comprehend 
2 
 
 
nanoscale devices. The program has been budgeted to spend over $1.7 billion in the year 2014 in 
pursuance of its objectives.
7,8,9
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 1.1 Nanotechnology in Medicine  
 
While tremendous progress has been made in understanding fundamental biological 
processes over the last quarter century translation of these findings into new advanced therapies 
has lagged. Limitations in delivering therapeutic moieties to selective targets with minimal off-
target damage have largely been held responsible for the discrepancy.
 10,11
  A novel molecular 
pharmacological agent with potential potent biological activity but limited aqueous solubility or 
a short circulating half-life in vivo is likely to face substantive physiological and commercial 
barriers. These delivery impediments will limit or reduce activity and disfavor potential 
pharmaceutically interesting compounds from entering clinical drug trials.
12
 The goal of 
pharmaceutical research is to deliver a drug at the appropriate dosage to a target cell or tissue in a 
safe and reproducible manner.
3,13
 Conventional modes of drug administration as pills, eye drops, 
intravenous solutions, ointments, inhalers etc., fall short of meeting these expectations in many 
ways. The oral route for example is one of the most commonly employed and preferred modes 
for drug administration due to its minimally-invasive nature. However the adequate delivery of 
peptide and protein drug candidates fuelled by the recent advances in recombinant 
biotechnology,
14
 have not been attained via this route.
15, 16
  This is the consequence of numerous 
factors including: the acid environment of the human stomach, proteolytic processing and the 
first pass effect of the liver and intestinal uptake resistance. All of these factors reduce, alter and 
block absorption of almost all macromolecules even before they enter systemic circulation.
17
 The 
vast majority of experimental therapeutics are known to have poor biopharmaceutical and 
pharmacokinetic properties.
18
 Nano-vectors have been shown to improve the pharmacological 
characteristics of these drug moieties.  The utilization of nanotechnology for drug delivery has 
4 
 
 
been employed to enhance the delivery of poorly soluble drugs, facilitate drug targeting in a 
cell/tissue-specific manner and enabled the co-delivery of two or more drugs as well the 
intracellular delivery of larger macromolecular drugs.
 
By enhancing the efficacy of these drugs, 
new candidate drugs are advancing in clinical trials with improved safety and effectivness.
12
 The 
application of nanotechnology to drug delivery is expected to alter the landscape of 
pharmaceutical and biotechnology industries in the foreseeable future.
10,19,20,21,22
 As of 2013, 
almost 250 nanotechnology based medicines had been approved or were in various stages of 
clinical investigation.
23
  
Despite these advancements in nano-medicine; several challenges remain – 1) 
overcoming physicochemical and biological hurdles such as low stability, low permeability, 
short half-life, enzymatic susceptibility, targeting and 2) immunogenicity.
14
 Although a majority 
of these nano-therapeutic products have improved the pharmaceutical efficacy of clinically 
approved drugs; nanotechnology as a whole has not yet generated entirely new therapies that 
would not have otherwise existed.
 5 
This new line of investigation portends well for future 
advances in nanotechnology research.  
5 
 
 
 1.2 The role of nanotechnology in drug delivery  
 
Nanomedicine can be defined as the construction, repair, monitoring and control of 
human biological systems at the molecular level using engineered delivery systems at the 
nanoscale level comprising of conjugated, adsorbed, encapsulated or dispersed drugs and 
imaging agents
.2,9,24,25,
 
26
 Drug delivery using nanotechnology is a very broad and expanding area 
of investigation with rapidly emerging delivery modalities. This literature review will 
concentrate on selected prominent drug delivery systems that can be systemically administered 
via parenteral routes.  
 The competence of a nano-carrier is a function of its capability to safely, selectively and 
reliably deliver a therapeutic at the required dosage at the target site in the appropriate time 
Figure 1.1. Timeline of Nanotechnology-based drug delivery.  
Reprinted with permission from (Shi, J., Votruba, A.R., Farokhzad, O.C. and Langer, R. (2010) Nanotechnology in drug 
delivery and tissue engineering: from discovery to applications. Nano Lett. United States 10, 3223-3230). Copyright (2010) 
American Chemical Society  
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frame.
3,13,27,28
 A variety of nano-materials - both organic and inorganic - have been employed for 
the purposes of delivery vehicles to develop new and effective therapeutic modalities. Nano-
carriers in general, possess several desirable attributes. When delivered via nano-carriers; the 
volumes of systemic drug distribution are reduced;
29
 the pharmacokinetics of biodistribution are 
enhanced and the ability to specifically target tissues and organs is enabled, resulting in 
improved therapeutic efficiency.
30,31,32,33 
The preferential delivery of a drug to its target sites, 
along with the particle’s ability to release drugs in a sustained or stimuli triggered manner will 
lead to reduced off-target effects and decreased toxicity. Utilization of nano-carriers also has the 
added advantage of improving the solubility of hydrophobic drugs in water; thus enhancing their 
delivery through parenteral administration. Nano-carrier based delivery systems have also been 
shown to improve the half-lives of a wide variety of hydrophobic moieties  and peptide 
drugs.
34,35,36 
Moreover, nanotechnology based delivery vehicles composed of biocompatible 
molecules
37,38,39,40
 are projected as safer alternatives to existing vehicles that have been known to 
cause peripheral neuropathy and hypersensitivity.
41,42
    
There are three fundamental factors that go into the development of a competent nano-
targeting system, viz - characteristics of the diseased state, choice of therapeutics and the nature 
of the delivery vehicle.
5
 The choice of the therapeutic and the nature of its action needs to be 
carefully considered during the selection of a delivery platform. The drug’s site and mechanism 
of action define what carrier system will achieve optimal delivery. For example; drugs that 
require intracellular sites of action require intracellular delivery for bioactivity and therefore 
necessitate a delivery vehicle that enables homogenous tissue penetration.
5
 Fundamental research 
into the nature of diseased state biomarkers and associated ligands, play vital roles in the design 
of functionalized delivery vehicles. Even in cases where targeting is not employed, an 
7 
 
 
understanding into the characteristics of the diseased site, tissue accumulation and cellular 
uptake can help us engineer more efficient non-specific drug delivery systems by modulating the 
biophysical properties of nano-carriers.
43,44
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 1.3 The ideal nano-delivery system 
 
The search for ‘ideal nano-delivery systems’ involve numerous design elements. The 
large repertoire of available nano-carriers, apart the ones that are in development, present nano-
systems with a variety of structural, functional and physiochemical characteristics that  translate 
into case specific advantages and/or limitations.  
The selection of a nano-carrier is contingent on the pathology of the diseased state and 
the limitations imposed thereby; and while it would be difficult to absolutely define the ideal 
nanosystems, there are certain parameters generally sought out for the successful development 
and manufacturing of drug delivery vehicles for the purposes of targeted delivery. These include 
(i) biocompatibility of constituent material(s); (ii) simple and robust assembly processes; (iii) 
functionalization / pre-functionalization capability; (iv) intracellular stability and 
biodegradability; (v) long circulating half-life; (vi) suitable size, charge density, surface 
hydrophilicity and flexibility; and (vii) negligible immunogenicity.  
It has been indicated that the complexity involved in nanoparticle fabrication and 
functionalization causes batch to batch variations leading to quality and purity concerns;
12
 and 
that the development of development of targeted nano-carriers via a single step synthesis 
mediated by the self-assembly of pre-functionalized biomaterials would serve to alleviate these 
concerns by simplifying the optimization and the scalable manufacture of these 
systems.
21,45,46,47,48
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 1.4 Targeted drug delivery 
 
Generally speaking, increasing target selectivity
49
 and improving a drug’s ability to 
overcome biological barriers thereby increasing the per dose efficacy of a therapeutic are typical 
goals of the medicinal chemist 
20,
 
50
.  
 1.4.1 Passive Targeting 
 
Diseased tissues tend to exhibit numerous alterations in their physiology as compared to 
healthy tissues. Passive targeting seeks to take advantage of the differences between normal and 
diseased tissues to effect site specific targeted drug delivery.
3
 Passive drug targeting proceeds via 
the extravasation of the nanoparticle at the target site by exploiting the distinct 
pathophysiological features of tumorous and inflamed tissues which exhibit leaky vasculature.
13
 
Needless to say, this mode of drug targeting is widely employed clinically in cancer therapy. The 
leakiness of tumor vasculature is a consequence of angiogenesis, and the presence of 
permeability enhancing cytokines and vasoactive factors.
51
 A majority of tumors show a vascular 
pore cut-off sizes of 380-780 nm as opposed to 2-4 nm for normal vasculature.
29,52,53,54
 Tumor 
angiogenesis is characterized by undefined, branching in blood vessels with irregular diameters 
as well as with other vascular structures viz venules, arterioles and capillaries. This increased 
vascular permeability coupled with an impaired lymphatic system in tumors enhances 
permeability and the retention (EPR) effect of the nano-carriers in tumorous and inflamed 
tissues.
55,56
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Nano-carrier systems also have another distinct advantage. Their larger size compared to 
free drug molecules results in accumulation at higher concentrations in the target tissues; and 
their tendency to localize specifically in the Reticulo-Endothelial System (RES) makes them 
particularly well suited for passive targeting of macrophages in the spleen and liver thus enabling 
passive targeting as a modality for treating intracellular infections.
 57
 The long circulating times 
needed for the successful administration of passively targeted drugs via nano-carriers are greatly 
inhibited due to opsonization by the mononuclear phagocytic system. To this end, hydrophilic 
polymers such as polyethylene glycol (PEG) have been successfully utilized as surface 
modifying agents, to generate chemically inert, low immunogenic and low antigenic nano-
carriers,.  Also derivatization of their free hydroxyl groups on the polymer backbone offers sites 
for the addition of other adducts.
58
  ‘Stealth’ liposomes comprised of distearoyl 
phosphatidylethanolamine (DSPE) or dipalmitoyl phosphatidylethanolamine grafted with 3-7% 
methoxy-PEG-2000 showed circulation half-lives of up to 45 h in humans
59,60,61
 as opposed to 
the 2 h half-lives seen with their non-PEGylated variants.
62
  
The tight segregation of the blood from the brain by the blood-brain barrier membrane
63
 
greatly diminishes the therapeutic potential of numerous drugs designed to treat neurological 
disorders.
64
  Drug loading into nanoparticles leads to greater selectivity in targeting of 
biologically active compounds by modifying cell and tissue distribution, thus enhancing the 
efficacy and ameliorating the toxicity of the drug. 
65,66,67,68
 Moreover, the blood-brain barrier has 
been shown to exhibit increased permeability in instances of ischemic hypoxia induced by 
stroke; and during the course of HIV-induced dementia, stroke, septic encephalopathy, multiple 
sclerosis and Alzheimer’s disease.69,70,71,72  This permeability change enables improved uptake of 
nanotechnology mediated drug delivery to the brain and central nervous system.                
11 
 
 
 1.4.2 Active Targeting 
 
The majority of the two dozen or so nano-materials clinically approved by the Food and 
Drug Administration (as of 2010) were derivatives of first generation nanosystems such as 
liposomes and polymersomes.
73
 These nanosystems provide numerous advantages such as 
enhanced drug activity, improved solubility of hydrophobic drugs, longer half-lives, reduced 
immunogenicity, reduced peripheral drug toxicity, sustained and stimulated drug release etc.,
 12
 
in comparison to conventional modes of drug delivery. However, the ability to specifically target 
cells rather than tissues in localized diseases and to facilitate drug uptake via receptor mediated 
endocytosis and other associated modalities was found to be lacking in these systems. It is 
believed that ‘Active Targeting’ facilitated by the modification and/or conjugation of 
nanoparticles with ligands has the potential to bridge this gap.
74
        
 While the accumulation of nanoparticles in tumors is largely determined by the 
physiochemical characteristics of the nanoparticles, the addition of ligands can improve retention 
and uptake via endocytotic mechanisms.
74;75
 Higher intracellular drug concentrations facilitated 
by this modality resulted in improved therapeutic activity.
 76
  Cancerous tissue - apart from 
having altered vasculatures - also overexpresses certain receptors and epitopes such as 
transferrin, FOLR, TfR, αVβ3, MUC1, BCL-2, GNRHR, VPAC, PACAP, VEGFR2, CEA etc.  
that could be exploited as targets.
77,78,79,80,81,82,83,84,85,86,87,88,89,90,91
 Active targeting of nanodrugs is 
especially relevant for bioactive molecules that require intracellular delivery for optimal 
activity.
74
 Active targeting has been considered in resistant cancer cells,
92
 and it is speculated 
that long-circulating targeted nanodrugs might be able to locate and kill migrating metastatic 
cancer cells.
12
 Active targeting is used in therapies where cellular uptake of a drug  would benefit 
from facilitated processes that can access active sites on or in cell.
93
  This is important in immune 
12 
 
 
and endothelial cell targeting for cardiovascular disorders, where localization is directed by 
ligand-receptor interactions rather than EPR effects.
5
 Moreover, active ligand-mediated targeting 
has been found to be valuable in facilitating transcytosis of drugs across endothelial barriers.
94
  
 Ligands can be coupled to nano-carriers either covalently or non-covalently. Covalent 
coupling methodologies employ reactive sites on both the carrier and ligand.  Commonly 
employed chemistries include disulfide bond formation, reactions between-- primary amines and 
carboxylic acids, maleimides and thiols, primary amines and free aldehydes and aldehydes and 
hydrazide.
92,127
 The physical associations involved in non-covalent bonding (hydrophobic or 
electrostatic) eliminates the need for harsher chemistries and reagents at the expense of random 
ligand orientations, weak binding leading to loss of the ligand and poor control of the reaction 
leading to batch to batch variations in degrees of complexation. 
13 
 
 
  1.5 Classification of Nanoscale systems for drug delivery 
 
The classification of nano-carriers is a difficult exercise owing to the wide spectrum of available 
nano-systems currently in use as well as in development. Another challenge involves the 
realization that in many instances a description of the nanocarrier might be a function of its 
intended application and not its composition. For example, multifunctional nanocarriers are used 
to describe a variety of organic and/or inorganic nanoparticles that have been selectively 
modified and re-engineered to perform various therapeutic and diagnostic functions by 1) 
improving stability, 2) lengthening circulatory half-life and biodistribution, 3) incorporating 
passive and active targeting capabilities, 4) tuning responsiveness to pH and/or temperature and 
other pathological and physiological variations, 5) incorporating various contrast agents and 
imaging modalities (viz - magnetic resonance imaging, gamma-scintigraphy, ultra sonography, 
computed tomography etc.) and 6) including magnetic sensitivity.
95,96,97,98
  Some of the magnetic 
particles have been tried as magnetic contrast agents,
99
 hyperthermia agents for thermal ablation 
of tumors,
100
 and magnetic vectors for drug targeting
101
 amongst other applications.
102,103
 As 
such, the nomenclature of these systems refers to the modality of operation and function of these 
nano-particles; not their architecture and constituents.  
14 
 
 
 The specific nano-delivery agents that will be presented provide a brief overview of the 
major carriers employed for drug delivery. They will be classified based on their composition 
and assembly characteristics. 
Figure 1.2 Classification of Nanocarrier Systems for Drug Delivery 
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 1.5.1 Liposomes 
 
 Liposomes are possibly the oldest and most widely studied drug delivery systems and have been 
in use since the 1960s.
104
 These artificially produced vesicles range from 30 nm to several 
micrometers in size and consist of an aqueous core surrounded by uni- or multi-lamellar 
membranes comprised of phospholipids and cholesterol.
105
 Their utility lies in their ability to 
fuse with cellular membranes
106
 and lipid bilayers membranes or to enter cells through clathrin 
mediated endocytosis.
107,108109
 The properties of liposomes have been extensively investigated 
and have been modulated to express a great deal of variation in size, lipid composition, surface 
charge and other characteristics.
110
 The aqueous core of the liposomes is known to be able to 
encapsulate a large payload of hydrophilic and moderately hydrophobic drugs; and their ability 
to naturally associate with tumors and the EPR effect has led to the development of numerous 
FDA approved drugs based on the liposome platform.
111,112
   
 Numerous studies have been conducted to surface modify classical liposomes in an effort 
to increase their targeting capabilities and circulating half-lives. These include incorporation of 
linear dextrans,
113
 gangliosides containing sialic acid,
114
 lipid derivatives of hydrophilic 
polymers such as polyvinyl alcohol,
115
 polyethylene glycol
116,117
 and poly-N-vinylpyrrolidones
118
 
for stabilization and protection from uptake by the mononuclear phagocytic system (MPS). 
Targeted therapy has also been demonstrated using liposomes conjugated with a monoclonal 
antibody via a PEG linker,
119
 and protease-sensitive polymer-caged liposomes have been 
developed to enable selective targeting and drug release at the cancerous site by exploiting the 
16 
 
 
natural tendency of affected cells to produce cancer associated proteases to destabilize the 
liposome resulting in drug extravasation.
120
   
Liposomes also appear to be the preferred carriers for purposes of radionuclide based 
targeting for cancer therapy. A variety of liposomes such as multi-vesicular liposomes (MUVEL) 
- small vesicles containing radionuclides trapped into large liposomes, polymer coated long 
circulating liposomes  - with low bilayer permeability and low lipid exchange, sterically 
stabilized liposomes (SSL) - with high load capacity and tumor affinity, etc. have been 
developed exclusively for this purpose.
121,122,123,124,125
  The therapeutic efficacy of targeted 
radiotherapy is due to the tumor’s absorption of alpha (α) or beta (β) radiation emitted by the 
radionuclide. β-emitters such as 90Y, 32P, 166Ho, 89Sr, 188Re and 186Re are by far the most widely 
utilized radionuclides. β-electrons have low linear energy transfer (LET) values and long path-
lengths. They can pass through tissue, and interact with atoms via energy loss causing ionization, 
Figure 1.3 Electron microscopy pictures of POPC:POPE (6:4)  liposomes made using extrusion.  
Seabra, M.B. (2006) Studies of a Channel-Forming Peptide Inserted into Liposomes formed by POPC:POPS and 
POPC:POPE, Kansas State University. 
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generating free radicals thus causing DNA damage by inducing single strand breaks. On the 
other hand α-particles have high LET values and shorter path lengths, and are used to generate 
more localized cellular effects with high chromosomal damage during mitosis and irreparable 
double strand DNA breaks.  Short half-life α-particles emitters 225Ac, 211At and 213Bi are 
commonly employed for targeted alpha particle therapy (TAT).
126
 Naturally varying 
considerations exist in the selection of liposomal carriers based on whether they are employed 
for beta - or alpha - radiation therapy. For instance studies relating to the effect of surface charge 
of the liposomes on the radionuclide delivery demonstrated that the use of neutral lipids such as 
DMPC-Cholesterol in liposomal preparation substantially increased the effective maximum 
absorbed dosage of beta emitters such as 
32
P, 
67
Cu, 
90
Y and 
131
I at the tumor site as opposed to 
cationic DC-cholesterol lipids. On the other hand a study performed on cholesterol stabilized 
PEGylated liposomes with 
225
Ac and 
213
Bi showed high retention of the radionuclide and 
daughter isotopes where large (> 650 nm) cationic liposomes were involved.
126
  
Generally speaking, due to the low LET values exhibited by beta electrons, 
considerations of liposomal rupture due to beta-emissions are not as critical as in the case of 
alpha emitters where the high LET values of alpha particles coupled with the high energy recoil 
generated during the formation of daughter nuclides can damage and rupture the liposomal 
membrane. Moreover, the greater availability of beta-emitters for radiotherapy enables a greater 
choice in the selection of radionuclides as opposed to those employed in alpha particle therapy. 
The chemistry of the parent 
225
Ac used in most alpha particle therapies has a chemistry that is not 
well understood; and that precludes the effective utilization of these emitters in chelate 
complexes and from integration in larger compounds for the purposes of liposomal 
encapsulation. Time is yet another factor to be considered in case of radiotherapy. Unlike 
18 
 
 
conventional drugs, radioactive moieties decay over time, thus losing treatment potency. This is 
especially true in cases of radionuclides such as 
213
Bi (t1/2 = 45.7 min), where the long times 
taken for liposomal preparation come at the expense of therapeutic efficacy.  Discussion of 
problems associated with alpha particle delivery will be detailed in chapter 3.                     
Despite their versatility, biocompatibility, relative non-toxicity and wide application 
platform, liposome preparation is lengthy and tedious, and preparation steps have to be very 
carefully monitored to ensure reproducibility in size and entrapment efficiency.
127
 Moreover, 
liposomes have been demonstrated to alter the pharmacokinetic properties of the drugs and are 
prone to systemic leakage.
128
 All of these parameters must be factored in while selecting 
liposomes as candidates for therapeutic delivery.    
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 1.5.2 Micellar Assemblies  
 
Micelles are self-assemblies of amphiphilic macromolecules - with distinct hydrophobic and 
hydrophilic block domains - that form supramolecular core-shell structures in aqueous 
environments.
129
 Amphiphilic molecules tend to accumulate at the boundary of two phases with 
the hydrophobic blocks oriented away from the aqueous environment to achieve a state of 
minimum free energy. Hydrophobic interactions are the main driving force behind micellar 
assembly above a specific concentration termed the ‘Critical Micellar Concentration’ (CMC). 
Each amphiphile has a unique CMC in distilled water, which can increase or decrease depending 
on the presence of various solutes.
130
 Micelles maintain their assembly as long as their 
concentrations in solution exist above the CMC. However, in some cases they can resist 
disassembly below their CMC, if physical interactions between chains in the micellar core can 
out-compete the thermodynamic forces involved in micellar destabilization.
131
 Micelles usually 
range from 10-100 nm in diameter and exhibit a core-shell architecture, in which the inner core - 
comprised of the hydrophobic regions of the amphiphiles serve as an environment that can entrap 
lipophilic drugs.
132
 The CMC and morphological features exhibited by micelles are a function of 
the nature of their hydrophilic and hydrophobic block constituents. Eisenberg et al. have 
demonstrated the formation of a variety of micellar structures such as, spheres, rods, vesicles, 
tubules and lamellae depending on solvent conditions and the relative size of hydrophobic and 
hydrophilic segments, resulting in varied pharmacokinetic properties.
133,134,135,136
   Numerous 
copolymers can be used for the production of micelles, but constraints of biocompatibility and 
biodegradability limits this choice therapeutic applications.
120
 Usually, the preferred choice for 
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the hydrophilic block has been PEG. In most micellar assemblies, the molecular weight of PEG 
tends to exceed that of the hydrophobic core forming block.
137
 This outer hydrophilic corona 
region tends to become highly water bound resulting in a splayed appearance giving rise to 
various conformations, such as a polymer brush.
138
 These conformations give micelles new 
characteristics that suppress binding to serum proteins and phagocytic attack in blood thereby 
decreasing clearance by the RES.
129
 PEGylated co-polymer micelles also have lower CMC than 
traditional surfactants resulting in lower cellular toxicity.
129
 The highly hydrated corona and the 
hydrophobic core generate a polarity gradient which aids in the solubilization of a range of 
hydrophobic compounds of varied polarities, by mere physical association without the need for 
any drug modification.
119
 Using micellar delivery system, the biodistribution and 
Figure 1.4 . Formation of Liposomes and Micelles above the Critical Micellar Concentration 
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pharmacokinetics of many drugs are positively altered by means of increased circulatory half-life 
and tumor accumulation.
139
  
 Based on their shared molecular architecture, micelles can be divided into four general 
categories.                  
 1.5.2.1 Phospholipid Micelles 
 
Typical membrane phospholipids are branched and assemble into bilayers, and are used 
for the generation of liposomes.   An interesting exception is the phospholipid 1,2-
distearoylphosphatidylethanolamine (DSPE), which when conjugated with PEG assembles into 
nano-sized micellar structures. These DSPE-PEG micelle cores are stable due to the low CMC of 
the DSPE with the PEG forms the outer 
hydrophilic shell. PEGylated phospholipid 
micelles avoid MPS uptake, exhibit 
extended circulatory half-lives,
140,141
 and are 
described as sterically stabilized micelles 
(SSM).
59,60,61
 These nano-carrier constructs 
have PEGs with molecular weights ranging 
from 1000-5000 Da and are biocompatible, 
easy to produce and non-toxic.
142,143
 The 
CMC of these phospholipid micelles is a 
function of PEG chain length, with lower 
CMCs for shorter chains. However, SSMs 
with PEG molecular weights less than 1000 Da failed to provide the necessary polarity to form 
Figure 1.5. Representation of a DSPE-PEG(2000) Micelle. 
Adapted with permission from (Kastantin, M., Ananthanarayanan, 
B., Karmali, P., Ruoslahti, E. and Tirrell, M. (2009) Effect of the 
lipid chain melting transition on the stability of DSPE-PEG(2000) 
micelles. Langmuir. United States 25, 7279-7286). Copyright 
(2009) American Chemical Society.  
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micelles whereas the ones with weights greater than 5000 Da made the moieties excessively 
soluble to maintain functionality.
144
 A number of therapeutic agents have been used for delivery 
with SSM, viz diazepam,
142
 campothecin,
34
 paclitaxel
40
 and vasoactive intestinal peptide 
(VIP).
145
 The incorporation of a water insoluble phospholipid molecule such as 
phosphatidylcholine to increase the solubilization potential of phospholipid micelles had led to 
the development sterically stabilized mixed micelles (SSMM) with differences in size and 
solubility depending on variations in phosphatidylcholine composition and PEG chain 
length.
40,142
 Phospholipid micelles are stable and can be reconstituted upon freeze drying without 
the need for cryo - and/or lyo-protecting agents.
34
 However, they exhibit limited stability in 
water when compared to other types of micelles.
119
      
 1.5.2.2 Pluronic Micelles 
 
These are block copolymer micelles where polyethylene oxide (PEO) forms the 
hydrophilic block and polypropylene oxide (PPO)provides the hydrophobic block. These blocks 
are arranged in structural variations of the basic pattern PEOx-PPOy-PEOx , where x and y 
represent the number of time a PEO or a PPO block is repeated.   They are characterized by their 
core-shell architecture where, in water, the hydrophilic segments form a palisade surrounding the 
Figure 1.6. Drug Encapsulation in encapsulated in spherical Pluronic F127 micelles.  
Adapted with permission from (Basak, R. and Bandyopadhyay, R. (2013) Encapsulation of hydrophobic drugs in Pluronic F127 
micelles: effects of drug hydrophobicity, solution temperature, and pH. Langmuir. United States 29, 4350-4356). Copyright 2013 
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segregated hydrophobic core. The toxicity of the pluronic micelles have been correlated to their 
hydrophobicity while their biological distribution has been correlated with their charge and 
surface properties.
146,147
  Pluronic micelles are formulated by combining two or more types of 
blocks generating a wide range of hydrophobicities and have also been used in vitro in 
chemotherapy to overcome multi drug resistance.
148
 Pluronics have been modified by covalent 
chemical conjugation to generate new polymers. A case in point would be pluronics conjugated 
with polyacrylic acid (PAA) to generate nano-micellar systems incorporating the solubility 
capabilities of poloaxamers with the bio-adhesive and pH sensitivities of the PAA.
119
    
 1.5.2.3 Polyester Micelles 
 
Polyester micelles are made up of FDA approved, biocompatible and biodegradable 
amphiphilic polymer conjugates such as, PEG-poly(lactic acid) (PLA), PEG-poly(lactic-co-
glycolic acid) (PLGA) and PEG-poly(caprolactone).
135
 An increase in the poly(lactone) chain 
length resulted in increased hydrophobicity and subsequently increased loading efficiency of the 
model drug indomethacin. Alternatively, the use of PLA - a more hydrophilic lactone, resulted in 
a more rapid release of the drug due to weaker interactions between the drug and the 
poly(lactide) core. Similarly, shorter chain length PEG increased drug loading and decreased rate 
of release compared to longer chain length PEG.
149
 Drug loading efficiency and release in these 
systems is a function of the nature of the hydrophobic core as well as the PEG chain length and 
the ratio between them. Although these micelles have been investigated for delivery of paclitaxel 
and doxorubicin, concerns regarding the acid metabolites generated during the hydrolytic 
breakdown of polyester lactones in vivo remain to be addressed.
119
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 1.5.2.4 Poly(L-amino acid) Micelles 
 
Poly(L-amino acid) micelles are Poly(L-Histidine)-PEG block co-polymers blended in 
with poly(L-lactic acid)-PEG micellar systems (PLLA-PEG) that have been investigated as pH 
sensitive drug carriers for cancer therapy.
150,151,152
 Cancerous cells - due to a higher rate of 
aerobic and anaerobic glycolysis compared to normal cells - tends to have pH < 7.2.
 148,153,154
 The 
imidazole side-chain of histidine has a pKa in this range; which leads to an increase in histidine 
hydrophobicity, destabilization of the micelle and subsequent drug release. The pH sensitivity of 
Poly(L-amino acid) micelles has been modulated by varying the %wt. of the  poly(L-lactic acid)-
PEG composition. Moreover, Poly(L-histidine) (PLHS) has been indicated to demonstrate 
fusogenic activity in endosomes facilitating cytosolic drug release in cancer cells.
148
 PLHS-
PEG/DSPE-PEG as well as PLHS-PEG/PLLA-PEG co-polymer micelles have been developed 
as pH sensitive nanocarriers for the purposes of cytosolic drug delivery.
155
  Drugs have been 
conjugated to these poly(amino acid) copolymers via chemical modifications of the drugs, but 
not without concerns relating to drug decoupling at the target site.
156,157,158
 Also, immunogenicity 
is a potential concern with these systems upon the increase in the number and diversity of amino 
acids used.
135
 However, the use of D-amino acids might help to alleviate that concern.    
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 1.5.3 Nanoparticulates in drug delivery 
 
Nanoparticulates are colloidal macromolecular nanocarrier systems ranging from 10-100 
nm and deemed as potentially attractive candidates for the entrapment and encapsulation of 
hydrophobic drugs.  Solid nanoparticulates can either be defined as nanocapsules - where the 
active drug molecule is encapsulated within the carrier; or matrix based nanospheres - where the 
drug molecules are adsorbed and dispersed throughout the nanomaterial.
159
 Nanoparticulates can 
be engineered using ‘top down’ or ‘bottom up’ methods.160 In the former, the larger material is 
broken down into smaller particles whereas the bottom up approach involves the 
thermodynamically regulated, molecule by molecule synthesis of the nanomaterial in a 
controlled environment.
161
    Based on their composition; nanoparticulates are classified into the 
following categories:     
 1.5.3.1 Polymeric Nanoparticles 
 
These nanoparticles are engineered from synthetic polymeric constituents such as PLA, 
PGA, PLGA, poly-ε-caprolactone, poly(methyl methacrylate), etc.3 and formulated to be 
biocompatible and biodegradable; maximize tissue compatibility and minimize cyto-toxicity.
119
 
Based on the methods of assembly and function, they fall into two categories; 
 1.5.3.1.1 Polymeric Nanospheres 
 
A polymeric nanosphere is defined as polymer matrix colloidal nanoparticulate that 
entraps, encapsulates, chemically binds to, or adsorbs a drug molecule.
 130
 These particles are 
between 100-200 nm and demonstrate poly-dispersity.
 130
 The hydrophobic surfaces of these 
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particles however make them susceptible to clearance by the RES and efforts have been made to 
alter the surface characteristics of these by absorbing various surfactants and moieties like 
poloxamine, poloxamer and Brij to their surface.
162,163,164,165
 Nanospheres prepared using 
amphiphilic co-polymers such as methoxypolyethylene glycol - poly(lactic acid) (MePEG-b-
PLA) and high molecular weight hydrophobic blocks, not only demonstrated higher stability, but 
also provided sites for functionalization and conjugation.
166,167
 The presence of di- block 
copolymers in nanospheres resulted in a phase separated structure consisting of a solid core.
164
  It 
was observed in case of methoxypolyethylene glycol - poly(D,L- Lactic acid) (MePEG-b-
PDLLA) copolymers, that the aggregation behavior was and the physiochemical properties were 
strongly dependent on copolymer composition.
168
,
169
 An increase in PDLLA molecular mass 
resulted in the central core of the nanocapsules becoming more solid like and a decrease resulted 
in nanoparticles which were defined as micelle-like assemblies.                   
 1.5.3.1.2 Polymeric Nanocapsules / Polymersomes 
 
These are colloidal vesicular systems in which the drug is confined within a cavity or 
Figure 1.7.Assembly and Encapsulation in Polymersomes.  
Adapted with permission from (Qiao, Z.Y., Ji, R., Huang, X.N., Du, F.S., Zhang, R., Liang, D.H. and Li, Z.C. (2013) 
Polymersomes from dual responsive block copolymers: drug encapsulation by heating and acid-triggered release. 
Biomacromolecules. United States 14, 1555-1563). Copyright (2013) American Chemical Society. 
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reservoir surrounded by a polymer coating or membrane.
130,170
 If the central cavity consists of an 
oily liquid surrounded by a single layer of polymer, the resulting structure is a nanocapsule.
168
 
Nanocapsules are have been indicated for the encapsulation and delivery of hydrophobic drugs 
such as methotrexate, xanthone, Ru 58668 and 3-methylxanthone, and nanocapsules comprising 
of PEG copolymers and chitosan are suitable for oral delivery.
171,172,173,174
  On the other hand, if 
the aqueous reservoir is encapsulated by a polymeric bilayer, the resulting structure is termed as 
a polymersome.
175
 Polymersomes are essentially the polymer equivalents of liposomes, the 
difference being that the external bilayer is constituted of amphiphilic di-block copolymers such 
as PEG-b-PBD (poly(butadiene)) and PEG-b-PEE (poly(ethylethylene)).
176,177
 Polymersomes are 
particularly suited for the targeting of water soluble drugs. PEGylated variants have a greater 
PEG surface density and consequently exhibit longer circulation times compared to stealth 
liposomes.
178
  
 1.5.3.2 Dendrimers 
 
Dendrimers are 1-10 nm sized synthetic hyper-branched polymeric macromolecules that 
comprise of a series of well-defined branches around a central inner core
179,180.181
 Dendrimers are 
synthesized by convergent or divergent approaches.
178
 The former approach capitalizes on the 
symmetric nature of the dendrimer with synthesis commencing at the periphery and terminating  
at the core; while the divergent approaches commences at the core upon which each successive 
layer is built.
182
 Dendrimers are structurally well-defined and display low poly-dispersity despite 
their large molecular mass. The branching of the dendrimers generates semi-globular / globular 
structures which are available for functionalization.
177
 Consequently glycol-dendrimers, peptide-
dendrimers and silicon-dendrimers have been synthesized using carbohydrates, peptides and 
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silicon as functionalities.
 178,183
 Drugs are 
associated with the dendrimers by 
physical encapsulation in the void spaces 
or by attachment of the pro-drug to the 
dendrimer surface.
181
 Dendrimers have 
been studied for the delivery of 
fluorouracil
184
 and indomethacin.
185
 
Dendrimer size has been exponentially 
correlated with the duration of 
extravasation across the endothelium, 
with larger dendrimers indicating faster 
extravasations.
186
 The positive charges on 
the polyamine and/or polyamide linkages 
used for dendrimer construction indicate 
potential for cellular toxicity and 
immunogenicity. However, partial derivatization of the dendrimer surface with PEG and/or fatty 
acids has been shown to mitigate these concerns significantly by shielding the positive charge on 
the surface.
187,188
        
 
 1.5.3.3 Solid Lipid Nanoparticles 
 
Solid Lipid Nanoparticles (SLN) constitute a class of nanoscale carriers where a central 
solid hydrophobic core comprised of physiological lipid/s are dispersed in an aqueous surfactant 
Figure 1.8. Convergent and divergent synthesis of dendrimers and 
dendrons.  
Reprinted with permission from (Rosen, B.M., Wilson, C.J., Wilson, 
D.A., Peterca, M., Imam, M.R. and Percec, V. (2009) Dendron-mediated 
self-assembly, disassembly, and self-organization of complex 
systems. Chem.Rev. United States 109, 6275-6540). Copyright (2009) 
American Chemical Society. 
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by micro-emulsification or high pressure homogenization.
189
 The drugs in this case are dissolved 
and dispersed in the solid hydrophobic core.
190
 These nanoparticles due to their narrow size 
range (100 - 200 nm) evade the RES and also cross the tight endothelial cells of the blood-brain 
barrier to be taken up by the brain.
191
 The biodegradable nature of the non-toxic constituent 
physiological lipids makes them very safe to use. SLN also demonstrate higher stable drug 
entrapment, especially in case of very hydrophobic drugs and provide controlled release lasting 
several weeks. SLN are conjugated hydrophilic polymers and/or surfactants to minimize their 
hepatic uptake and improve bioavailability.
119
 SLN can be stabilized by the incorporation of 
stearic acid - PEG 2000, however cytotoxic effects due to the release of free stearic acid, upon 
degradation needs to be factored in as a cost of stabilization.
192
 The loading efficiency of SLN 
can be modulated by employing complex lipids with varying chain lengths. Overall, SLN are a 
safe delivery system for hydrophobic drugs especially to the brain and production is scalable 
with excellent reproducibility.
157,193
       
 1.5.4 Niosomes 
 
Niosomes or Non-ionic surfactant vesicles (NSV) are nanoscopic lamellar structures that 
self-assemble into closed bilayers upon hydrating a preparation of non-ionic surfactants such as 
alkyl or dialkyl polyglycerol ethers; cholesterol and a charge inducing agent.
194
 In many ways 
Niosomes are liposomal analogs and are prepared much like liposomes through non-spontaneous 
processes involving the input of energy in the form of heat, ultrasound, physical agitation, 
application of pressure or a combination thereof.
195
 Consequently, just like liposomes, most NSV 
preparation methods involve some hydration of the non-ionic surfactant at an elevated 
temperature followed by an optional size reduction to obtain a colloidal suspension.
196
  However, 
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there are some fundamental distinctions. While liposomes are made up of neutral or charged 
double chained phospholipids; niosomes are made up of uncharged single chain surfactants. And 
since non-ionic surfactants are more stable than, and more resistant to air-oxidation than 
phospholipids, niosome preparation is usually much easier than that of their liposomal 
counterparts.
195
 Liposomes are expensive and difficult to prepare, require special storage and 
handling and the constituent phospholipids have a predisposition to become oxidized.  The 
interest in ninosomes as potential nano-carriers is a result of their versatility, cost-efficacy, 
stability and ability to surmount some of the drawbacks associated with liposomes.
197
  
  Niosomes are essentially comprised of three different constituents; i) Non-ionic 
surfactant, ii) Cholesterol and, iii) Charged molecule.  
1.5.4.1 Non-ionic surfactants are amphiphilic or amphipathic, non-ionic molecules and 
are the basic component of niosomes. Non-ionic surfactants are preferred due to their diversity, 
stability, non-toxic nature and biocompatibility.
198
 The hydrophobic and hydrophilic segments in 
these amphipathic molecules are bonded by esters, amides or ethers.  Non-ionic surfactants such 
as alkyl ethers, alkyl glyceryl ethers, sorbitan fatty acid ethers, Brij 30 (polyoxyethylene 4 lauryl 
ether), Brij 58 (polyoxyethylene acetyl ether), Span 60, Tween 40 etc. have been used for the 
preparation of niosomes, with polyglycerol monoalkyl ethers and their polyoxylate analogs being 
the most widely employed single chain surfactants.
195, 196
 Moreover, Gemini surfactants - two 
hydrophobic chains linked with two hydrophobic head groups via spacers,
199,200
 and 
bolasurfactants - two identical polar azacrown ethers linked together with a long alkyl chain,
201
 
have been used to develop novel NSVs. The diversity available surfactants and numerous 
permutations thereof, make NSV a highly tunable system.  
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1.5.4.2--Cholesterol - due to its interaction with non-ionic surfactants greatly influences the 
physical and structural properties of niosomes, and numerous surfactants form NSV only after 
addition of anywhere between 30 - 50 mol% of cholesterol.
202
 Cholesterol modulates the 
cohesion of the NSVs, their mechanical strength and permeation to water. The rigidity imparted 
by cholesterol is vital to the stability of the NSV in conditions of stress.
203
 When surfactants with 
hydrophilic-lipophilic balance (HLB) values greater than 10 are involved in NSV formation, the 
incorporation of cholesterol is a structurally critical compensation for the presence of larger 
hydrophilic head groups.
204
 Nevertheless, the concentration of cholesterol in NSVs is much less 
than that typically found in liposomes resulting in higher niosomal drug entrapment efficiency.
195
  
1.5.4.3 Charged Molecules - Negatively charged molecules such as Dicetyl phosphate (DCP) 
and phosphatidic acid, or positively charged molecules such as cetylpyridinium chloride and 
sterylamine (SA) are added (2.5 - 5 mol% ) to prevent aggregation and stabilize the niosomal 
bilayer.
196
  
When a water soluble carrier such as sorbitol, sucrose stearate, maltodextrin etc. is coated 
with a thin film of dry non-ionic surfactant, the resulting preparation is termed ‘Proniosomes’.205 
These proniosomes can be reconstituted via hydration to generate Niosomes. Since proniosomes 
are obtained as a dry powder; they can be formulated to make beads, capsules or tablets with 
convenient unit dosing and demonstrate reduced aggregation, fusion, leakage and increased drug 
entrapment efficiency.
196, 206
   
 Niosomes, due to the presence of amphiphilic, lipophilic and hydrophilic moieties can 
incorporate drugs with a wide range of solubility, and indicate potential applications for the 
delivery of numerous pharmacological agents.
195
 Niosomal preparations have been investigated 
for the purposes of drug, gene and vaccine delivery through parenteral, oral, ocular, pulmonary 
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and transdermal routes. The breadth of these studies precludes them from comment in this thesis. 
Marianecci et al. (2013)
196
 provides an excellent and comprehensive review on the numerous 
potential applications of niosomes. A worthwhile mention however is the ability of niosomes to 
deliver drugs via topical application. Dermal / transdermal drug delivery is an alternative route 
for therapeutic administration that enables localized delivery of high concentrations of the drug, 
while bypassing the limitations associated with systemic circulation and/or gastrointestinal 
degradation. The stratum cornuem of the epidermis works as a barrier for permeation and 
consequently severely restricts the administration of most drugs through transdermal routes.
196
 
Niosomes loaded with drugs demonstrate enhanced permeation characteristics and niosomes 
formulations demonstrated greater skin permeation of enoxacin and higher stability of tretinoin 
when compared to their respective liposomal counterparts.
207, 208
 pH sensitive niosomes 
generated with Span 60, cholesterol and cholesteryl hemisuccinate (CHEMS) were proposed for 
the topical delivery of ibuprofen and demonstrated a significant increase in drug permeation 
through the skin.
209
  
Despite the numerous advantages proffered by niosomes over liposomes, niosomal 
preparation is generally exhaustive, utilizes numerous moieties, involves the application of non-
spontaneous energy consuming processes and takes considerable time.  Niosomes have yet to be 
(as of 2013) employed as a clinical therapeutic, and no specific, long term studies to study the 
toxicity of niosomes in vivo are available.
196
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 1.5.5 Branched Amphiphilic Peptide Capsules 
 
Branched Amphiphilic Peptide Capsules represent a novel class of nanocarriers. First 
described by Gudlur et al.
210
 in 2012, they are self-assembling structures where a water filled 
cavity is surrounded by an amphiphilic branched peptide bilayer. They are essentially stable, 
non-immunogenic, biocompatible and biodegradable nanocarriers that are structurally similar to 
liposomes and polymersomes. The properties, applications and biophysical characterization of 
these carrier systems will be discussed at length in the proceeding chapters.     
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 1.6 Other Peptide Based Carriers 
 
   Apart from realm of nano-carriers; it is worthwhile to mention cell penetrating peptide 
based modalities for drug delivery into the cells. Cell penetrating peptides (CPP) are short 
cationic sequences of natural derivation, or synthetic constructs that function as vectors to 
promote cellular uptake.
211
 The ‘Tat’ peptide sequence derived from the HIV transactivator 
transcription protein was discovered in 1998 and demonstrated to gain intracellular access by 
translocating the cellular membrane.
212,213
  The number of CPPs has grown ever since and 
commonly used sequences such as penetratin, polyarginine, transportan and Tat are used to 
deliver a diverse cargo such as small molecule therapeutics,
214
 proteins,
215
 and nucleic acids
216
 
into the cell; with high translocation and minimal toxicity in a variety of cell lines.
217
  
Table 1 Examples of cell-penetrating peptides, their sequences, structures and proposed mechanisms of cellular uptake. 
Adapted from Koren et al (2012)218 and Fonseca et al (2009)219 
Cell Penetrating 
Peptide 
Amino Acid Sequence Structure Proposed 
Mechanism 
Tat(49-57) RKKRRQRRR Random Coil / PPII helix Pore formation, direct 
penetration 
Pep-1 KETWWETWWTEWSQPKKKRKV Amphipathic, α-helical Pore formation, direct 
penetration 
Penetratin (pAntp) RQIKIWFQNRRMKWKK Amphipathic, α-helical, β-
sheet(high concentration) 
Endocytosis, direct 
penetration 
pVEC LLIILRRRRIRKQAHAHSK Amphipathic, β-sheet Transporter mediated, 
direct penetration 
The mechanism of CPP uptake across the plasma membrane remains unresolved. The length of 
the molecule, the sequence of amino acids, charge delocalization on the peptide, and the 
properties of the associated cargo have all been held as determining factors.
219
 However, it has 
become apparent that a single CPP could employ multiple pathways of entry into the cell.
220
 
CPPs have not only demonstrated energy independent direct-translocation into the cell; but also 
35 
 
 
have been seen to exploit the energy dependent endocytotic modes of entry such as 
macropinocytosis, clathrin mediated endocytosis, caveolae/lipd-raft mediated endocytosis and 
clathrin/caveolae independent endocytosis.
221
 The major advantage of CPP is their ability to 
transport cargo into the intracellular compartments of the cell such as the nucleus, mitochondria, 
lysosome and cytoplasm.
221
 Pep-1 (Chariot
TM
 Protein Delivery Reagent, Active Motif, USA), an 
amphipathic 21-residue sequence, became the first commercially available peptide carrier for the 
non-covalent delivery of proteins into cells.
222,223
  Subsequently, a number of nano-carriers such 
as liposomes, micelles, nanocapsules, polymeric nanospheres, dendrimers, solid-lipid 
nanoparticles, etc. have been conjugated, encapsulated or physically adsorbed to CPPs to 
facilitate their intracellular transport; and have been shown to mediate the intracellular transport 
of a variety of pharmacologically relevant and biologically active agents in a non-cell-type-
specific manner.
224,225,226 
36 
 
 
 1.7 References
                                                 
1
 Feynman, R. P. There's plenty of room at the bottom. (Caltech, February, 1960) Engineering 
and Science 23(5), 22–36  
2
 Emerich, D.F. and Thanos, C.G. (2003) Nanotechnology and medicine. Expert Opin. Biol. 
Ther.3, 655-663 
3
 Sahoo, S.K. and Labhasetwar, V. (2003) Nanotech approaches to drug delivery and 
imaging. Drug Discov. Today. 8, 1112-1120   
4
 Silva, G.A. (2004) Introduction to nanotechnology and its applications to medicine. Surg. 
Neurol. 61, 216-220  
5
 Farokhzad, O.C. and Langer, R. (2009) Impact of Nanotechnology on Drug Delivery. ACS 
Nano. 3, 16-20 
6
 Whitesides, G.M. (2003) The 'right' size in nanobiotechnology. Nat.Biotechnol.  21, 1161-1165  
7
 Roco, M.C. (2003) Nanotechnology: convergence with modern biology and medicine. Curr. 
Opin. Biotechnol. 14, 337-346  
8
 Roco, M.C. and Bainbridge, W.S. (2002) Converging Technologies for Improving Human 
Performance: Integrating From the Nanoscale. Journal of Nanoparticle Research. 4, 281-
295 
9
 National Science and Technology Council Committee on Technology, sub-committee on 
Nanoscale Science, Engineering and Technology. The National Nanotechnology 
Initiative Supplement to the President’s 2014 budget. Washington (DC): Office of 
Science and Technology Policy; 2013 
10
 Langer, R. (1998) Drug delivery and targeting. Nature. 392, 5-10 
37 
 
 
                                                                                                                                                             
11
 Duncan, R. (2003) The dawning era of polymer therapeutics. Nat. Rev. Drug Discov.  2, 347-
360  
12
 Shi, J., Votruba, A.R., Farokhzad, O.C. and Langer, R. (2010) Nanotechnology in drug 
delivery and tissue engineering: from discovery to applications. ACS Nano Lett. 10, 
3223-3230  
13
 Vasir, J.K. and Labhasetwar, V. (2005) Targeted drug delivery in cancer therapy. Technol. 
Cancer. Res. Treat. 4,363-374  
14
 Kim, J.K., Kim, H.J., Chung, J.Y., Lee, J.H., Young, S.B. and Kim, Y.H. (2014) Natural and 
synthetic biomaterials for controlled drug delivery. Arch. Pharm. Res. 37, 60-68 
15
 Hamman, J.H., Enslin, G.M. and Kotze, A.F. (2005) Oral delivery of peptide drugs: barriers 
and developments. Bio. Drugs. 19, 165-177  
16
 Pawar, R., Ben-Ari, A. and Domb, A.J. (2004) Protein and peptide parenteral controlled 
delivery. Expert Opin. Biol. Ther. 4, 1203-1212  
17
 Sahoo, S.K., Parveen, S. and Panda, J.J. (2007) The present and future of nanotechnology in 
human health care. Nanomedicine: Nanotechnology, Biology and Medicine. 3, 20-31  
18
 Brayden, D.J. (2003) Controlled release technologies for drug delivery. Drug Discov.Today. 
8, 976-978  
19
 LaVan, D.A., McGuire, T. and Langer, R. (2003) Small-scale systems for in vivo drug 
delivery. Nat Biotech. 21, 1184-1191 
20
 Ferrari, M. (2005) Cancer nanotechnology: opportunities and challenges. Nat.Rev.Cancer.  
5, 161-171 
21
 Zhang, L., Gu, F.X., Chan, J.M., Wang, A.Z., Langer, R.S. and Farokhzad, O.C. (2008) 
Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. 
Ther.  83, 761-769  
38 
 
 
                                                                                                                                                             
22
 Langer, R. (1990) New methods of drug delivery. Science.  249, 1527-1533  
23
 Etheridge, M.L., Campbell, S.A., Erdman, A.G., Haynes, C.L., Wolf, S.M. and McCullough, J. 
(2013) The big picture on nanomedicine: the state of investigational and approved 
nanomedicine products. Nanomedicine: Nanotechnology, Biology and Medicine. 9, 1-14  
24
 Moghimi, S.M., Hunter, A.C. and Murray, J.C. (2005) Nanomedicine: current status and future 
prospects. FASEB J. 19, 311-330  
25
 Emerich, D.F. (2005) Nanomedicine--prospective therapeutic and diagnostic 
applications. Expert Opin. Biol. Ther. 5,1-5  
26
 Jain, K.K. (2003) Nanodiagnostics: application of nanotechnology in molecular 
diagnostics. Expert Rev. Mol. Diagn. 3, 153-161  
27
 Kubik, T., Bogunia-Kubik, K. and Sugisaka, M. (2005) Nanotechnology on duty in medical 
applications.Curr.Pharm.Biotechnol. 6, 17-33  
28
 Kayser, O., Lemke, A. and Hernandez-Trejo, N. (2005) The impact of nanobiotechnology on 
the development of new drug delivery systems. Curr. Pharm. Biotechnol. 6, 3-5  
29
 Drummond, D.C., Meyer, O., Hong, K., Kirpotin, D.B. and Papahadjopoulos, D. (1999) 
Optimizing liposomes for delivery of chemotherapeutic agents to solid 
tumors. Pharmacol. Rev. 51, 691-743  
30
 Au, J.L., Jang, S.H., Zheng, J., Chen, C.T., Song, S., Hu, L. and Wientjes, M.G. (2001) 
Determinants of drug delivery and transport to solid tumors. J. Control. Release. 74, 31-
46 
31
 Fetterly, G.J. and Straubinger, R.M. (2003) Pharmacokinetics of paclitaxel-containing 
liposomes in rats. AAPS Pharm. Sci. 5, E32  
32
 Hoarau, D., Delmas, P., David, S., Roux, E. and Leroux, J.C. (2004) Novel long-circulating 
lipid nanocapsules. Pharm. Res. 21, 1783-1789 
39 
 
 
                                                                                                                                                             
33
 Moghimi, S.M. and Szebeni, J. (2003) Stealth liposomes and long circulating nanoparticles: 
critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. 
Lipid Res. 42, 463-478  
34
 Koo, O.M., Rubinstein, I. and Onyuksel, H. (2005) Camptothecin in sterically stabilized 
phospholipid micelles: a novel nanomedicine. Nanomedicine. 1, 77-84  
35
 Kristl, J., Volk, B., Gasperlin, M., Sentjurc, M. and Jurkovic, P. (2003) Effect of colloidal 
carriers on ascorbyl palmitate stability. Eur. J. Pharm. Sci. 19, 181-189 
36
 Arnedo, A., Irache, J.M., Merodio, M. and Espuelas Millan, M.S. (2004) Albumin 
nanoparticles improved the stability, nuclear accumulation and anticytomegaloviral 
activity of a phosphodiester oligonucleotide. J. Control. Release. 94, 217-227  
37
 Zhang, J.A., Anyarambhatla, G., Ma, L., Ugwu, S., Xuan, T., Sardone, T. and Ahmad, I. 
(2005) Development and characterization of a novel Cremophor EL free liposome-based 
paclitaxel (LEP-ETU) formulation. Eur. J. Pharm. Biopharm.  59, 177-187  
38
 Ibrahim, N.K., Desai, N., Legha, S., Soon-Shiong, P., Theriault, R.L., Rivera, E., Esmaeli, B., 
Ring, S.E., Bedikian, A., Hortobagyi, G.N. and Ellerhorst, J.A. (2002) Phase I and 
pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle 
formulation of paclitaxel. Clin. Cancer Res. 8, 1038-1044  
39
 Kim, T.Y., Kim, D.W., Chung, J.Y., Shin, S.G., Kim, S.C., Heo, D.S., Kim, N.K. and Bang, 
Y.J. (2004) Phase I and pharmacokinetic study of Genexol-PM, a Cremophor-free, 
polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin. 
Cancer Res.10, 3708-3716  
40
 Krishnadas, A., Rubinstein, I. and Onyuksel, H. (2003) Sterically stabilized phospholipid 
mixed micelles: in vitro evaluation as a novel carrier for water-insoluble drugs. Pharm. 
Res. 20, 297-302  
40 
 
 
                                                                                                                                                             
41
 Gelderblom, H., Verweij, J., Nooter, K. and Sparreboom, A. (2001) Cremophor EL: the 
drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer. 
37, 1590-1598  
42
 ten Tije, A.J., Verweij, J., Loos, W.J. and Sparreboom, A. (2003) Pharmacological effects of 
formulation vehicles : implications for cancer chemotherapy. Clin. Pharmacokinet.  
42, 665-685  
43
 Verma, A., Uzun, O., Hu, Y., Hu, Y., Han, H.S., Watson, N., Chen, S., Irvine, D.J. and 
Stellacci, F. (2008) Surface-structure-regulated cell-membrane penetration by monolayer-
protected nanoparticles. Nat. Mater. 7, 588-595  
44
 Gratton, S.E., Ropp, P.A., Pohlhaus, P.D., Luft, J.C., Madden, V.J., Napier, M.E. and 
DeSimone, J.M. (2008) The effect of particle design on cellular internalization 
pathways. Proc.Natl.Acad.Sci.U.S.A. 105, 11613-11618  
45
 Davis, M.E. (2009) The first targeted delivery of siRNA in humans via a self-assembling, 
cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol. Pharm 6, 659-668  
46
 Decuzzi, P., Pasqualini, R., Arap, W. and Ferrari, M. (2009) Intravascular delivery of 
particulate systems: does geometry really matter? Pharm. Res. 26, 235-243  
47
 Patil, Y.B., Toti, U.S., Khdair, A., Ma, L. and Panyam, J. (2009) Single-step surface 
functionalization of polymeric nanoparticles for targeted drug delivery. Biomaterials.  
30, 859-866  
48
 Kim, B.S., Park, S.W. and Hammond, P.T. (2008) Hydrogen-bonding layer-by-layer-
assembled biodegradable polymeric micelles as drug delivery vehicles from 
surfaces. ACS Nano. 2, 386-392  
49
 Allen, T.M. (2002) Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer.  
2, 750-763 
41 
 
 
                                                                                                                                                             
50
 Jain, R.K. (1998) The next frontier of molecular medicine: delivery of therapeutics. Nat. 
Med. 4, 655-657  
51
 Oeffinger, B.E. and Wheatley, M.A. (2004) Development and characterization of a nano-scale 
contrast agent. Ultrasonics. 42, 343-347  
52
 Fu, B.M., Adamson, R.H. and Curry, F.E. (1998) Test of a two-pathway model for small-
solute exchange across the capillary wall. Am. J. Physiol. 274, H2062-73  
53
 Firth, J.A. (2002) Endothelial barriers: from hypothetical pores to membrane proteins. J. Anat.  
200, 541-548  
54
 Hobbs, S.K., Monsky, W.L., Yuan, F., Roberts, W.G., Griffith, L., Torchilin, V.P. and Jain, 
R.K. (1998) Regulation of transport pathways in tumor vessels: role of tumor type and 
microenvironment. Proc. Natl. Acad. Sci. U.S.A. 95, 4607-4612  
55
 Maeda, H., Wu, J., Sawa, T., Matsumura, Y. and Hori, K. (2000) Tumor vascular permeability 
and the EPR effect in macromolecular therapeutics: a review. J. Control. Release.  
65, 271-284  
56
 Matsumura, Y. and Maeda, H. (1986) A new concept for macromolecular therapeutics in 
cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the 
antitumor agent smancs. Cancer Res.  46, 6387-6392  
57
 Vasir JK, Labhasetwar V. (2005) Targeted drug delivery in cancer therapy. Technol. Cancer 
Res Treat 4:363- 74. 
58
 Moghimi, S.M., Hunter, A.C. and Murray, J.C. (2001) Long-circulating and target-specific 
nanoparticles: theory to practice. Pharmacol. Rev. 53, 283-318  
59
 Klibanov, A.L., Maruyama, K., Torchilin, V.P. and Huang, L. (1990) Amphipathic 
polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett.  
268, 235-237  
42 
 
 
                                                                                                                                                             
60
 Allen, T.M., Hansen, C., Martin, F., Redemann, C. and Yau-Young, A. (1991) Liposomes 
containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation 
half-lives in vivo. Biochimica et Biophysica Acta (BBA) - Biomembranes.1066, 29-36  
61
 Woodle, M.C. (1993) Surface-modified liposomes: assessment and characterization for 
increased stability and prolonged blood circulation. Chem. Phys. Lipids. 64, 249-262  
62
 llen, T.M. and Everest, J.M. (1983) Effect of liposome size and drug release properties on 
pharmacokinetics of encapsulated drug in rats. J. Pharmacol. Exp. Ther.  226, 539-544  
63
 Pardridge, W.M. (1999) Vector-mediated drug delivery to the brain. Adv. Drug Deliv. 
Rev. 36, 299-321  
64
 Calvo, P., Gouritin, B., Chacun, H., Desmaele, D., D'Angelo, J., Noel, J.P., Georgin, D., 
Fattal, E., Andreux, J.P. and Couvreur, P. (2001) Long-circulating PEGylated 
polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm. Res. 
18, 1157-1166  
65
 Alyautdin, R.N., Tezikov, E.B., Ramge, P., Kharkevich, D.A., Begley, D.J. and Kreuter, J. 
(1998) Significant entry of tubocurarine into the brain of rats by adsorption to 
polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion 
study. J. Microencapsul. 15, 67-74  
66
 Garcia-Garcia, E., Gil, S., Andrieux, K., Desmaele, D., Nicolas, V., Taran, F., Georgin, D., 
Andreux, J.P., Roux, F. and Couvreur, P. (2005) A relevant in vitro rat model for the 
evaluation of blood-brain barrier translocation of nanoparticles. Cell Mol. Life Sci. 
62, 1400-1408  
67
 Feng, S.S., Mu, L., Win, K.Y. and Huang, G. (2004) Nanoparticles of biodegradable polymers 
for clinical administration of paclitaxel. Curr. Med. Chem. 11, 413-424   
68
 de Kozak, Y., Andrieux, K., Villarroya, H., Klein, C., Thillaye-Goldenberg, B., Naud, M.C., 
Garcia, E. and Couvreur, P. (2004) Intraocular injection of tamoxifen-loaded 
43 
 
 
                                                                                                                                                             
nanoparticles: a new treatment of experimental autoimmune uveoretinitis.Eur. J. 
Immunol. 34, 3702-3712  
69
 Ballabh, P., Braun, A. and Nedergaard, M. (2004) The blood-brain barrier: an overview: 
structure, regulation, and clinical implications. Neurobiol. Dis. 16, 1-13  
70
 Oki, T., Takahashi, S., Kuwabara, S., Yoshiyama, Y., Mori, M., Hattori, T. and Suzuki, N. 
(2004) Increased ability of peripheral blood lymphocytes to degrade laminin in multiple 
sclerosis. J. Neurol. Sci.  222, 7-11  
71
 Inoue, S. (2001) Basement membrane and beta amyloid fibrillogenesis in Alzheimer's 
disease. Int. Rev. Cytol. 210, 121-161  
72
 Cornford, E.M. and Cornford, M.E. (2002) New systems for delivery of drugs to the brain in 
neurological disease. Lancet. Neurol. 1, 306-315   
73
 Riehemann, K., Schneider, S.W., Luger, T.A., Godin, B., Ferrari, M. and Fuchs, H. (2009) 
Nanomedicine--challenge and perspectives. Angew.Chem.Int.Ed Engl.  48, 872-897  
74
 Bartlett, D.W., Su, H., Hildebrandt, I.J., Weber, W.A. and Davis, M.E. (2007) Impact of 
tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles 
measured by multimodality in vivo imaging. Proc. Natl. Acad. Sci.U.S.A.  104, 15549-
15554  
75
 Pirollo, K.F. and Chang, E.H. (2008) Does a targeting ligand influence nanoparticle tumor 
localization or uptake? Trends. Biotechnol. 26, 552-558  
76
 Davis, M.E., Chen, Z.G. and Shin, D.M. (2008) Nanoparticle therapeutics: an emerging 
treatment modality for cancer. Nat. Rev. Drug Discov. 7, 771-782   
77
 Ishida, O., Maruyama, K., Tanahashi, H., Iwatsuru, M., Sasaki, K., Eriguchi, M. and Yanagie, 
H. (2001) Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular 
targeting property to the solid tumors in vivo. Pharm. Res.18, 1042-1048 
44 
 
 
                                                                                                                                                             
78
Omori, N., Maruyama, K., Jin, G., Li, F., Wang, S.J., Hamakawa, Y., Sato, K., Nagano, I., 
Shoji, M. and Abe, K. (2003) Targeting of post-ischemic cerebral endothelium in rat by 
liposomes bearing polyethylene glycol-coupled transferrin. Neurol. Res. 25, 275-279  
79
 Maruyama, K., Ishida, O., Kasaoka, S., Takizawa, T., Utoguchi, N., Shinohara, A., Chiba, M., 
Kobayashi, H., Eriguchi, M. and Yanagie, H. (2004) Intracellular targeting of sodium 
mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, 
for boron neutron-capture therapy (BNCT). J. Control. Release. 98, 195-207 
80
 Missailidis, S., Thomaidou, D., Borbas, K.E. and Price, M.R. (2005) Selection of aptamers 
with high affinity and high specificity against C595, an anti-MUC1 IgG3 monoclonal 
antibody, for antibody targeting. J. Immunol. Methods. 296, 45-62 
81
 Mitra, A., Mulholland, J., Nan, A., McNeill, E., Ghandehari, H. and Line, B.R. (2005) 
Targeting tumor angiogenic vasculature using polymer-RGD conjugates. J. Control. 
Release. 102, 191-201 
82
 Schiffelers, R.M., Ansari, A., Xu, J., Zhou, Q., Tang, Q., Storm, G., Molema, G., Lu, P.Y., 
Scaria, P.V. and Woodle, M.C. (2004) Cancer siRNA therapy by tumor selective delivery 
with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32, e149 
83
 Gosk, S., Vermehren, C., Storm, G. and Moos, T. (2004) Targeting anti-transferrin receptor 
antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells 
using in situ perfusion. J. Cereb. Blood Flow Metab. 24,1193-1204 
84
 Ni, S., Stephenson, S.M. and Lee, R.J. (2002) Folate receptor targeted delivery of liposomal 
daunorubicin into tumor cells. Anticancer Res. 22, 2131-2135 
85
 Moody, T.W., Leyton, J., Gozes, I., Lang, L. and Eckelman, W.C. (1998) VIP and Breast 
Cancer. Ann. N.Y. Acad. Sci. 865,290-296 
86
 Li, L., Wartchow, C.A., Danthi, S.N., Shen, Z., Dechene, N., Pease, J., Choi, H.S., Doede, T., 
Chu, P., Ning, S., Lee, D.Y., Bednarski, M.D. and Knox, S.J. (2004) A novel 
45 
 
 
                                                                                                                                                             
antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-
labeled nanoparticles. Int. J. Radiat. Oncol. Biol. Phys. 58, 1215-1227 
87
 Fonseca, M.J., Jagtenberg, J.C., Haisma, H.J. and Storm, G. (2003) Liposome-mediated 
targeting of enzymes to cancer cells for site-specific activation of prodrugs: comparison 
with the corresponding antibody-enzyme conjugate. Pharm. Res. 20, 423-428 
88
 Dharap, S.S., Qiu, B., Williams, G.C., Sinko, P., Stein, S. and Minko, T. (2003) Molecular 
targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides. J. 
Control. Release. 91, 61-73 
89
 Medina, O.P., Kairemo, K., Valtanen, H., Kangasniemi, A., Kaukinen, S., Ahonen, I., Permi, 
P., Annila, A., Sneck, M., Holopainen, J.M., Karonen, S.L., Kinnunen, P.K. and 
Koivunen, E. (2005) Radionuclide imaging of tumor xenografts in mice using a 
gelatinase-targeting peptide. Anticancer Res. 25, 33-42 
90
 Pastorino, F., Brignole, C., Marimpietri, D., Cilli, M., Gambini, C., Ribatti, D., Longhi, R., 
Allen, T.M., Corti, A. and Ponzoni, M. (2003) Vascular damage and anti-angiogenic 
effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res. 63, 7400-7409 
91
 Farokhzad, O.C., Jon, S., Khademhosseini, A., Tran, T.N., Lavan, D.A. and Langer, R. (2004) 
Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer 
cells. Cancer Res. 64, 7668-7672 
92
 Sapra, P. and Allen, T.M. (2003) Ligand-targeted liposomal anticancer drugs. Prog. Lipid Res. 
42, 439-462 
93
 Forssen, E. and Willis, M. (1998) Ligand-targeted liposomes. Adv.Drug Deliv.Rev. 29, 249-
271  
94
 Gabathuler, R. (2010) Approaches to transport therapeutic drugs across the blood-brain barrier 
to treat brain diseases.Neurobiol.Dis. 37, 48-57     
46 
 
 
                                                                                                                                                             
95
 Torchilin, V.P. (2012) Multifunctional nanocarriers. Adv.Drug Deliv.Rev. 64, 
Supplement, 302-315  
96
 Liong, M., Lu, J., Kovochich, M., Xia, T., Ruehm, S.G., Nel, A.E., Tamanoi, F. and Zink, J.I. 
(2008) Multifunctional inorganic nanoparticles for imaging, targeting, and drug 
delivery. ACS Nano. 2, 889-896  
97
 Cheng, Z., Al Zaki, A., Hui, J.Z., Muzykantov, V.R. and Tsourkas, A. (2012) Multifunctional 
Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging 
Capabilities. Science. 338, 903-910  
98
 Cheng, Z., Al Zaki, A., Hui, J.Z., Muzykantov, V.R. and Tsourkas, A. (2012) Multifunctional 
Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging 
Capabilities. Science. 338, 903-910  
99
 Cunningham, C.H., Arai, T., Yang, P.C., McConnell, M.V., Pauly, J.M. and Conolly, S.M. 
(2005) Positive contrast magnetic resonance imaging of cells labeled with magnetic 
nanoparticles. Magn. Reson. Med. 53, 999-1005  
100
 Johannsen, M., Gneveckow, U., Eckelt, L., Feussner, A., Waldofner, N., Scholz, R., Deger, 
S., Wust, P., Loening, S.A. and Jordan, A. (2005) Clinical hyperthermia of prostate 
cancer using magnetic nanoparticles: presentation of a new interstitial technique. Int. J. 
Hyperthermia. 21, 637-647  
101
 Alexiou, C., Tietze, R., Schreiber, E., Jurgons, R., Richter, H., Trahms, L., Rahn, H., 
Odenbach, S. and Lyer, S. (2011) Cancer therapy with drug loaded magnetic 
nanoparticles—magnetic drug targeting. J. Magn. Magn. Mater. 323, 1404-1407  
102
 Chomoucka, J., Drbohlavova, J., Huska, D., Adam, V., Kizek, R. and Hubalek, J. (2010) 
Magnetic nanoparticles and targeted drug delivering. Pharmacological 
Research. 62, 144-149  
47 
 
 
                                                                                                                                                             
103
 Chomoucka, J., Drbohlavova, J., Huska, D., Adam, V., Kizek, R. and Hubalek, J. (2010) 
Magnetic nanoparticles and targeted drug delivering. Pharmacological 
Research. 62, 144-149  
104
 Bangham, A.D., Standish, M.M. and Watkins, J.C. (1965) Diffusion of univalent ions across 
the lamellae of swollen phospholipids. J. Mol. Biol. 13, 238-252  
105
 Samad, A., Sultana, Y. and Aqil, M. (2007) Liposomal drug delivery systems: an update 
review. Curr. Drug Deliv. 4, 297-305  
106
  Marsden, H.R., Tomatsua, I.,  Kros, A. (2011)  Model systems for membrane fusion. Chem. 
Soc. Rev. 40, 1572-1585. 
107
 Hart, S.L. (2005) Lipid carriers for gene therapy. Curr. Drug  Deliv. 2, 423-428  
108
 Ewert, K., Evans, H.M., Ahmad, A., Slack, N.L., Lin, A.J., Martin-Herranz, A. and Safinya, 
C.R. (2005) Lipoplex structures and their distinct cellular pathways. Adv. Genet  53, 119-
155  
109
 Pollock, S., Antrobus,R., Newton,R., Kampa,B., Rossa,J., Latham, S. Nichita,N.B., 
Dwek,R.A., Zitzmann, N. (2010) Uptake and trafficking of liposomes to the endoplasmic 
reticulum. FASEB J. 24(6):1866-1878. 
110
 Sethi, V., Onyuksel, H. and Rubinstein, I. (2005) Liposomal vasoactive intestinal 
peptide. Methods Enzymol. United States 391, 377-395  
111
 Moses, M.A., Brem, H. and Langer, R. (2003) Advancing the field of drug delivery: taking 
aim at cancer. Cancer. Cell. 4, 337-341  
112
 Allen, T.M. and Cullis, P.R. (2004) Drug delivery systems: entering the mainstream. Science. 
303, 1818-1822  
113
 Pain, D., Das, P.K., Ghosh, P.C., and Bachhawat, B.K. (1984) Increased circulatory half-life 
of liposomes after conjunction with dextran. J. Biosci. 6:811–816. 32 
48 
 
 
                                                                                                                                                             
114
 Allen, T.M. and Chonn, A. (1987) Large unilamellar liposomes with low uptake into the 
reticuloendothelial system. FEBS Lett. 223, 42-46  
115
 Takeuchi, H., Kojima, H., Yamamoto, H. and Kawashima, Y. (2001) Evaluation of 
circulation profiles of liposomes coated with hydrophilic polymers having different 
molecular weights in rats. J. Control. Release. 75, 83-91  
116
 Papahadjopoulos, D., Allen, T.M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S.K., Lee, 
K.D., Woodle, M.C., Lasic, D.D. and Redemann, C. (1991) Sterically stabilized 
liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. 
Natl. Acad. Sci. U.S.A. 88, 11460-11464  
117
 Lasic, D.D., Martin, F.J., Gabizon, A., Huang, S.K. and Papahadjopoulos, D. (1991) 
Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended 
circulation times. Biochim. Biophys. Acta. 1070, 187-192  
118
 Torchilin, V.P., Levchenko, T.S., Whiteman, K.R., Yaroslavov, A.A., Tsatsakis, A.M., Rizos, 
A.K., Michailova, E.V. and Shtilman, M.I. (2001) Amphiphilic poly-N-
vinylpyrrolidones: synthesis, properties and liposome surface modification. Biomaterials. 
22, 3035-3044  
119
 Zhang, Y., Schlachetzki, F., Li, J.Y., Boado, R.J. and Pardridge, W.M. (2003) Organ-specific 
gene expression in the rhesus monkey eye following intravenous non-viral gene 
transfer. Mol. Vis.  9, 465-472  
120
 Basel, M.T., Shrestha, T.B., Troyer, D.L. and Bossmann, S.H. (2011) Protease-sensitive, 
polymer-caged liposomes: a method for making highly targeted liposomes using 
triggered release. ACS Nano. 5, 2162-2175  
121
 Miederer, M., Scheinberg, D.A. and McDevitt, M.R. (2008) Realizing the potential of the 
Actinium-225 radionuclide generator in targeted alpha particle therapy applications. Adv. 
Drug Deliv. Rev. 60, 1371-1382  
49 
 
 
                                                                                                                                                             
122
 Kim, Y.S. and Brechbiel, M.W. (2012) An overview of targeted alpha therapy. Tumour 
Biol. 33, 573-590  
123
 Sofou, S., Thomas, J.L., Lin, H.Y., McDevitt, M.R., Scheinberg, D.A. and Sgouros, G. (2004) 
Engineered liposomes for potential alpha-particle therapy of metastatic cancer. J. Nucl. 
Med. 45, 253-260  
124
 Sofou, S., Kappel, B.J., Jaggi, J.S., McDevitt, M.R., Scheinberg, D.A. and Sgouros, G. (2007) 
Enhanced retention of the alpha-particle-emitting daughters of Actinium-225 by liposome 
carriers. Bioconjug. Chem. 18, 2061-2067  
125
 Henriksen, G., Schoultz, B.W., Michaelsen, T.E., Bruland, Ø.S. and Larsen, R.H. (2004) 
Sterically stabilized liposomes as a carrier for α-emitting radium and actinium 
radionuclides. Nucl. Med. Biol. 31, 441-449  
126
 Hamoudeh, M., Kamleh, M.A., Diab, R. and Fessi, H. (2008) Radionuclides delivery systems 
for nuclear imaging and radiotherapy of cancer. Adv. Drug Deliv. Rev. 60, 1329-1346  
127
 Koo, O.M., Rubinstein, I. and Onyuksel, H. (2005) Role of nanotechnology in targeted drug 
delivery and imaging: a concise review. Nanomedicine: Nanotechnology, Biology and 
Medicine. 1, 193-212  
128
 Gabizon, A.A., Shmeeda, H. and Zalipsky, S. (2006) Pros and cons of the liposome platform 
in cancer drug targeting.J.Liposome Res. 16, 175-183  
129
 Sutton, D., Nasongkla, N., Blanco, E. and Gao, J. (2007) Functionalized micellar systems for 
cancer targeted drug delivery. Pharm. Res. 24, 1029-1046  
130
 Krimm, S. (1980) The hydrophobic effect: Formation of micelles and biological membranes, 
Charles Tanford, Wiley-Interscience, New York, 1980, 233 pp. Journal of Polymer 
Science: Polymer Letters Edition. 18, 687-687  
131
 Allen, C., Maysinger, D. and Eisenberg, A. (1999) Nano-engineering block copolymer 
aggregates for drug delivery. Colloids and Surfaces B: Biointerfaces.16, 3-27  
50 
 
 
                                                                                                                                                             
132
 Letchford, K. and Burt, H. (2007) A review of the formation and classification of amphiphilic 
block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and 
polymersomes. European Journal of Pharmaceutics and Biopharmaceutics. 65, 259-269  
133
 Yu, Y., Zhang, L. and Eisenberg, A. (1998) Morphogenic Effect of Solvent on Crew-Cut 
Aggregates of Apmphiphilic Diblock Copolymers. Macromolecules. 31, 1144-1154  
134
 Shen, H., Zhang, L. and Eisenberg, A. (1999) Multiple pH-Induced Morphological Changes 
in Aggregates of Polystyrene-block-poly(4-vinylpyridine) in DMF/H2O 
Mixtures. J.Am.Chem.Soc. 121, 2728-2740  
135
 Choucair, A. and Eisenberg, A. (2003) Interfacial solubilization of model amphiphilic 
molecules in block copolymer micelles. J.Am.Chem.Soc. 125, 11993-12000  
136
 Choucair, A. and Eisenberg, A. (2003) Control of amphiphilic block copolymer morphologies 
using solution conditions. Eur.Phys.J.E.Soft Matter. 10, 37-44  
137
 Kwon, G.S. (2003) Polymeric micelles for delivery of poorly water-soluble 
compounds. Crit.Rev.Ther.Drug Carrier Syst. 20, 357-403  
138
 Vonarbourg, A., Passirani, C., Saulnier, P. and Benoit, J.P. (2006) Parameters influencing the 
stealthiness of colloidal drug delivery systems. Biomaterials. 27, 4356-4373  
139
 Garrec, D., Ranger, M. and Leroux, J. (2004) Micelles in anticancer drug delivery. American 
Journal of Drug Delivery. 2, 15-42  
140
 Sethi V, Onyuksel H, Rubinstein I. (2003) Enhanced circulation half-life and reduced 
clearance of vasoactive intestinal peptide (VIP) loaded in sterically stabilized 
phospholipid micelles (SSM) in mice with collagen-induced arthritis (CIA) AAPS 
PharmSci.;5 (Suppl 1):M1045. 
141
 Lukyanov, A., Gao, Z., Mazzola, L. and Torchilin, V. (2002) Polyethylene Glycol-Diacyllipid 
Micelles Demonstrate Increased Accumulation in Subcutaneous Tumors in Mice. Pharm. 
Res. 19, 1424-1429  
51 
 
 
                                                                                                                                                             
142
 Working, P.K. and Dayan, A.D. (1996) Pharmacological-toxicological expert report. 
CAELYX. (Stealth liposomal doxorubicin HCl). Hum. Exp. Toxicol.  15, 751-785 
143
 Wade A, Weller PJ. (1994) Handbook of pharmaceutical excipients. Washington (DC): 
American Pharmaceutical Association and Pharmaceutical Press. 
144
 Ashok, B., Arleth, L., Hjelm, R.P., Rubinstein, I. and Onyuksel, H. (2004) In vitro 
characterization of PEGylated phospholipid micelles for improved drug solubilization: 
effects of PEG chain length and PC incorporation. J. Pharm. Sci. 93,2476-2487  
145
 Onyuksel, H., Ikezaki, H., Patel, M., Gao, X.P. and Rubinstein, I. (1999) A novel formulation 
of VIP in sterically stabilized micelles amplifies vasodilation in vivo. Pharm. Res. 
16, 155-160  
146
 Kataoka, K., Harada, A. and Nagasaki, Y. (2001) Block copolymer micelles for drug 
delivery: design, characterization and biological significance. Adv. Drug Deliv. 
Rev. 47, 113-131  
147
 Johnston, T.P. and Miller, S.C. (1985) Toxicological evaluation of poloxamer vehicles for 
intramuscular use.J. Parenter. Sci. Technol. 39, 83-89  
148
 Kabanov, A.V., Batrakova, E.V. and Alakhov, V.Y. (2002) Pluronic block copolymers for 
overcoming drug resistance in cancer.Adv. Drug Deliv. Rev. 54, 759-779  
149
 Lin, W.J., Juang, L.W. and Lin, C.C. (2003) Stability and release performance of a series of 
pegylated copolymeric micelles. Pharm. Res. 20, 668-673  
150
 Lee, E.S., Na, K. and Bae, Y.H. (2003) Polymeric micelle for tumor pH and folate-mediated 
targeting. J. Control. Release. 91, 103-113  
151
 Lee, E.S., Na, K. and Bae, Y.H. (2005) Doxorubicin loaded pH-sensitive polymeric micelles 
for reversal of resistant MCF-7 tumor. J. Control. Release. 103, 405-418  
52 
 
 
                                                                                                                                                             
152
 Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., 
Okusaka, T., Ueno, H., Ikeda, M. and Watanabe, N. (2004) Phase I clinical trial and 
pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br. J. 
Cancer. 91, 1775-1781  
153
 Ojugo, A.S., McSheehy, P.M., McIntyre, D.J., McCoy, C., Stubbs, M., Leach, M.O., Judson, 
I.R. and Griffiths, J.R. (1999) Measurement of the extracellular pH of solid tumours in 
mice by magnetic resonance spectroscopy: a comparison of exogenous (19)F and (31)P 
probes. NMR Biomed. 12, 495-504  
154
 Engin, K., Leeper, D.B., Cater, J.R., Thistlethwaite, A.J., Tupchong, L. and McFarlane, J.D. 
(1995) Extracellular pH distribution in human tumours. Int. J. Hyperthermia. 11, 211-216  
155
 Wu, H., Zhu, L. and Torchilin, V.P. (2013) pH-sensitive poly(histidine)-PEG/DSPE-PEG co-
polymer micelles for cytosolic drug delivery. Biomaterials. 34, 1213-1222 
156
 Lavasanifar, A., Samuel, J. and Kwon, G.S. (2002) Poly(ethylene oxide)-block-poly(L-amino 
acid) micelles for drug delivery. Adv. Drug Deliv. Rev. 54, 169-190  
157
 Li, Y. and Kwon, G.S. (2000) Methotrexate esters of poly(ethylene oxide)-block-poly(2-
hydroxyethyl-L-aspartamide). Part I: Effects of the level of methotrexate conjugation on 
the stability of micelles and on drug release. Pharm. Res. 17, 607-611  
158
 Bae, Y., Nishiyama, N., Fukushima, S., Koyama, H., Yasuhiro, M. and Kataoka, K. (2005) 
Preparation and biological characterization of polymeric micelle drug carriers with 
intracellular pH-triggered drug release property: tumor permeability, controlled 
subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug. 
Chem. 16, 122-130  
159
 Mishra, B., Patel, B.B. and Tiwari, S. (2010) Colloidal nanocarriers: a review on formulation 
technology, types and applications toward targeted drug delivery. Nanomedicine: 
Nanotechnology, Biology and Medicine. 6, 9-24  
53 
 
 
                                                                                                                                                             
160
 Alexis, F., Rhee, J.W., Richie, J.P., Radovic-Moreno, A.F., Langer, R. and Farokhzad, O.C. 
(2008) New frontiers in nanotechnology for cancer treatment. Urol. Oncol. 26, 74-85  
161
 Keck C, Kobierski S, Mauludin R, Muller RH. (2008) Second generation of drug nanocrystals 
for delivery of poorly soluble drugs: smart crystals technology. DSOIS; 24:124-8. 
162
 Illum, L. and Davis, S.S. (1984) The organ uptake of intravenously administered colloidal 
particles can be altered using a non-ionic surfactant (Poloxamer 338). FEBS 
Lett. 167, 79-82 
163
 Troster, S.D. and Kreuter, J. (1992) Influence of the surface properties of low contact angle 
surfactants on the body distribution of 14C-poly(methyl methacrylate) nanoparticles. J. 
Microencapsul. 9, 19-28  
164
 Müller, R.H. and Wallis, K.H. (1993) Surface modification of i.v. injectable biodegradable 
nanoparticles with poloxamer polymers and poloxamine 908. Int. J. Pharm. 89, 25-31  
165
 Müller, R.H. and Wallis, K.H. (1993) Surface modification of i.v. injectable biodegradable 
nanoparticles with poloxamer polymers and poloxamine 908. Int. J. Pharm. 89, 25-31  
166
 Gref, R., Minamitake, Y., Peracchia, M.T., Trubetskoy, V., Torchilin, V. and Langer, R. 
(1994) Biodegradable long-circulating polymeric nanospheres. Science. 263, 1600-1603  
167
 Peracchia, M.T., Gref, R., Minamitake, Y., Domb, A., Lotan, N. and Langer, R. (1997) PEG-
coated nanospheres from amphiphilic diblock and multiblock copolymers: Investigation 
of their drug encapsulation and release characteristics. J. Controlled Release. 46, 223-231  
168
 Riley, T., Stolnik, S., Heald, C.R., Xiong, C.D., Garnett, M.C., Illum, L., Davis, S.S., Purkiss, 
S.C., Barlow, R.J. and Gellert, P.R. (2001) Physicochemical Evaluation of Nanoparticles 
Assembled from Poly(lactic acid)−Poly(ethylene glycol) (PLA−PEG) Block Copolymers 
as Drug Delivery Vehicles. Langmuir. 17, 3168-3174   
169
 Heald, C.R., Stolnik, S., Kujawinski, K.S., De Matteis, C., Garnett, M.C., Illum, L., Davis, 
S.S., Purkiss, S.C., Barlow, R.J. and Gellert, P.R. (2002) Poly(lactic acid)−Poly(ethylene 
54 
 
 
                                                                                                                                                             
oxide) (PLA−PEG) Nanoparticles:  NMR Studies of the Central Solidlike PLA Core and 
the Liquid PEG Corona. Langmuir. 18, 3669-3675   
170
 Soppimath, K.S., Aminabhavi, T.M., Kulkarni, A.R. and Rudzinski, W.E. (2001) 
Biodegradable polymeric nanoparticles as drug delivery devices. J. Controlled 
Release.70, 1-20  
171
 Ameller, T., Marsaud, V., Legrand, P., Gref, R., Barratt, G. and Renoir, J.M. (2003) 
Polyester-poly(ethylene glycol) nanoparticles loaded with the pure antiestrogen RU 
58668: physicochemical and opsonization properties. Pharm. Res. 20,1063-1070  
172
 de Faria, T.J., Machado de Campos, A. and Lemos Senna, E. (2005) Preparation and 
Characterization of Poly(D,L-Lactide) (PLA) and Poly(D,L-Lactide)-Poly(Ethylene 
Glycol) (PLA-PEG) Nanocapsules Containing Antitumoral Agent Methotrexate. 
Macromolecular Symposia. 229, 228-233  
173
 Teixeira, M., Alonso, M.J., Pinto, M.M. and Barbosa, C.M. (2005) Development and 
characterization of PLGA nanospheres and nanocapsules containing xanthone and 3-
methoxyxanthone. Eur.J.Pharm.Biopharm.  59, 491-500  
174
 Prego, C., Torres, D., Fernandez-Megia, E., Novoa-Carballal, R., Quinoa, E. and Alonso, M.J. 
(2006) Chitosan-PEG nanocapsules as new carriers for oral peptide delivery. Effect of 
chitosan pegylation degree. J.Control.Release. 111, 299-308  
175
 Discher, D.E. and Eisenberg, A. (2002) Polymer vesicles. Science. 297, 967-973  
176
 Discher, B.M., Won, Y.Y., Ege, D.S., Lee, J.C., Bates, F.S., Discher, D.E. and Hammer, D.A. 
(1999) Polymersomes: tough vesicles made from diblock copolymers. Science.  
284, 1143-1146  
177
 Discher, B.M., Won, Y.Y., Ege, D.S., Lee, J.C., Bates, F.S., Discher, D.E. and Hammer, D.A. 
(1999) Polymersomes: tough vesicles made from diblock copolymers. Science.  
284, 1143-1146  
55 
 
 
                                                                                                                                                             
178
 Photos, P.J., Bacakova, L., Discher, B., Bates, F.S. and Discher, D.E. (2003) Polymer vesicles 
in vivo: correlations with PEG molecular weight. J. Control. Release. 90, 323-334  
179
 Quintana, A., Raczka, E., Piehler, L., Lee, I., Myc, A., Majoros, I., Patri, A.K., Thomas, T., 
Mule, J. and Baker, J.R.,Jr (2002) Design and function of a dendrimer-based therapeutic 
nanodevice targeted to tumor cells through the folate receptor. Pharm. Res 19, 1310-1316  
180
 Boas, U. and Heegaard, P.M. (2004) Dendrimers in drug research. Chem. Soc. Rev. 33, 43-63  
181
 Mainardes, R.M. and Silva, L.P. (2004) Drug delivery systems: past, present, and 
future. Curr. Drug  Targets.  5,449-455  
182
 Hawker, C.J. and Frechet, J.M.J. (1990) Preparation of polymers with controlled molecular 
architecture. A new convergent approach to dendritic macromolecules. J. Am. Chem. 
Soc. 112, 7638-7647  
183
 Cloninger, M.J. (2002) Biological applications of dendrimers. Curr. Opin. Chem. 
Biol. 6, 742-748  
184
 Tripathi, P.K., Khopade, A.J., Nagaich, S., Shrivastava, S., Jain, S. and Jain, N.K. (2002) 
Dendrimer grafts for delivery of 5-fluorouracil. Pharmazie. 57, 261-264  
185
 Chauhan, A.S., Jain, N.K., Diwan, P.V. and Khopade, A.J. (2004) Solubility enhancement of 
indomethacin with poly(amidoamine) dendrimers and targeting to inflammatory regions 
of arthritic rats. J. Drug Target. 12, 575-583  
186
 El-Sayed, M., Kiani, M.F., Naimark, M.D., Hikal, A.H. and Ghandehari, H. (2001) 
Extravasation of poly(amidoamine) (PAMAM) dendrimers across microvascular network 
endothelium. Pharm. Res. 18, 23-28  
187
 Jevprasesphant, R., Penny, J., Jalal, R., Attwood, D., McKeown, N.B. and D'Emanuele, A. 
(2003) The influence of surface modification on the cytotoxicity of PAMAM 
dendrimers. Int. J. Pharm. 252, 263-266  
56 
 
 
                                                                                                                                                             
188
 Nigavekar, S.S., Sung, L.Y., Llanes, M., El-Jawahri, A., Lawrence, T.S., Becker, C.W., 
Balogh, L. and Khan, M.K. (2004) 3H dendrimer nanoparticle organ/tumor 
distribution. Pharm. Res. 21, 476-483  
189
 Müller, R.H., Mäder, K. and Gohla, S. (2000) Solid lipid nanoparticles (SLN) for controlled 
drug delivery – a review of the state of the art. European Journal of Pharmaceutics and 
Biopharmaceutics. 50, 161-177  
190
 Kaur, I.P., Bhandari, R., Bhandari, S. and Kakkar, V. (2008) Potential of solid lipid 
nanoparticles in brain targeting. J. Control. Release. 127, 97-109  
191
 Blasi, P., Giovagnoli, S., Schoubben, A., Ricci, M. and Rossi, C. (2007) Solid lipid 
nanoparticles for targeted brain drug delivery. Adv. Drug Deliv. Rev. 59, 454-477  
192
 Zara, G.P., Cavalli, R., Bargoni, A., Fundaro, A., Vighetto, D. and Gasco, M.R. (2002) 
Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid 
lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and 
distribution of doxorubicin in brain and other tissues. J. Drug Target. 10, 327-335  
193
 Wissing, S.A., Kayser, O. and Muller, R.H. (2004) Solid lipid nanoparticles for parenteral 
drug delivery. Adv. Drug Deliv. Rev. 56, 1257-1272  
194
 Uchegbu, I.F. and Vyas, S.P. (1998) Non-ionic surfactant based vesicles (niosomes) in drug 
delivery. Int. J. Pharm. 172, 33-70  
195
 Kazi, K.M., Mandal, A.S., Biswas, N., Guha, A., Chatterjee, S., Behera, M. and Kuotsu, K. 
(2010) Niosome: A future of targeted drug delivery systems. J. Adv. Pharm. Technol. 
Res. 1, 374-380  
196
 Marianecci, C., Di Marzio, L., Rinaldi, F., Celia, C., Paolino, D., Alhaique, F., Esposito, S. 
and Carafa, M. (2013) Niosomes from 80s to present: The state of the art. Adv. Colloid 
Interface Sci. 205 C:187-206 
57 
 
 
                                                                                                                                                             
197
 Azeem, A., Anwer, M.K. and Talegaonkar, S. (2009) Niosomes in sustained and targeted 
drug delivery: some recent advances. J. Drug Target. 17, 671-689  
198
 Rajera, R., Nagpal, K., Singh, S.K. and Mishra, D.N. (2011) Niosomes: a controlled and 
novel drug delivery system. Biol. Pharm. Bull. 34, 945-953  
199
 Hait S.K., Maulik S.P. (2002) Gemini surfactants: a distinct class of self-assembling 
molecules. Curr Sci; 82:1101-11. 
200
 Silva, S.G., Alves, C., Cardoso, A.M.S., Jurado, A.S., Pedroso de Lima, M.C., Vale, M.L.C. 
and Marques, E.F. (2013) Synthesis of Gemini Surfactants and Evaluation of Their 
Interfacial and Cytotoxic Properties: Exploring the Multifunctionality of Serine as 
Headgroup. European Journal of Organic Chemistry. 1758-1769  
201
 Yan, Y., Lu, T. and Huang, J. (2009) Recent advances in the mixed systems of 
bolaamphiphiles and oppositely charged conventional surfactants. J. Colloid Interface 
Sci. 337, 1-10  
202
 Liu, T., Guo, R., Hua, W. and Qiu, J. (2007) Structure behaviors of hemoglobin in PEG 
6000/Tween 80/Span 80/H2O niosome system. Colloids Surf. Physicochem. Eng. 
Aspects.293, 255-261  
203
 Mahale, N.B., Thakkar, P.D., Mali, R.G., Walunj, D.R. and Chaudhari, S.R. (2012) 
Niosomes: Novel sustained release nonionic stable vesicular systems — An 
overview. Adv. Colloid Interface Sci. 183–184, 46-54  
204
 Talsma H, Steenbergen Mv, Borchert J, Crommelin D.(1994) A novel technique for the one-
step preparation of liposomes and nonionic surfactant vesicles without the use of organic 
solvents. Liposome formation in a continuous gas stream: the 'bubble' method. J Pharm 
Sci; 83:276-80.  
205
 Hu, C. and Rhodes, D.G. (1999) Proniosomes: a novel drug carrier preparation. Int. J. Pharm. 
185, 23-35  
58 
 
 
                                                                                                                                                             
206
 Yasam, V.R., Jakki, S.L., Natarajan, J. and Kuppusamy, G. (2013) A review on novel 
vesicular drug delivery: proniosomes. Drug Deliv. [Epub ahead of print] 
207
 Fang, J.Y., Hong, C.T., Chiu, W.T. and Wang, Y.Y. (2001) Effect of liposomes and niosomes 
on skin permeation of enoxacin.Int. J. Pharm. 219, 61-72  
208
 Manconi, M., Sinico, C., Valenti, D., Lai, F. and Fadda, A.M. (2006) Niosomes as carriers for 
tretinoin. III. A study into the in vitro cutaneous delivery of vesicle-incorporated 
tretinoin. Int.J.Pharm. 311, 11-19  
209
 Carafa, M., Marianecci, C., Rinaldi, F., Santucci, E., Tampucci, S. and Monti, D. (2009) Span 
and Tween neutral and pH-sensitive vesicles: characterization and in vitro skin 
permeation. J. Liposome Res. 19, 332-340  
210
 Gudlur, S., Sukthankar, P., Gao, J., Avila, L.A., Hiromasa, Y., Chen, J., Iwamoto, T. and 
Tomich, J.M. (2012) Peptide nanovesicles formed by the self-assembly of branched 
amphiphilic peptides. PLoS One. 7, e45374  
211
 Fischer, R., Fotin-Mleczek, M., Hufnagel, H. and Brock, R. (2005) Break on through to the 
other side-biophysics and cell biology shed light on cell-penetrating 
peptides. Chembiochem. 6, 2126-2142  
212
 Frankel, A.D. and Pabo, C.O. (1988) Cellular uptake of the tat protein from human 
immunodeficiency virus. Cell. 55, 1189-1193  
213
 Green, M. and Loewenstein, P.M. (1988) Autonomous functional domains of chemically 
synthesized human immunodeficiency virus tat trans-activator protein. Cell. 55, 1179-
1188  
214
 Rothbard, J.B., Garlington, S., Lin, Q., Kirschberg, T., Kreider, E., McGrane, P.L., Wender, 
P.A. and Khavari, P.A. (2000) Conjugation of arginine oligomers to cyclosporin A 
facilitates topical delivery and inhibition of inflammation. Nat. Med 6, 1253-1257  
59 
 
 
                                                                                                                                                             
215
 Fawell, S., Seery, J., Daikh, Y., Moore, C., Chen, L.L., Pepinsky, B. and Barsoum, J. (1994) 
Tat-mediated delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. U.S.A. 
91, 664-668  
216
 Chiu, Y.L., Ali, A., Chu, C.Y., Cao, H. and Rana, T.M. (2004) Visualizing a correlation 
between siRNA localization, cellular uptake, and RNAi in living cells. Chem. Biol. 
11, 1165-1175  
217
 Nagahara, H., Vocero-Akbani, A.M., Snyder, E.L., Ho, A., Latham, D.G., Lissy, N.A., 
Becker-Hapak, M., Ezhevsky, S.A. and Dowdy, S.F. (1998) Transduction of full-length 
TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration.Nat. 
Med.4, 1449-1452  
218
 Koren, E. and Torchilin, V.P. (2012) Cell-penetrating peptides: breaking through to the other 
side. Trends. Mol. Med.18, 385-393  
219
 Mueller, J., Kretzschmar, I., Volkmer, R. and Boisguerin, P. (2008) Comparison of cellular 
uptake using 22 CPPs in 4 different cell lines. Bioconjug. Chem. 19, 2363-2374  
220
 Fonseca, S.B., Pereira, M.P. and Kelley, S.O. (2009) Recent advances in the use of cell-
penetrating peptides for medical and biological applications. Adv. Drug Deliv.Rev.  
61, 953-964  
221
 Conner, S.D. and Schmid, S.L. (2003) Regulated portals of entry into the cell. Nature. 
422, 37-44  
222
 Henriques, S.T. and Castanho, M.A. (2008) Translocation or membrane disintegration? 
Implication of peptide-membrane interactions in pep-1 activity. J. Pept. Sci. 14, 482-487  
223
 Morris, M.C., Depollier, J., Mery, J., Heitz, F. and Divita, G. (2001) A peptide carrier for the 
delivery of biologically active proteins into mammalian cells. Nat. Biotechnol. 19, 1173-
1176  
60 
 
 
                                                                                                                                                             
224
 Gupta, B., Levchenko, T.S. and Torchilin, V.P. (2005) Intracellular delivery of large 
molecules and small particles by cell-penetrating proteins and peptides. Adv. Drug Deliv. 
Rev.  57, 637-651  
225
 Torchilin, V.P. (2008) Cell penetrating peptide-modified pharmaceutical nanocarriers for 
intracellular drug and gene delivery. Biopolymers. 90, 604-610  
226
 Lindberg, S., Copolovici, D.M. and Langel, U. (2011) Therapeutic delivery opportunities, 
obstacles and applications for cell-penetrating peptides. Ther. Deliv.  2, 71-82  
 
 
 
 
 
 
 
61 
 
 
Chapter 2 - Branched Oligopeptides Form Nano-Capsules with 
Lipid Vesicle Characteristics 
This chapter has been reproduced in its current format with permission from ‘Sukthankar, P., Gudlur, S., 
Avila, L.A., Whitaker, S.K., Katz, B.B., Hiromasa, Y., Gao, J., Thapa, P., Moore, D., Iwamoto, T., Chen, 
J. and Tomich, J.M. (2013) Branched Oligopeptides Form Nanocapsules with Lipid Vesicle 
Characteristics. Langmuir. 29 (47), 14648-14654’ © 2013 American Chemical Society 
 2.1 Introduction 
 
There is a need for new safe drug delivery vehicles that can better target specific tissues or 
organs and minimize off-target accumulation
1
. In Gudlur et al.
2
, we described, for the first time, 
a drug delivery system in which two peptides of different lengths; and designed to mimic diacyl 
glycerols (Fig. 2.1) form water filled 
vesicles.  In that paper we referred to 
these constructs as vesicles. Owing 
to the heuristic association of lipids 
with vesicles; we have introduced 
the term ‘capsule’ in an effort to 
negate the confusion between our 
peptidic nano-spheres and traditional lipid vesicles. The branch point lysine orients the two 
peptide segments at a 90˚ angle, similar to the geometry of diacyl phospholipids. The 
bis(FLIVI)-K-KKKK and bis(FLIVIGSII)-K-KKKK peptides together self-assemble with beta-
like secondary structure to form a new class of capsules that are readily taken up by cells in 
culture while retaining trapped solutes.  Since neither peptide alone forms stable capsules, we 
hypothesized that two sizes are required to accommodate the curvature of assembled capsules.  
Figure 2.1. Branched Bilayer Forming Sequences 
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The fact that they undergo self-assembly gives us the ability to modify individual peptides with 
various ligands or markers that can then be incorporated into the aggregate.  In the first paper we 
adducted the C-terminal lysine with fluorescent dyes and in another case included a cysteine 
residue at the C-terminus that was used to attach methyl mercury
2
.  The labeled peptides are 
usually incorporated at 30 mole percent with unlabeled peptides, without affecting assembly or 
cellular uptake.  The peptide capsules were also tested for thermal stability using Differential 
Scanning Calorimetry up to 95˚C and were 
found to maintain their structural and functional 
integrity at all studied temperatures.  In this 
study we report on the phospholipid vesicle-like 
characteristics of our assemblies.  The peptides 
are mixed and dried as monomers. Within 
minutes of adding water to the dried peptides, 
fibrils form, which soon coalesce into 20 nm 
capsules.  It is during this phase that solutes 
become entrapped. Thereafter, the capsules 
begin fusing, and by 24 h appear as much larger 
structures (up to 1 μm, with most having 
diameters of 50-200 nm) (see Fig. 2.2).  We 
were able to follow the fusion process by observing the dilution of a self-quenching fluorescent 
dye.  Since cell and tissue uptake is size dependent, we also examined the effects of extruding 
the larger capsules through membranes with various pore sizes. Dropping the temperature to 4° 
C suspends the fusion process allowing for storage of the uniform sized material. These studies 
Figure 2.2. Scanning Transmission Electron 
Micrograph (STEM) Hg-Labeled Peptides 24 hr after 
mixing.  
Capsules were prepared with 30% Me-Hg label in both 
peptides at 0.1 mM. The images were captured using 
annular dark field mode and then inverted to produce the 
final image. 
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together provide further evidence supporting the hypothesis that these branched sequences self-
assemble into bilayers and form capsules in an aqueous environment.   
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 2.2 Materials and Methods 
 
 2.2.1 Peptide Synthesis 
 
 Peptides were synthesized by solid phase peptide chemistry on 4-(2,4-Dimethoxyphenyl-Fmoc-
aminomethyl) phenoxyacetyl-norleucyl-cross-Linked Ethoxylate Acrylate Resin
3
  (Peptides 
International Inc; Louisville, Kentucky) on a 0.1 mmol scale using Fmoc (N-(9-fluorenyl) 
methoxycarbonyl)/tert-butyl chemistry on an ABI Model 431 peptide synthesizer (Applied 
Biosystems; Foster City, CA). The Fmoc amino acids were obtained from Anaspec, Inc 
(Fremont, CA). The branch point was introduced by incorporating N
α,ε
 di-Fmoc-L-Lysine in the 
fifth position from the C-terminus. De-protection of this moiety leads to the generation of two 
reactive amino sites that subsequently and simultaneous generate the bifurcated peptide branch 
point. This enables the addition of the hydrophobic tail segments FLIVI and FLIVIGSII to the 
common hydrophilic oligo-Lysine segment by the stepwise addition of Fmoc amino acids
4
.  The 
N-terminal ends of the peptide were acetylated on the resin using Acetic Anhydride / N, N-
Diisopropylethylamine / 1-Hydroxybenzotriazole prior to cleavage. The peptide was cleaved 
from the resin using TFA/water (98:2, v/v) for 90 min at RT to generate C-terminal 
carboxamide. The peptide product was washed 3x with diethyl ether and re-dissolved in water 
prior to lyophilization.  The water used throughout this study is deionized, reverse osmosis 
treated and then distilled.  The RP-HPLC purified peptides were dried in vacuo and characterized 
on a Bruker Ultraflex III matrix-assisted laser desorption ionization time of flight mass 
spectrometer (MALDI TOF/TOF) (Bruker Daltonics, Billerica, MA) using 2,5-dihydroxybenzoic 
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acid matrix (Sigma-Aldrich Corp., St. Louis, MO). The dried peptides were stored at room 
temperature.   
 2.2.2 Peptide Modifications (Me-Hg-Cys) 
 
 The synthesis of the cysteine modified peptides were effected  on a 0.1mmol scale with standard 
Fmoc(N-(9-fluorenyl)methoxycarbonyl)/tert-butyl chemistry on CLEAR-Amide Resin (Peptides 
International Inc; Louisville, Kentucky) by means of N-α-Fmoc-S-p-methoxytrityl-L–cysteine 
(Anaspec, Inc; Fremont, CA) coupled to the resin at C-terminus. The remainder of the synthesis, 
cleavage, post cleavage processing and characterization was performed as previously described, 
to generate bis(FLIVI)-K-KKKK-C-CONH2 and bis(FLIVIGSII)-K-KKKK-C-CONH2 
respectively
2
. Both cysteine adducted peptides were solubilized in water and reacted with 1 
equivalent of Methylmercury(II) iodide (Sigma-Aldrich Corp., St. Louis, MO) at pH 9.8 for 6 h 
at RT
5, 6
. The resulting solution was reduced in vacuo and subsequently lyophilized to generate 
the desired product. The percent methyl mercury incorporated was determined by measuring the 
concentration of free cysteine remaining after the coupling reaction. Unlabeled peptides of equal 
concentration served as the control.  Samples were treated with 4 mg/mL 5, 5’-Dithiobis-(2-
nitrobenzoic acid) (Sigma-Aldrich Corp., St. Louis, MO) in pH 8.2, 0.1 M phosphate buffer. The 
fully reacted sample absorbance values were measured at 412 nm on a CARY 50 Bio UV/Vis 
spectrophotometer (Varian Inc., Palo Alto, CA) using a 0.3 cm path length quartz cuvette (Starna 
Cells Inc., Atascadero, CA)
7
. The concentrations of the peptides were calculated using the molar 
extinction coefficient (ε) of phenylalanine residues (two per sequence) at 257.5 nm (195 cm-1 M-
1
)
8, 9
.  
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 2.2.3 Capsule Formation and Encapsulation 
 
 The bis(FLIVI)-K-KKKK and bis(FLIVIGSII)-K-KKKK peptides were dissolved individually 
in neat 2,2,2-Trifluoroethanol. In this solvent the peptides are helical and monomeric thereby 
ensuring complete mixing when combined. Concentrations were determined as diluted samples 
in water using the absorbance of phenylalanine as previously described. The bis(FLIVI)-K-
KKKK and bis(FLIVIGSII)-K-KKKK peptide samples were mixed in equimolar ratios to 
generate a final concentration of 0.1 mM, then dried in vacuo. The dried peptide samples were 
then hydrated to form capsules of desired concentration by the drop-wise addition of water. 
 2.2.4 S/TEM Sample Preparation 
 
The 30% Me-Hg capsules were prepared in a manner similar to that previously detailed, by co-
dissolving 0.7 mole equivalents of bis(FLIVI)-K-KKKK and bis(FLIVIGSII)-K-KKKK with 0.3 
mole equivalents of their respective cysteine containing Me-Hg labeled variants  in water, to a 
final concentration containing 0.1 mM  each of bis(FLIVI)-K-KKKK and bis(FLIVIGSII)-K-
KKKK. The dried peptide mixture was hydrated and allowed to stand for the indicted time 
intervals. Carbon Type A (15-25 nm) on 300 mesh support film grids with removable Formvar 
(Ted Pella Inc., Redding, CA) were immersed in chloroform to strip off the Formvar. These were 
subsequently negatively (hydrophilic) glow discharged
10
  at 5 mA for 20 s using a EMS 150 ES 
Turbo-Pumped Sputter Coater/Carbon Coater (Electron Microscopy Sciences, Hatfield, PA) - the 
carbon end of the grids being exposed to the plasma discharge making the carbon film 
hydrophilic and negatively charged, thus allowing easy spreading of aqueous suspensions. 
Capsule sample solutions (6 μL) were spotted on to grids and allowed to stand for 5 min, after 
which, excess solution was wicked off the grid with a Kimwipe™ tissue (Kimberly-Clark 
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Worldwide Inc., Roswell, GA) and allowed to air dry before loading it into the FEI Tecnai 
F20XT Field Emission Transmission Electron Microscope (FEI North America,  Hillsboro, 
Oregon) with a 0.18 nm STEM HAADF resolution and a 150X – 2306 x 106 X range of 
magnification
11
. Scanning transmission electron microscopy was carried out in the annular dark 
field mode with a single tilt of 17°.   
 2.2.5 Capsule Assembly Time Course Experiment 
 
 For the purposes of the time course experiment, 30% Me-Hg labeled 0.1mM, bis(FLIVIGSII)-
K-KKKK:bis(FLIVI)-K-KKKK  peptide capsules were prepared as before and spotted on 
negative glow discharged TEM grids at 0, 5, 25, 55 and 115 min post hydration to account for 
different time points (5,10, 30, 60 and 120 min respectively) during the process of assembly and 
fusion. For the purposes of the ‘0’ min time point; separate 2.5 μL 0.1mM bis(FLIVIGSII)-K-
KKKK and 2.5 μL 0.1 mM bis(FLIVI)-K-KKKK peptide samples were co-spotted on to the grid 
immediately upon hydration. After letting the sample stand on the grid for 5 min, the excess 
solution was wicked off, and the sample stained with 5 μL of an aqueous solution of 2% multi-
isotope Uranyl Acetate (Uranium bis(acetato-o)dioxo-dihydrate). This was then allowed to stand 
for 5 min, after which the excess stain was wicked off and the sample allowed to air dry before 
studying it under a FEI Tecnai F20XT Field Emission Transmission Electron Microscope in the 
previously specified manner.   
 2.2.6 Coarse-grained Modeling 
 
 A modified MARTINI force field
2, 12-14 
was used to describe the peptide and water molecules. 
The peptide backbone was represented by particle types for β secondary structure in the 
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hydrophobic segments, and coil particle types for the poly-lysine C-termini.  The thickness of the 
bilayer membrane and the average area of each peptide were calculated by performing 100 ns 
molecular dynamics (MD) simulations of pure model bilayers
2
.  In order for the bilayer to 
maintain the capsule curvature restriction, the outside leaflet requires a greater amount of the 
longer peptide (2:1= bis(FLIVIGSII)-K-KKKK:bis(FLIVI) -K-KKKK) than the inside leaflet 
(1:2 = bis(FLIVIGSII)-K-KKKK:bis(FLIVI)-K-KKKK ).  This ratio was based on preliminary 
results obtained using a titration assay that measured the solvent exposed thiols of added C-
terminal cysteines in the assembled capsules (data not shown).  To avoid overlap of peptides, the 
initial diameter (~28 nm) of the capsule is built larger than the experimentally observed 20nm. 
After 200 steps of energy minimization, a total of ~2 ns equilibrium simulations were carried out 
at 298K by incorporating several steps, in which harmonic potentials with gradually increasing 
strength was imposed on the peptides. All simulations were performed in CHARMM
14, 15 
on the 
Beocat Research Cluster at Kansas State University. VMD
16
 was used for preparation of the 
snapshots presented in this work.  
 2.2.7 Eosin Self-Quenching Curve 
 
 The fluorescence self-quenching of eosin was recorded by exciting 0, 10, 20, 40, 80, 90, 100, 
125, 150, 175, 200, 400, 600, 800, 1000, 1500 and 2126 μM aqueous concentrations of eosin Y 
(Sigma-Aldrich Corp., St. Louis, MO) at 490 nm and scanning for observed emissions from 495-
800 nm with a CARY Eclipse Fluorescence spectrophotometer (Varian Inc., Palo Alto, CA) 
(Scan rate: 600 nm/min; PMT detector voltage: 600 V; Excitation slit: 5 nm; Emission slit: 5 nm) 
using a 0.3 cm path length quartz cuvette. The resulting data was plotted as change in 
fluorescence intensity as well as change in λmax as a function of increasing eosin concentration. 
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Fluorescence intensity was seen to increase with eosin Y concentration until about 100 μM after 
which the trend was reversed, and the intensity of fluorescence proceeded to decrease such that 
the fluorescence intensity of 1.13 mM eosin Y solution was lower than that of a 10 μM solution 
of the same. A consistent red shift of λmax towards higher wavelengths was witnessed as a 
function of increasing concentrations of eosin Y – all consistent with the phenomenon of 
fluorescence self-quenching
17
.      
 2.2.8 Salt Wash Study 
 
The bis(FLIVIGSII)-K-KKKK:bis(FLIVI)-K-KKKK  peptide capsules (1.0 mM) were prepared 
using the protocol described earlier. One hour post hydration, the capsule containing solution 
was centrifuged at 14,000 x g in Amicon ultra- 0.5 mL, 30K molecular weight cut-off (MWCO) 
centrifugal units with regenerated cellulose filters (Millipore, Billerica, MA) using a Thermo 
Electron Legend 14 personal micro-centrifuge (Thermo Fisher Scientific Inc., Waltham, MA). At 
the conclusion of the spin, the removable-filter unit was inverted and placed in a fresh tube and 
spun at 2000 x g for 5 min to recover the remaining volume containing the capsules. The filtered 
preformed capsules were then incubated in a 2.13 mM aqueous eosin Y solution for 30 min to 
coat the exterior surface.  The capsule-eosin solution was filtered as described above to remove 
the excess eosin.  This solution was used as a control and its fluorescence measured by excitation 
at 490 nm and scanning for observed emissions from 495-800 nm with a CARY Eclipse 
Fluorescence spectrophotometer as previously described. The samples were split into two 
aliquots – the first aliquot was washed with water prior to centrifugal MWCO filtration and the 
other with an equal volume of 200 mM Sodium Trifluoroacetate (Na-TFA, Sigma-Aldrich Corp., 
St. Louis, MO) - and simultaneously subjected to the MWCO centrifugation process along with 
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isolation and re-solvation of the capsule containing solution. The samples were rescanned with 
the spectrometer.  Subsequently both samples were washed and centrifuged with just water 
multiple times and measured for eosin fluorescence after each centrifugal cycle. A cycle by cycle 
comparison between water washed capsules versus Na-TFA salt-water washed capsules 
demonstrated a significant decrease in the eosin fluorescence signal.  
 2.2.9 Capsule Fusion Study 
 
 1.0 mM and 20.0 mM dried samples of bis(FLIVIGSII)-K-KKKK:bis(FLIVI)-K-KKKK  
peptide capsules were made in a manner analogous to the one previously described. Both these 
samples were simultaneously solvated; the 1 mM sample with aqueous 2.13 mM eosin Y and the 
20.0 mM sample with water, and then allowed to stand for 30 min. All samples were subjected to 
three 30 kDa MWCO centrifugation process cycles starting with a 5 min incubation with 200 
mM Na-TFA salt, and then spin filtered. For the second and third centrifugation cycles, the eosin 
encapsulating capsules were washed with water prior to centrifugation. At the end, both the 1.0 
mM and 20.0 mM capsules were suspended in water; then immediately mixed in equal volumes; 
an aliquot of which was stored at 4˚C and the other placed in a 0.3 cm quartz cuvette and 
scanned for observed emission from 495-800 nm for 4 h with a scan every 5 min, upon excitation 
at 490 nm, with a CARY Eclipse Fluorescence spectrophotometer (Scan rate: 600 nm/min; PMT 
detector voltage: 800 V; Excitation slit: 5 nm; Emission slit: 5 nm). The 4˚C aliquot was scanned 
for change in fluorescence intensity at 6 h and 24 h intervals post mixing. The resulting data was 
plotted as change in intensity and change in λmax as a function of capsule fusion over time.  
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 2.2.10 Resizing the Capsules 
 
 A 0.1 mM solution of bis(FLIVIGSII)-K-KKKK:bis(FLIVI)-K-KKKK  peptide capsules with  
30% Me-Hg label was prepared in a manner as described previously and allowed to stand for 24 
h. A 6 µL aliquot was then loaded on a negatively glow discharged TEM grid, allowed to dry for 
5 min, with the excess solution wicked off and then air dried as previously described. The 24 h 
capsule solution was divided into two parts and then individually loaded in gas-tight syringes and 
extruded respectively through 0.1 µm and 0.03 µm 19 mm Whatman® Nuclepore™ Track-
Etched Polycarbonate Membranes using the Avanti® Mini-Extruder (Avanti Polar Lipids, Inc., 
Alabaster, AL); with at least 40 passes through the membrane per sample. The extruded samples 
were immediately spotted on negatively glow discharged TEM grids as with the 24 h sample and 
observed using a FEI Tecnai F20XT Field Emission Transmission Electron Microscope as 
before.  
 2.2.11 Beta Amyloid Test 
 
 Due to the speed at which these peptides adopt beta-structure in water we tested the sequences 
to see if they were amyloids using the Thioflavin T assay
13
. In the presence of amyloid proteins 
the fluorescence excitation and emission spectra of the dye are right shifted and enhanced 
emission at the new wavelength. 
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 2.3 Results and Discussion 
 
For this system to find utility as a drug delivery vehicle, there are numerous parameters requiring 
definition and control. These issues include — understanding capsule formation, controlling their 
size and tuning their stability.  The work presented here addresses the first two of these 
properties.  As shown in Fig. 2.2, at 24 h post hydration of the peptide mixture, we always 
observe a heterogeneous population of capsules. Preparing a defined and uniform size for these 
nano-capsules can be highly useful since size is known to play a key role in where these 
materials segregate when used in vivo
19-22
.  Studies were performed to track capsule formation 
by following the time course for the appearance of the smallest observable capsules. Knowing 
this size provides guidance regarding the size of molecules capable of being entrapped.  Even 
though larger capsules ultimately form due to fusion, this initial size likely limits the size of the 
trapped solutes added during the initial hydration step.   
To begin, the four peptides— bis(FLIVI)-K-KKKK,  bis(FLIVIGSII)-K-KKKK, bis(FLIVI)-K-
KKKK-C-Hg-Me and bis(FLIVIGSII)-K-KKKK-C-Hg-Me are dissolved in 100% 
trifluoroethanol (TFE).  A ratio of 1:1 is set for all of the FLIVI and FLIVIGSII peptides. The 
methyl mercury peptides are present at a 30 mole percent and provide an electron dense heavy 
metal for visualizing the structures in S/TEM. In the electron beam, the irradiated Hg emits an X-
ray at a specific energy that can be detected and is visualized as a white glow in the S/TEM 
images.  In TFE, the peptides adopt a helical conformation, indicating a monomeric state where 
they can mix completely.  When the solvent is removed in vacuo, the helical conformation is 
preserved as judged by the FTIR wave number for the Amide I band at 1650 cm
-1
 (data not 
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Figure 2.3. Time course of capsule formation. S/TEM images of Hg-Labeled peptides taken at the indicated times.  
Capsules contain 30% Me-Hg label in both the bis(FLIVI) and bis(FLIVIGSII) peptides at 0.1 mM. The images were captured 
using annular dark field mode and then inverted to produce the final image.  The scale bars at the bottom of the micrographs, in 
nm, are 200, 500, 200, 100, 200, and 500, for the 0, 5, 10, 30, 60 and 120 min time points, respectively.  
shown).  Water is added to the dry material and mixed.  In water, the peptides begin to adopt a 
beta (extended) conformation and start assembling.  Aliquots were removed at the indicated 
times and dried on copper grids for imaging. Representative images at various time points are 
shown in Fig 2.3.  At t = 0, the peptides (glowing elements) appear as amorphous structures. 
However by 5 min, the peptides appear as long micron length nano fibrils that occur in clusters. 
Incubation of the nano fibrils with Thioflavin T did not result in any spectral shift, suggesting 
that an absence of amyloid structure in these fibrils
23
.  The fibril structures appear to be transient 
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Figure 2.4. Snapshots of initial and equilibrated structures of capsule coarse-grained model. 
 The C-terminus group is represented by a yellow sphere; outside peptides are shown as light grey lines, with inside shown as 
cyan lines. The outside diameter of capsule is ~22nm 
and quickly break down by 10 min, when the first capsules also start to appear.  Small and 
relatively uniform capsules of ~20 nm in diameter begin to accumulate by 30 min.  By 60 min, 
the small capsules begin to associate and form what appears to be, ‘spheres of spheres’.  The 
associations lead to spheres with different diameters as judged by the dark centers associated 
with the alignment of the 20 nm capsules. By 120 min the small capsules are no longer visible 
and appear to have all fused to make well-defined capsules of the sizes ranging from 100 nm to 
greater than 500 nm. These results illustrate the dynamic nature of the self-assembly process of 
the capsules.  Based on the observation that 20 nm-sized capsules are the first to appear, we built 
a similarly sized capsule in silico using coarse-grained modeling to assess whether the peptide 
could be assembled into a bilayer that formed a stable capsule structure, and to illustrate a 
plausible three dimensional structure of the same.  The system was modeled using a modified 
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version of the MARTINI coarse-grained (CG) force field
2, 12, 13,
 
24 
that was implemented in 
CHARMM
14, 15
. The model capsule, shown in Fig. 2.4 left panel, contains a total of 1680 
peptides, of which 1080 and 600 peptides are on the outside and the inside leaflet, respectively. 
To overcome strain due to curvature, the outer leaflet contains 66.7% of the larger peptide while 
the inner leaflet contains only 33.3%.  After energy minimization and equilibration simulation, 
the capsule slightly contracted but well retained the overall structure.  The thickness of the 
outside leaflet is somewhat longer than that of the inside leaflet, due to higher ratio of the longer 
peptide. The inside volume of the capsule is about 760 nm
3
. The cross section of capsule (Fig. 
2.4, right panel) shows that the two peptide leaflets have minimal inter-digitation, which is 
consistent with earlier IR results showing parallel beta-sheets
2
.  Inter-digitated strands would 
result in anti-parallel IR signatures.       
As shown in Fig. 2. 2 the capsules continually grow in size at room temperature and 
reach sizes in excess of a micron by 24 h.  To further establish that the growth is through direct 
fusion of small capsules, we measured the dilution of the self-quenching fluorescent dye eosin Y 
(2 mM) as a function of the loaded capsules fusing with a large excess of capsules containing 
just water. The surface of the capsules is highly cationic due to the presence of all the lysine 
residues and it adsorbs anionic compounds such as 5,6-Carboxyfluorescein in a saturable 
manner
2
.  Eosin Y is also anionic at neutral pH and can interact strongly with the outer surface of 
the capsules. The following protocol was developed to displace any surface-bound anionic 
molecules without compromising the integrity of the capsules or releasing their contents.  This 
protocol involves first washing the eosin Y loaded capsules with 200 mM Na-TFA at neutral pH, 
followed by two water washes.  The TFA
-
 salt is a strong counter ion and easily displaces most 
of the dye in the first wash.  Water alone was also effective but required 5 washes to reach the 
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1% residual bound level.  Each wash takes additional time that, in turn, affects the size of the 
capsules as shown in the next set of experiments.  Use of the strong counter ion will also allow 
us to wash capsules free of negatively charged endotoxin (LPS), which can elicit innate immune 
responses in vivo. Eosin bound to the outer 
surface of preformed capsules shows an 
emission maximum at 535 nm, which 
corresponds to free eosin, indicating that its 
bound concentration is sufficiently low to 
prevent self-quenching.  After filtering the 
capsules containing 30% Me-Hg with the 
0.22 μ polycarbonate filter and the previously 
described washing steps, a sample was 
removed for imaging by TEM, with a 
representative image shown in Fig. 2.5.  Most 
of the capsules are in the 20-30 nm in size with several beginning to associate to form larger 
structures.  
Being able to wash the surface clean of the anionic eosin Y allows us to assess the 
behavior of encapsulated material.  At 2.0 mM the self-quenching dye has a λmax of 522 nm with 
an intensity just 22% of its maximum unquenched concentration, which has a red shifted λmax of 
550 nm. By mixing a small percentage of the salt/water washed eosin filled capsules with an 
excess of water filled capsules (1:20), the initial fusions lead to a rapid dilution of the dye.  As 
shown in Fig. 2.6A fluorescence intensity increases with a concomitant red shift at the earliest 
times. The fluorescence intensity increases as a consequence of the decreased self-quenching 
Figure 2.5. TEM image of Me-Hg labeled washed capsules 
just prior to fusion experiment. 
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associated with each fusion event.  The reaction was allowed to proceed for 235 min. At the end 
of the reaction the sample was salt washed and passed through a 30 kDa filter to measure any 
released dye.  No significant fluorescence was observed, indicating that the capsules remained 
intact throughout the experiment. Another control with all eosin-loaded capsules and no water 
capsules showed no increase in fluorescence over the same time frame. Fig. 2.6B is a derivative 
plot that shows the percent fluorescence increase at a given time point relative to the maximal 
fluorescence intensity observed. Because of the red shift that occurs during this process, the 
plotted intensity values were taken at the individual λmax values for each time point.  An apparent 
equilibrium is reached around 3 h.  This endpoint represents the time where all the capsules have 
attained equivalent entrapped concentrations.  Further fusions will continue as judged by EM 
studies; however there is no discernible change in the entrapped concentration of the larger 
structures.  
 The insert to Fig. 2.6A shows the fluorescence for an aliquot of the fusion sample stored for 6.5 
h at 4° C. Note that the fluorescence spectrum is similar to that of the earliest time point in Fig. 
2.6A. The 6.5 h time window is well beyond the duration needed for the capsules to reach a 
maximum fluorescent intensity at room temperature. This result suggests that lowering the 
temperature to 4° C is sufficient to prevent the capsules from changing size through fusion; thus 
providing for a convenient means to control the capsule size. The cessation of fusion at the lower 
temperature is most likely a kinetic effect, with the process slowed down enough to afford better 
size control. The fusion experiment also provides further evidence that the capsules are hollow 
and water filled.  Given the amphiphilic nature of the peptides, the most reasonable explanation 
of how a water-filled capsule could form is that they behave like diacyl phospholipids and 
assemble into bilayers thereby creating a hydrophilic lined hollow space (see Fig. 2.4).  The A. 
B. C. 
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capsule’s propensity to fuse at room temperature tends to result in a heterogeneous population 
with a significant range of sizes on the order of microns. This property is undesirable for 
potential applications as drug delivery vehicles due to strict size dependent cellular uptake in 
vivo.  Liposomes made from diacyl phospholipids are easily resized to uniform diameters using 
membrane extrusion filters.  Given the behavioral similarities of the peptide capsules to lipid 
vesicles, applying membrane extrusion to resize the peptide capsules seems appropriate.  In the 
resizing experiment the Me-Hg labeled peptides were mixed and allowed to fuse for 24 h at RT.  
The size distribution observed is typical for a 24 h sample. At that point an aliquot of the peptide 
capsule solution was extruded back and forth numerous times through a 100 nm membrane filter 
followed by a final extrusion using a 30 nm membrane filter.  Immediately after repeated 
extrusions through each membrane, a small volume was spread on a TEM grid and dried. The 24 
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Figure 2.6 Capsule Fusion Study.  
Salt washed eosin Y trapped capsules were mixed with water filled capsules in the ratio of 1:20 at RT. A) Five min fluorescence 
scans of eosin encapsulated vesicles spectra were taken at 5 min intervals for 235 min. The inset shows spectrum of sample stored 
at 4° C for 6.5 h. The units shown are identical to those in panel A.  B)  Measured maximum eosin fluorescence intensity as a 
function of time during the fusion reaction.  The t = 0 represents quenched value of salt washed eosin encapsulate in the capsules 
(2.0 mM). The data was fitted to a second order exponential with the error bars representing the SEM with n = 3.   
 
A. 
B. 
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hr sample (Fig. 2.7A) shows the larger peptide capsules normally seen at this time point.  The 
100 nm, extruded sample (Fig. 2.7B) shows a mixed population of heterogeneous capsules that 
range in size from 20 to 60 nm in diameter.  Few if any 100 nm capsules have ever been 
observed using this technique suggesting that this size is disfavored over smaller ones.  The 30 
nm filter extruded capsules (Fig. 2.7C) are observed as a relatively homogeneous population 
with most capsules ranging in diameter from 20-30 nm.  The 30 nm pore size is the smallest 
available through our vendor and attempting to go even smaller may not be feasible since our 
capsules assemble as 20 nm structures.  After extruding, if the capsules are allowed to sit for any 
appreciable time at RT they rapidly begin re-fusing (data not shown). In the absence of 
refrigeration, we envision using the samples immediately after the extrusion process to ensure 
size uniformity. Upon dilution in the blood stream or tissues, the likelihood of fusion is remote.  
This study clearly shows that regulating the size of the capsules is straightforward. 
Figure 2.7 Filter Resizing Study.  
TEM images are shown for the A) 24 h control. B) 100 nm membrane extruded material and C) 30 nm membrane extruded 
material. All figures are displayed as inverse images 
A B C 
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 2.4 Conclusion 
 
In this report we characterized several properties of peptide capsules that form through the self-
assembly of two branched peptides, bis(FLIVI)-K-KKKK and bis(FLIVIGSII)-K-KKKK (Fig. 
1).  The assembly process is initiated with the formation of nano-fibrils that condense into 20 nm 
water filled spheres. It is during this phase that solutes can be encapsulated.  Washes with strong 
counter-ions followed by water washes remove any surface bound materials without disrupting 
the loaded capsules. Subsequently the nano capsules begin to associate to form spheres of 
spheres that ultimately fuse to form larger capsules.  The larger capsules continue to fuse and 
grow to more than micron diameter structures.  Fusion kinetics were followed by observing the 
dilution of the encapsulated self-quenching eosin Y dye, as dye labeled capsules combined with 
an excess of water containing capsules. The capsules are easily resized to form homogeneous 
populations in the 20-30 nm range by extruding them through polycarbonate filters with 
controlled pore sizes.  In addition, dropping the temperature to 4° C suspends the fusion process 
allowing the production of uniform and stable peptide capsules that could be used in vivo. 
 2.5 Abbreviations 
 
TFA, Trifluoroacetic acid; Na-TFA, Sodium Trifluoroacetate; TFE, 2,2,2 – Trifluoroethanol; 
S/TEM, Scanning Transmission Electron Microscopy; FTIR, Fourier Transform Infrared 
Spectroscopy; MWCO, Molecular Weight Cut Off; MD, Molecular Dynamics; SEM, Standard 
Error of Mean.  
 
81 
 
 
 2.6 Acknowledgement 
This is publication 14-071-J from the Kansas Agricultural Experiment Station. Partial support for 
this project was provided by PHS-NIH grant # RO1 074096 (to J.M.T) and the Terry Johnson 
Cancer Center for summer support (for P.S. and S.G.) 
82 
 
 
 
 2.7 References
                                                 
1. Couvreur, P. Nanoparticles in drug delivery: Past, present and future. Advanced Drug 
Delivery Reviews 2013, 65 (1), 21–23. 
 
2. Gudlur, S., Sukthankar, P., Gao, J. Avila, L.A., Hiromasa, Y., Chen, J., Iwamoto, T., 
Tomich, J.M. Peptide Nanovesicles Formed by the Self-Assembly of Branched 
Amphiphilic Peptides. PLOS ONE. 2012 7 (9) e45374.   
 
3. Kempe M. and Barany G. CLEAR: A Novel Family of Highly Cross-Linked Polymeric 
Supports for Solid Phase Synthesis, J. Am. Chem. Soc. 1996 118,7083-7093. 
 
4. Iwamoto, T., Grove, A., Montal, M.O., Montal, M. and Tomich, J.M. Chemical synthesis 
and characterization of peptides and oligomeric proteins designed to form transmembrane 
ion channels. Int. J. Pept. Protein Res. 1994 43:597-607.  
 
5. Gruen, L.C. Stoichiometry of the reaction between methyl mercury (II) iodide and soluble 
sulphides. Anal. Chim. Acta. 1970 50: 299-303.  
 
6. Forbes W.F., Hamlin C.R. Determination of –SS and –SH groups in proteins. I. A 
reassessment of the use of methylmercuric iodide. Canadian Journal of Chemistry. 1968 
46, 3033-3040. 
 
7. Anderson, W.L., Wetlaufer, D.B. A new method for the disulfide analysis of peptides. 
Analyt. Biochem. 1975 67, 493-502  
 
83 
 
 
                                                                                                                                                             
8. Chen, R. F. Measurements of absolute values in biochemical fluorescence spectroscopy. J. 
Research National Bureau Standards. 1972 76A (6), 593-606.  
 
9. Sponer H. Remarks on the Absorption Spectra of Phenylalanine and Tyrosine in 
Connection with the Absorption in Toluene and Paracresol.  J. Chem. Phys. 1942 10, 672.  
 
10. Aebi, U. and Pollard, T.D. A glow discharge unit to render electron microscope grids and 
other surfaces hydrophilic. J. Electron Microsc. Tech. 1987 7, 29-33.  
 
11. Utsunomiya, S. and Ewing, R.C. Application of High-Angle Annular Dark Field Scanning 
Transmission Electron Microscopy, Scanning Transmission Electron Microscopy-Energy 
Dispersive X-ray Spectrometry, and Energy-Filtered Transmission Electron Microscopy to 
the Characterization of Nanoparticles in the Environment. Environ. Sci. Technol. 2003 37, 
786-791.  
 
12. Monticelli L, Kandasamy SK, Periole X, Larson RG, Tieleman DP, and Marrink SJ. The 
MARTINI coarse-grained force field: Extension to proteins. J. Chem. Theory. and Comput. 
2008 4 (5),819–834.  
 
13. LeVine, H., 3rd. Thioflavine T interaction with synthetic Alzheimer’s disease β -
amyloidpeptides: Detection of amyloid aggregation in solution Protein Science. 1993 2, 
404-410.  
 
14. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M. 
CHARMM - A program for macromolecular energy, minimization, and dynamics 
calculations. J. Comput. Chem. 1983 4 (2), 187–217. 
 
84 
 
 
                                                                                                                                                             
15. Brooks BR, Brooks CL, Mackerell AD, Nilsson L, Petrella RJ, Roux B, Won Y, Archontis 
G, Bartels C, Boresch S, Caflisch A, Caves L, Cui Q, Dinner AR, Feig M, Fischer S, Gao J, 
Hodoscek M, Im W, Kuczera K, Lazaridis T, Ma J, Ovchinnikov V, Paci E, Pastor RW, 
Post CB, Pu JZ, Schaefer M, Tidor B, Venable RM, Woodcock HL, Wu X, Yang W, York 
DM, Karplus M. CHARMM: The biomolecular simulation program. J Comput Chem. 2009 
30 (10), 1545–1614. 
 
16. Humphrey W, Dalke A, Schulten K. VMD: Visual molecular dynamics. J Mol Graph 1996 
14 (1), 33–38. 
 
17. Bellin, J.S. and Oster, G. Photoreduction of Eosin in the Bound State. J. Am. Chem. Soc. 
1957 79, 2461-2464.  
 
18. LeVine, H., 3rd. Thioflavine T interaction with synthetic Alzheimer’s disease β -
amyloidpeptides: Detection of amyloid aggregation in solution Protein Science. 1993 2, 
404-410.  
  
19. Sun X, Rossin R, Turner JL, Becker ML, Joralemon MJ, Welch MJ, Wooley KL. An 
Assessment of the Effects of Shell Cross-linked Nanoparticle Size, Core Composition, and 
Surface PEGylation on in Vivo Biodistribution. Biomacromolecules. 2005 6(5), 2541–
2554. 
 
20. Stolnik S, Illum L, Davis SS. Long circulating microparticulate drug carriers. Adv Drug 
Deliv Rev. 1995 16 (2–3), 195–214.  
 
21. Huang S-D. Stealth nanoparticles: high density but sheddable PEG is a key for tumor 
targeting. J Control Release. 2010 145(3), 178–181. 
 
85 
 
 
                                                                                                                                                             
22. Decuzzi P, Godin B, Tanaka T, Lee SY, Chiappini C, Liu X, Ferrari M. Size and shape 
effects in the biodistribution of intravascularly injected particles. J Control Release. 2010 
141(3), 320–327. 
 
23. Groenning, M. Binding mode of Thioflavin T and other molecular probes in the context of 
amyloid fibrils—current status J Chem Biol. 2010 3(1),1-18. 
 
24. Marrink SJ, Risselada HJ, Yefimov S, Tieleman DP, de Vries AH. The MARTINI force 
field: Coarse grained model for biomolecular simulations. J Phys Chem B. 2007 111 
(27),7812–7824 
  
 
 
Chapter 3 - Branched Amphiphilic Peptide Capsules: Cellular 
Uptake and Retention of Encapsulated Solutes  
This chapter has been reproduced in its current format with permission from ‘Sukthankar, P., Avila, LA; 
Whitaker, S.K; Iwamoto, T; Morgenstern, A; Apostolidis, C; Liu, K; Hanzlik, R.P., Dadachova, E; 
Tomich, J.M. (2014) Branched Amphiphilic Peptide Capsules: Cellular Uptake and Retention of 
Encapsulated Solutes. Biochimica et Biophysica Acta – Biomembranes. 1838 (9), 2296-305 © 2014 
Elsevier. 
 3.1 Introduction 
 
There is a great deal of interest in the area of nanoparticle-mediated therapies. Nano-
carrier mediated targeted cellular therapy is a rapidly growing area of research for the treatment 
of malignant and infectious diseases. Particle emitting radioisotopes complemented with a 
targeting moiety are being recognized as some of the most promising cytotoxic candidates for the 
treatment of cancerous tumors.  Nano-particles enjoy distinct advantages in the delivery of drug 
payloads. Their nano sizes enable them to be directly injected into systemic circulation
1,2
 and 
afford them longer circulating times.
3,4
 Furthermore, the circulating time can be increased by the 
surface modification of nanoparticles with hydrophilic moieties such as polyethylene glycol,
5,6,7 
and nanoparticles composed of biodegradable polymers can be tuned to release their drug 
payload in a controlled fashion; either by micelle dissociation, polymer degradation, diffusion or 
in combination.
8,9,10
 Mechanisms of nanoparticle internalization into cells are influenced by their 
physiochemical properties. Biocompatible nanocomposites such as lipid based carriers 
(liposomes and micelles); polymeric vesicles designed from amphiphilic block co-polymers
11
 
such as polyethylene glycol-polylactic acid (PEG-PLA) and PEG-polycaprolactone (PEG-
PCL);
12
 nanocapsules;
13,14
 Bola-amphiphiles (amphiphilic molecules possessing two polar heads 
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on both sides of an aliphatic chain) such as aminoundecyltriethoxysilane (AUT);
15,16 
and carbon 
nanotubes
17
 have been studied for their efficacy as delivery systems.    
Liposomes are preferred over other delivery systems due to their ability to encapsulate 
both hydrophobic and hydrophilic contents. They can also be modified with respect to their fatty 
acid and head group composition, and surface alterations to modulate drug release and target 
affinity.  Some of the issues associated with liposomes such as degradation by hydrolysis, 
oxidation, sedimentation, aggregation, or fusion during storage are being addressed with the 
development of niosomes
18
 and proniosomes,
19,20
 however further testing is need to fully 
establish safety and efficacy.  
The selection of any nanoparticle for a specific pharmacological use is contingent on its 
mechanism of cellular uptake and intracellular trafficking.
21
 In addition, concerns relating to the 
successful encapsulation of cargo, stability, specificity, bio-reactivity, biodegradability and 
toxicity are also relevant. The ability to release their contents is not necessarily a requirement for 
certain cargos. In the case of Targeted Alpha particle Therapy (TAT) - a treatment modality for 
metastatic cancer and infectious diseases - the advantageous properties of 
225
Ac 
22
 are partially 
offset by its systemic toxicity
23
 due to the potential accumulation of its daughter nuclides in off-
target sites. Utilization of alpha-emitters requires containment systems that allow the high-energy 
alpha particles to penetrate target tissues while retaining the radionuclide and its daughter 
isotopes. This poses a considerable challenge since the energy (5 to 8 MeV / 
225Ac α-particle) 
released is sufficient to disrupt the integrity of most traditional nano-carriers. This property has 
hampered the development of 
225
Ac as a viable radio-therapeutic agent.
24,25
 The current use of 
chelating agents for 
225
Ac radioimmunotherapy has been challenging as a consequence of the 
poorly defined coordination chemistry of Ac(III), owing to the lack of stable isotopes to enable 
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routine chemical analysis.
26
  Chelators like EDTA, DTPA, DOTA and PEPA
27,28
 have been used 
to complex with 
225
Ac with varying degrees of success. On the other hand the potential of the 
otherwise promising 
225
Ac -HEHA macrocylic complex in radiotherapy
29
 has been marred by 
instability, due to the coordinated 
225
Ac radionuclide decaying into its daughter isotopes.
26 
 
Efforts to develop bifunctional chelators capable of stably binding 
225
Ac to antibodies as 
well as competently containing resulting daughter nuclides at target sites, has not been 
successful.  This has forced the development of sterically stabilized pegylated liposomes
30
 and 
stable pegylated phosphatidylcholine-cholesterol liposomes
31 
for radioimmunotherapeutic 
applications despite the inherent instability and retention based limitations associated with 
traditional liposomal systems.  Moreover, novel liposomal carriers such as MUVELs 
(Multivesicular liposomes) - involving the passive entrapment of small vesicles into large 
liposomes - have been designed to enhance the targeting capabilities and the  retention of alpha 
particle emitting daughters of 
225
Ac, in an effort to better utilize their positive cytotoxic 
potential.
32
 All these liposome directed encapsulation techniques are however lengthy and 
tedious;
30-32
 and  involve considerable preparation times that include complex formation of 
225
Ac 
with a chelate, annealing procedures, extended waiting periods, extrusions and centrifugation; 
apart from addressing various issues to counter physiochemical problems such as possible 
Figure 3.1 Bilayer Forming Branched Amphiphilic Peptide Sequences 
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oxidation due to alpha emissions
33,34
 and beta
35
 and gamma
36
 radiation. The work presented 
herein presents an alternative and flexible means of radionuclide encapsulation that is easy to 
perform and generates stable in vivo constructs.   
Peptide based nano-assemblies show promise as nano-delivery vehicles for the safe, 
targeted transport of drugs to specific tissues and organs, with minimal off target accumulation
37
 
by overcoming some of the problems associated with traditional lipid and viral based delivery 
systems. BAPCs (Branched Amphiphilic Peptide Capsules) 
are a new class of self-assembling peptide nano-capsular 
spheres
38,39
 formed during the cooperative association of a 
mixture of two (15-23 residue) poly-cationic branched 
amphiphilic peptides (Fig 3.1).  The hydrophobic core 
sequences are derived from an internal fragment of 
CaIVS3, the human dihydropyridine sensitive L-type 
calcium channel segment.
,40
 The ability of the BAPCs to 
form bilayer-delimited spheres (Fig 3. 2) capable of trapping solutes is a consequence of the 
unique characteristics of its constituent peptides - bis(FLIVI)-K-K4 and bis(FLIVIGSII)-K-K4, 
which reversibly transition from an alpha helical conformation in 2,2,2-Trifluoroethanol, to a 
beta sheet in water.
38,39
 The branch point lysine in the sequence orients the two peptide segments 
at ~90˚ angle, mimicking the geometry of diacyl phospholipids. Coarse grain molecular dynamic 
simulations,
 38
 consistent with S/TEM analysis, indicate the presence of a single capsular bilayer 
(3 - 4 nm) comparable to that of a phospholipid system, which is below the discerning resolution 
of electron microscopy. 
Figure 3.2 S/TEM image of BAPCs. 
They containing 30% Hg label and imaged at 2 
h post hydration w/ negative glow discharge 
and uranyl acetate staining prepared as 
previously described.39  
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Recently, we described how the flexible BAPCs possess many of the properties of 
phospholipid vesicles, such as fusion, solute encapsulation and an ability to be resized by 
membrane extrusion through polycarbonate filters with defined pore sizes.
39
 We also 
demonstrated several biophysical characteristics including, their mode of assembly, high 
thermodynamic stability, and their kinetics of fusion. The BAPCs can – like their lipid 
counterparts – be both resized, and maintained there by placing them at 4° C.  The versatility of 
these peptides to self-assemble enables us to tag individual monomers with ligands and 
molecular markers for a variety of analytical and functional assays, making these constructs 
particularly suited as biocompatible vehicles for the targeted delivery of cargo into the cells.  In 
this report, we study the stability, cellular uptake, load capacity, retention within biological 
environments for extended periods of time, tolerance to a radionuclide load, biodistribution and 
capacity to maintain their structural integrity even when subjected to alpha particle emissions.  
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 3.2 Materials and Methods 
 3.2.1 Peptide Synthesis 
 3.2.1.1 Synthesis of bis(FLIVI)-K-K4 and bis(FLIVIGSII)-K-K4 variants  
 
Peptides were synthesized using solid phase peptide chemistry on 4-(2,4-
dimethoxyphenyl-Fmoc-aminomethyl) phenoxyacetyl-norleucyl-cross-Linked Ethoxylate 
Acrylate Resin
41
  (Peptides International Inc; Louisville, Kentucky) on a 0.1 mmol scale using 
Fmoc (N-(9-fluorenyl) methoxycarbonyl)/tert-butyl chemistry on an ABI Model 431 peptide 
synthesizer (Applied Biosystems; Foster City, CA).  This resin yields the carboxyamide at the C-
terminus upon cleavage. The Fmoc amino acids were obtained from Anaspec, Inc (Fremont, 
CA). The branch point was introduced by incorporating N
α,ε
 di-Fmoc-L-Lysine in the fifth 
position from the C-terminus. Deprotection of the two Fmoc protecting groups leads to the 
generation of two reactive sites that allow for the generation of the bifurcated peptide branch 
point. This enables the simultaneous addition of either of the hydrophobic tail segments, FLIVI 
and FLIVIGSII to the common hydrophilic oligo-Lysine segment by the stepwise addition of 
Fmoc amino acids.
42
  The N-termini of the peptide were acetylated on the resin using Acetic 
Anhydride / N, N-Diisopropylethylamine / 1-Hydroxybenzotriazole prior to cleavage. The 
peptide was cleaved from the resin using Trifluoroacetic acid (TFA)/H2O (98:2, v/v) for 90 min 
at RT.  The released peptide product was washed 3× with diethyl ether and re-dissolved in water 
prior to lyophilization.  The water used throughout this study is deionized, reverse osmosis 
treated and then distilled.  The RP-HPLC purified peptides were dried in vacuo and characterized 
on a Bruker Ultraflex III matrix-assisted laser desorption ionization time of flight mass 
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spectrometer (MALDI TOF/TOF) (Bruker Daltonics, Billerica, MA) using 2,5-dihydroxybenzoic 
acid matrix (Sigma-Aldrich Corp., St. Louis, MO). The dried peptides were stored at RT. 
 
 3.2.1.2 Synthesis of Rhodamine labeled Peptide bis(FLIVI)-K-K4 
 
‘Dye labeled peptides’ were synthesized by solid phase peptide chemistry on a 0.1 mmol 
scale on MBHA
43
 (4-methylbenzhydrylamine) resin (Anaspec, Inc., Fremont, CA). After 
coupling the first amino acid (N
α
 - Fmoc - N
ε
 -t- Boc - L – lysine), the resin was treated with 
TFA/Dichloromethane/ H2O (80:18:2, v/v/v) for 30 min to remove the side chain t-
butoxycarbonyl protecting group; exposing the lysyl ε amine. This was then manually reacted 
with the N-Hydroxysuccinimide ester of Rhodamine B (Sigma-Aldrich Corp., St. Louis, MO) in 
presence of N-N-Diisopropylethylamine to generate the label on the C-terminal Lysine.  The N
α
 - 
Fmoc was de-protected and the remainder of the synthesis was carried out as indicated earlier. 
The labeled peptide was cleaved from the resin using standard HF cleavage protocol.
44,45
 The 
concentrations of all peptides were calculated using the molar extinction coefficient (ε) of 
phenylalanine residues (two per sequence) at 257.5 nm (195 cm
-1
 M
-1
)
46,47
 on a CARY 50 Bio 
UV/Vis spectrophotometer (Varian Inc., Palo Alto, CA) using a 0.3 cm path length quartz 
cuvette (Starna Cells Inc., Atascadero, CA). The Rhodamine B adducted sequences were 
incorporated at a prescribed mole percentage along with the unlabeled bis(FLIVI)-K-K4 
sequence of the BAPCs and utilized in fluorescence experiments.         
 3.2.1.3 Synthesis of Pep-1 
Pep-1 (Ac-KETWWETWWTEWSQPKKKRKV-CONH-(CH2)2-SH) was synthesized by 
solid phase peptide synthesis using Fmoc-Cysteamine-SASRIN
™
 resin, 0.6 meq/gm, (Bachem, 
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Torrance, CA) on an Applied Biosystems 431A Peptide Synthesizer at a 0.1 mmol scale using 
standard Fmoc(N-(9-Fluorenyl)methoxycarbonyl)/tert-butyl chemistry as described.
42
 The Fmoc 
amino acids used for the synthesis were obtained from Anaspec, Inc (Fremont, CA). The N-
terminal amino group was acetylated and the peptide was cleaved from the resin using 
TFA/water/triisopropylsilane (94:4:2, v/v/v) for 90 min at RT to generate the C-terminal thiol. 
The peptide product was washed 3× with diethylether and redissolved in water prior to 
lyophilization. This was then purified using Reversed Phase - HPLC with 0.1% TFA / H2O and 
0.1%TFA / 90% Acetonitrile, as the binary solvent system. The purified peptide was dried in 
vacuo and characterized on a Bruker Ultraflex III matrix-assisted laser desorption ionization time 
of flight mass spectrometer (MALDI TOF/TOF) (Bruker Daltonics, Billerica, MA) using α-
Cyano-4-hydroxycinnamic acid matrix (Sigma-Aldrich Corp., St. Louis, MO). The dried 
peptides were stored at RT.  
 3.2.2 Capsule Formation and Encapsulation 
 
The bis(FLIVI)-K-KKKK and bis(FLIVIGSII)-K-KKKK peptides were dissolved 
individually in neat 2,2,2-Trifluoroethanol (TFE, Sigma-Aldrich Corp, St. Louis MO). In this 
solvent the peptides are helical and monomeric thereby ensuring complete mixing when 
combined. Concentrations were determined as diluted samples in water using the absorbance of 
phenylalanine as described in section 3.2.1.2. The bis(FLIVI)-K-KKKK and bis(FLIVIGSII)-K-
KKKK peptide samples were mixed in equimolar ratios to generate a fixed calculated 
concentration of 0.1 mM in the final volume(s), then dried in vacuo. The dried peptide samples 
were then hydrated to form capsules of desired concentration by the drop-wise addition of water.  
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 3.2.3 HeLa Cell Culture 
HeLa cells were obtained from Dr. Stella Y. Lee’s laboratory (Division of Biology, 
Kansas State University) and grown in Dulbecco’s minimum essential medium (Life 
Technologies, Grand Island, NY) with 10 % fetal bovine serum. Cell cultures were passaged 
every 3rd-4th day by trypsinizing them using TrypLETM Express (Life Technologies, Grand 
Island, NY) and were kept in a humidified incubator at 37°C and 5% CO2. The medium was 
replaced every 72 h with no addition of antibiotics. 
 3.2.4 Cellular uptake of Branched Amphiphilic Peptide Capsules   
 3.2.4.1 Cellular Uptake and Lysosomal co-localization of BAPCs  
 
HeLa cells were seeded on confocal 35 mm clear petri-dishes at a density of1x10
4
 
cells/mL and grown to ~ 80% confluence and washed twice with PBS. Thereafter, 750 μl of 
fresh medium was added along with a 250 μl aqueous suspension of BAPCs incorporating 30% 
Rhodamine B label on the bis(FLIVI)-K-K4 peptide.   The final concentration of BAPCs was 50 
μM. The cells were incubated for 4 h at 37°C at 5% CO2 . After a PBS wash, the cells were then 
incubated for 5 min with LysoTracker® Green DND-26 probe (Molecular Probes, Carlsbad, CA) 
at a final concentration of 75 nM and washed again with PBS. Cells were observed and images 
acquired using a Zeiss LSM 510 Meta Confocal Microscope (Carl Zeiss, Gottingen, Germany).  
           
 3.2.4.2 Cellular Uptake of BAPCs at different Temperatures  
 
HeLa cells were seeded on 12 mm culture dishes at a density of 1x10
4
 cells/mL and 
grown to ~60% confluence. Fresh media at 4°C and 37°C respectively was added to the cells. 
Immediately thereafter, 100 µL of media was replaced by a solution of BAPCs prepared with 30 
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% Rhodamine B label on the bis(FLIVI)-K-K4 peptide. The final peptide concentration was 100 
µM and cells were incubated for 2 h at 4 °C and 37 °C respectively. Cells were fixed with 3.7% 
formaldehyde at RT for 2 h, followed by a wash in PBS-T (PBS solution containing 1% Triton 
X-100) (Fisher Scientific LLC, Pittsburgh, PA). Subsequently, cells were incubated with Mouse 
Anti-β-tubulin mAb antibody,48 2G7D4 (Gen Script USA Inc., Piscataway, NJ) at dilutions of 
1:1000 for 6 h. After three washes with PBS-T, the tissues were incubated 3 h with secondary 
antibody, Alexa Fluor
®
 488 goat anti-mouse IgG (Molecular Probes, Carlsbad, CA). Stained 
tissues were washed again with PBS-T and mounted in glycerol containing the nuclear stain 
DAPI (2 µg mL
-1
; Sigma-Aldrich Corp., St. Louis, MO). Cells were observed and images 
acquired using a Zeiss LSM 510 Meta Confocal Microscope (Carl Zeiss, Gottingen, Germany).  
 3.2.5 Fluorescence and confocal microscopy 
 
Images for Figure 3.2 were taken using a LSM 700 laser scanning confocal microscope 
(Carl Zeiss, Gottingen, Germany) and for Figure 3. 3 were taken using a Zeiss LSM 510 Meta 
Confocal Microscope (Carl Zeiss, Gottingen, Germany).  The cell boundary and structure was 
visualized using "Differential interference contrast microscopy (DIC)". All measurements, 
except where stated, were performed with un-fixed, live cells.    
 3.2.6 Protein Uptake Studies 
 
HeLa cells were seeded into 11 mm wells (48-well plate) at a density of 1x10
4
 cells/well 
and grown to roughly 60% confluence. Immediately thereafter, fresh media was added to the 
cells and 100 µL of the same was replaced by a solution of BAPCs containing Tcytc (5(6)-
TAMRA labeled cytochrome c) and TRNaseA ((5(6)-TAMRA labeled RNase A) respectively. A 
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parallel experiment was performed following the same protocol, but with Pep-1 + Tcytc and Pep-
1 + TRNaseA respectively, as positive controls for protein uptake. The final concentrations of 
peptides in each well were; 50 μM for BAPCs and for 5 μM for Pep-1. Cells were incubated for 
3 h, washed twice with pre-warmed PBS prior to taking epifluorescence images. Subsequently, 
cells were trypsinized and allowed to re-attach for 18 h and images re-acquired. 
 3.2.7 Long term cellular uptake study 
 
HeLa cells were seeded on 11 mm culture dishes at a density of 1x10
4
 cells/well  and 
grown to ~60% confluence. Immediately thereafter, 100 µL of media was replaced by a solution 
of BAPCs containing 30 % Rhodamine B adducted bis(FLIVI)-K-K4; with a final BAPC 
concentration of 100 µM. The cells were incubated at 37°C in an atmosphere of 5% CO2 in air. 
The culture was kept for 14 days after which confocal microscopy images were acquired as 
previously detailed. Cells were trypsinized twice during this period and the media was replaced 
every 72 h.   
 3.2.8 Encapsulation and retention of 225Ac in BAPCs.  
 
The bis (FLIVIGSII)-K-K4 and bis (FLIVI)-K-K4 peptides (100 µM ea.) were mixed in 
their monomeric conformation in 50% TFE/H2O to ensure proper mixing and then dried. The 
dried peptides were rehydrated using a 0.15 M ammonium acetate buffer containing 100 Ci 
225
Ac with ligand DOTA (tetraazacyclododecane-1,4,7,10-tetraacetic acid; Macrocyclics, Dallas, 
TX) and allowed to incubate for 2 h. Non-encapsulated radionuclide was removed by spin 
filtering the mixture with a 30-kDa cut-off membrane filter followed by several buffer washes. 
At the indicated time points, aliquots of BAPCs were withdrawn, separated from supernatant on 
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the 30-kDa cut-off membrane filter and the 
225
Ac activity remaining in the BAPCs was 
quantified immediately and afterwards at 4 h to account for the daughters decay, on a 1282 
Compugamma CS, Universal Gamma Counter (LKB Wallac, Geithersburg, MD) equipped with 
the multi-channel analyzer using 150-600 keV energy window for 
225
Ac and its daughters. 
 3.2.9 Cellular uptake of the BAPC-encapsulated 225Ac into CasKi cells. 
CasKi cells (human metastatic cervical cancer cell line) were obtained from ATCC and 
grown as previously described.
49
  BAPCs carrying 
225
Ac were then used immediately to treat 
cells, to ensure that the BAPCs diameters remain within the 50-200 nm range. Samples of 10
6
 
cells in triplicate were mixed with BAPC encapsulated 
225
Ac; the cells were spun into pellet at 0, 
1, 2, 4, 6 and 24 h, and the 
225
Ac in the cellular pellet was quantified in the gamma counter as 
described in section 3.2.8. 
 3.2.10 Biodistribution of 225Ac and its daughter 213Bi  
 
All animal experiments were conducted with the permission of the Albert Einstein 
College of Medicine Institute for Animal Studies. 
225
Ac was encapsulated into BAPCs  by 
addition of  500 µL 0.15 M ammonium acetate buffer with pH of 6.5 containing 60 µCi  
225
Ac 
chloride, to 1 mM lyophilized peptides  for 30 min at room temperature. After incubation the 
non-incorporated 
225
Ac was removed by centrifugation on a micro-concentrator with a 30 kDa 
MW cut off filter. The degree of 
225
Ac incorporation into the BAPCs was calculated to be 
approximately 30% of the starting amount of 60 µCi. The 
225
Ac-BAPCs were then diluted with 
sterile 0.15 M ammonium acetate buffer and eight CD-1 male mice were injected 
intraperitoneally (IP) with 2 µCi 
225
Ac-BAPCs/100 µL. As controls eight CD-1 male mice were 
IP injected with 2 µCi free 
225
AcCl3/100 µL. At 1 and 24 hrs post-injection, four mice from each 
 98 
group were humanely sacrificed and their blood, liver, kidneys and bone were removed, weighed 
and counted for radioactivity in a gamma counter as described previously in section 3.2.8. 
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  3.3 Results and Discussion  
 
 3.3.1 Cellular Uptake of Branched Amphiphilic Peptide Capsules 
 
In our earlier studies we noted that synthetic branched amphiphilic peptides self-
assembled to form solvent filled bilayer delimited spheres (BAPCs) that had characteristic 
qualities        (e.g., thermal, proteolytic and chaotrope stability, cellular uptake, and low 
cytotoxicity) that made them potential 
candidates for drug delivery; and as such 
they might provide certain advantages 
over conventional lipid and/or viral 
based drug delivery systems.
38
 Apart 
from carrying out a number of 
biophysical studies we also carried out 
studies that characterized the initial 
assembly and subsequent fusion of the 
BAPCs. The ability to re-size and then 
maintain the BAPCs at fixed sizes 
allowed for the generation of stable 
capsules that could exploit cellular 
fenestration and transport processes.
39
 
These results prompted our current studies on the cellular uptake and release capabilities of these 
Figure 3.3 Lysosomal co-localization of BAPCs 
Confocal microscopy analysis of HeLa cells incubated at 37°C with 50 
μM 30% Rhodamine B labeled BAPCs for 4 h. A) HeLa cells with 
lysosomal stain (green)  B) Rhodamine B labeled BAPCs (red) C) 
Bright field Image D) Merge image showing co-localization of BAPCs 
and the lysosomes (yellow). Scale bar = 20 μm.      
 
 100 
nano-capsules. We hypothesized that cellular degradative processes would eventually cause 
release of the encapsulated solutes within the BAPCs.   Realizing that BAPCs initially form as 
20-30 nm (diameter) capsules, we also wanted to determine the maximum size of a solute that 
could be entrapped, as well as determine the limits of percent solute encapsulation from solution 
during the formation of the BAPCs. Initial studies demonstrated the loading, solute retention and 
cellular uptake capabilities of the BAPCs by observing the in vitro cellular co-localization of 
two-color fluorescence from Rhodamine B labeled BAPCs incorporating 5(6)- 
Carboxyfluorescein solution encapsulate.   
To examine cellular uptake and intra-cellular localization of BAPCs (Fig 3.3); 50 μM 
BAPCs prepared with a 30% Rhodamine B labeled bis(FLIVI)-K-K4 were incubated with HeLa 
cells for 4 h; with the Lysomes stained using LysoTracker Green DND-26, as described in 
section 3.2.4.1. As can be seen, the stained lysosomes (green) as well as the Rhodamine B 
labeled BAPCs (red) are visualized in the HeLa cells, in Fig 3.3A and Fig 3.3B respectively. 
Upon merging the two images (Fig 3.3D) both co-localized and non co-localized BAPCs are 
observed, with non co-localized particles predominating. At 2 h incubation most the BAPCs 
seem to be co-localized with the lysosomes (data not shown).  These results indicate that BAPCs 
enter cells through the endosomal route yet rapidly escape the late endosomes; most like due to 
lysis caused by the proposed proton-sponge effect, commonly observed for cationic particles.
50
 
In another experiment (Fig 3.4) HeLa cells were treated with the Rhodamine labeled 
BAPCs followed by immune-fluorescence labeling prior to fixation; to monitor uptake at two 
different temperatures, 4°C and 37°C.  The cell nuclei were stained with DAPI (blue) and 
cellular β-Tubulin was stained with Alexa Fluor® 488 goat anti-mouse IgG (green) as previously 
described in section 2.4.2 Cells incubated at 37°C (Fig 3.4B) readily took up the BAPCs while 
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those incubated at 4°C did not; instead the BAPCs appeared to accumulate at the cell surface 
(Fig 3.4A), presumably outside the cell.  
These results indicate that cellular uptake is energy dependent.  Endocytosis is a general 
mechanism of cellular uptake that is associated with receptor binding and/or attachment to the 
cellular membrane prior to internalization.
51
  Non-endocytotic membrane fusion based uptake is 
known to be a function of the phase transition of the cellular lipid bilayer,
52
 whereas penetration 
through the cellular membrane - observed with certain  poly-cationic cell penetrating peptides - 
appears to proceed in an energy independent manner.
53,54
 The exact mechanism of BAPC uptake 
is not fully understood and might proceed via any of the above-mentioned mechanisms; however 
it seems conceivable based on lysosomal co-localization and temperature dependent uptake data, 
that BAPCs are internalized by the cellular machinery via an energy dependent endocytotic 
pathway, The mechanistic studies of BAPC uptake were however not the main thrust of this 
work. 
Figure 3.4 Temperature Dependence of Cellular Uptake.  
Confocal microscopy analysis of HeLa cells incubated with 100 μM 30% Rhodamine B labeled BAPCs for 2 h. A) HeLa cells 
at 4 ˚C and B) at 37 ˚C. 
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 3.3.2 Encapsulation and retention.  
 
Early in our work with BAPCs, we tried to encapsulate several small proteins, namely  
TAMRA-labeled  RNase A (TRNaseA,13.7 kDa), and TAMRA-labeled cytochrome c (Tcytc, 
~12kDa), as well as the intrisically fluorescent GFP (26.9 kDa). These experiments were 
designed to test whether the BAPCs could deliver and then release the TAMRA-labeled proteins 
to induce a measurable cytotoxic effect. Both cytochrome c and RNaseA were successfully 
encapsulated in the BAPCs while the EGFP which has a tendency to aggregate in water was not.  
In Sukthankar et al., S/TEM studies with BAPCs adducted with methymercury showed that 
Figure 3.5 TAMRA Labeled Protein Uptake in HeLa Cells.  
Fluoresence microscopy images of HeLa cells after 3 h of incubation. The lower panel shows DIC images. A) BAPCs with Tcytc 
B) Tcytc with Pep-1 C) BAPCs with TRNAse A D) TRNase A with Pep-1. 
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nascent BAPCs are formed with an average diameter of 20 - 22 nm and a calculated internal 
volume of 4000 nm
3
.
39
 The larger molal volume of GFP may interfere with its encapsulation. 
Thus, we postulate that the small internal volume of the initial capsule limits the size of 
molecules that can be entrapped. That size limit is somewhere between 13.7 and 26.9 kDa.  
BAPCs individually loaded with Tcytc or TRNaseA were incubated with HeLa cells for 3 h.   
Pep-1, an amphipathic cell penetrating peptide carrier capable of inducing cellular uptake of a 
variety of proteins and peptides into cell lines with a high degree of efficiency,
55
 was employed 
as a control delivery agent for Tcytc
56
 and TRNaseA.     
Figure 3.5 demonstrates the ability of the BAPCs to encapsulate and deliver both Tcytc 
and TRNaseA into HeLa cells. In these representative images, the efficiency of Tcytc transport 
with BAPCs (Fig 3.5A) is slightly less than that with Pep-1 (Fig 3.5B); however in case of 
TRNaseA there is no significant difference between the carrying capacity of the BAPCs (Fig 
3.5C) versus Pep-1 (Fig 3.5D).  Cytochrome c
57
 and RNase A
58
 are both known to effect cellular 
apoptosis. Interestingly enough, no significant cellular apoptosis was observed in the case of 
either of the proteins taken up by HeLa cells using BAPCs; while Pep-1 mediated transport led to 
Figure 3.6 Long Term Cell Uptake Study 
HeLa cells incubated with BAPCs with a 30% Rhodamine B label on bis(FLIVI)-K-K4, observed after 2 weeks using confocal 
microscopy through two trypsinizations A) Dark field image with channel selected for the excitation of  Rhodamine B) Bright-
field image C) Overlap of the bright-field image and channel for Rhodamine.  
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frank cytotoxicity in the expected manner (data not shown). The ability of the BAPCs to persist 
within HeLa cells was then examined over a longer time period. A confocal microscopy based 
study conducted using HeLa cells treated with Rhodamine B labeled BAPCs (Fig 3.6) revealed 
that even after 14 days, the BAPCs persist within the cells and are transferred to daughter cells 
during mitosis without any apparent degradation. The degradation of the BAPCs labeled with 
Rhodamine B would tend to proceed with a dispersion of the dye / dye-peptide fragments and/or 
an increase in the fluorescence intensity of Rhodamine B due to a change in its local 
environment.
59
 None of these characteristics indicative of nanoparticles degrading within the cell 
were observed. This would - in retrospect - be consistent with expectation as cationic nano-
particles, especially those containing poly-lysine tend to escape and/or evade lysosomal 
degradation by charge destabilizing the endo-lysosomal membranes.
60
  It seems that the cellular 
machinery is unable to breakdown the BAPCs. In designing the BAPCs, we anticipated that they 
would be able to release cargo within the cytoplasm or a cellular compartment. However, the 
inability of the peptide capsules to do so make our constructs, in their current design, too stable 
for conventional targeted drug delivery. The peptides that constitute the BAPCs were designed to 
mimic diacyl phospholipids in molecular architecture. However, unlike liposomes where the 
non-solvated tail groups are held together primarily by hydrophobic interactions, BAPCs have 
the additional component of hydrogen bonding; as well as inter- and intra-molecular pi-stacking 
(π-π) between the Phenylalanine aromatic rings of peptide sequences  that apparently imbues the 
capsules with remarkable stability.   
 105 
 
 3.3.3 Encapsulation of Radionuclides using BAPCs 
 
Given the ability of BAPCs to take up but not release cargo, and their persistence in cells 
for extended periods of time suggested a potential application — α-particle therapy.  Targeted α-
particle therapy, using particle-emitting radionuclides holds promise as therapeutic agents in 
treating micrometastases.
61
 The effectiveness of this therapy is a function of the α-particle’s 
properties. They are emitted with energies in the MeV range, with Linear Energy Transfer (LET) 
having a mean energy deposition of 100 keV/μm, enabling them to produce more lethal DNA 
breaks per radiation track as compared to β--particles in the cell nucleus. It has been estimated 
that a few α-particle transversals are sufficient to kill a cell.62 The limited range of α-particles 
(50-100 μm) confines their toxicity to a small radius from the site of the isotope decay, enabling 
more specific tumor killing capability without damage to the surrounding normal tissue; as 
opposed to β--particles, which have a much longer range.26 Furthermore the cytocidal 
effectiveness of α-particles has been shown to be independent of oxygen concentration,63 dose 
rate and cell cycle position.
64
 Additionally, studies performed on a leukemia model indicated that 
α-emitter radionuclides exhibited cytotoxicity superior to that of β--radiation or γ-radiation and 
are capable of killing cancer cells which are resistant to chemotherapeutic drugs such as 
doxorubicin.
65
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 3.3.4 Targeted Alpha Particle Therapy 
 
There are a number of α-emitter radionuclides, one of which, 213Bi (t1/2 = 46 min), has 
been proposed for therapeutic use and clinically evaluated. However, 
213
Bi is generator produced 
and has a relatively short half-life requiring very rapid tumor targeting.  An alternative then 
involves utilizing 
225
Ac, which is the parent nuclide of 
213
Bi. A single 
225
Ac (t1/2 = 9.9 days) 
generates four alpha and three beta particles during its disintegration, along with two useful 
gamma emissions, including the 221 keV of 
221
Fr and the 440 keV of 
213
Bi (Figure 3.7), that can 
be used for in vivo imaging.
66,67
 The enhanced potency of 
225
Ac as opposed to 
213
Bi has been 
demonstrated in several pre-clinical studies.
65,68
 Ongoing research has focused on harnessing the 
cell-killing power of these radionuclides by directing them to metastatic cells via appropriate 
targeting vectors.    
 
225
Ac decay proceeds via a succession of daughter isotopes.  This decay releases 
28 MeV of energy in the form of α-particles.   However, for the sake of optimal killing 
efficiency, the α-emissions and therefore the 225Ac atom, must be delivered precisely and only to 
the region of interest. A problem closely associated with the ‘targeting nanogenerator 
approach’69 which involves stably chelating the 225Ac for delivery in vivo is that, after the initial 
225
Ac decay to 
221
Fr, the co-ordinate bonds from the chelating ligand to the 
 
central metal atom 
are not retained.  Thus the daughter isotopes distribute freely within the body causing unwanted 
cytotoxicity.   
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 Therefore it is desirable to confine the daughter isotopes of 
225
Ac within the carrier 
during circulation and targeting. This problem is compounded by the fact that the high kinetic 
energy of the α-particle emissions penetrates the phospholipid membrane in liposomes, which 
could otherwise be considered as suitable candidates for encapsulated delivery. Moreover, the 
recoil trajectory of the daughter nuclides (80-90 nm) penetrates the phospholipid membranes 
causing rupture and leakage
31
 leading to escape and redistribution within the body, increasing 
toxicity. Retention of daughter isotopes is size dependent. Theoretical calculations by Sofou et. 
al.
33
 suggest negligible (<0.001%) daughter retention for the last isotope for 100 nm diameter 
liposomes and 50% retention of the same for liposomes with a diameter larger than 650 nm. 
Even for giant liposomes (1 μm diameter), retention does not exceed 65%. The measured last 
daughter retention for the 650 nm liposomes was found to be substantially lower (11%) than 
Figure 3.7 The proposed decay scheme for 225Ac based on the recently published studies63, 64  
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what was calculated, owing to the tendency of 
225
Ac to bind to the negatively charged 
phospholipid membrane leading to non-uniform distribution within the liposome causing 
daughter loss after recoil. The large size of such liposomes required to carry effective loads have 
serious limitations with regard to fenestration and cellular uptake. This coupled with low 
daughter retention capabilities - makes them a cumbersome system for efficient targeted 
radiotherapy.  Considering the stability, uptake and retentive capabilities of the BAPCs; they 
were tested as a potential 
225
Ac carrier for targeted alpha particle therapy applications.  
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 3.3.5 Radio-therapeutic Potential of BAPCs  
 
Experiments were performed to monitor encapsulation of 
225
Ac into BAPCs, as well as its 
retention within them over 7 days. Uptake of BAPC-encapsulated 
225
Ac was then tested in vitro 
using human metastatic cervical cancer (CasKi) cells.  The 
225
Ac was well contained by the 
BAPCs, with retention being  95% of the original activity for the period of 7 days (Fig 3.8A).  
The cellular uptake of encapsulated 
225
Ac increased in a time dependent manner and reached 
33% at 24 h post incubation (Fig 3.8B).   It is important to note that a much lower dose of 
225
Ac 
(0.1 Ci) was used for this uptake experiment to avoid any cytocidal effects on the cells that 
could cloud the cellular uptake results. These findings were encouraging as they demonstrated 
the potential of BAPCs as candidates for 
225
Ac encapsulation and cellular uptake.  
 
Figure 3.8 Cellular Uptake and Retention of BAPCs encapsulated with 225Ac. 
A) Encapsulation and retention of 225Ac within BAPCs over 7 days and B) Cellular uptake of the BAPC-encapsulated 225Ac into 
CasKi cells over 24 h.  
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 3.3.6 Biodistribution of BAPCs encapsulating 225Ac 
 
To investigate the behavior of BAPCs in vivo we studied the distribution of BAPC 
encapsulated 
225
Ac and its daughter 
213
Bi (along with a control of free 
225
AcCl3 and 
213
Bi), in 
CD1 mice at 1 and 24 h post IP administration. Tissues were collected and analyzed at the 
indicated times. The 440 keV γ-emission of 213Bi was used to calculate the percentage of the 
injected dose per gram of organ (ID/g organ, %) as described in section 3.2.10. In Figure 3.9 we 
see the results of the in vivo distribution in mice for free 
213
Bi/
225
Ac versus encapsulated 
material. At 1 h post injection, when both ‘BAPC encapsulated 225Ac’ and ‘free 225Ac’ were still 
in the process of exiting the peritoneal cavity, there was no significant difference in organ uptake 
between BAPC encapsulated 
225
Ac and free 
225
Ac (except for bone, where free 
225
Ac is known to 
accumulate).  The uptake of 
225
Ac daughter 
213
Bi into the kidneys was higher than that of 
225
Ac, 
as free 
213
Bi targets kidneys. The differences between BAPC encapsulated 
225
Ac, and free 
225
Ac 
became more pronounced at 24 h post injection. The free 
225
Ac is completely cleared from the 
blood via binding to the plasma proteins and being delivered to various organs. BAPC 
encapsulated 
225
Ac stayed in circulation due to the small size of the BAPCs, consistent with 
nanomaterials in the 10-20 nm size range that tend to stay in circulation. Free 
225
Ac accumulated 
Figure 3.9 Biodistribution of free and BAPC-encapsulated, 225Ac and its daughter 213Bi, in CD1 mice. 
A) 1 h time point; B) 24 h time point. 
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significantly more in the liver (P=0.03) and in the bone (P=0.02) than the BAPC encapsulated 
225
Ac.  This confirms the tight retention of 
225
Ac within the vesicles. 
213
Bi daughter was present 
together with
   225
Ac pointing to retention of the daughters by the BAPCs as well.  The only organ 
where there was more 
213
Bi present in comparison with 
225
Ac was the kidneys - which serve as 
the ‘sink’ for 213Bi that has been released from any organ in the body. Overall, encapsulated 
225Ac cleared much more from the body than ‘free 225Ac’ through the combination of renal, 
hepatobilliary and intestinal goblet cell (GC) secretion (IGCSP) pathways
70
. Taken together,  
these results point to the ability of BAPCs to incorporate and retain 
225
Ac and its daughter 
isotopes through 
213
Bi.  
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 3.4 Conclusion 
 
It is evident that the extraordinary stability of the BAPCs, in their current design, limits 
their use as a drug delivery modality. However, this same characteristic makes them appear ideal 
for targeted alpha particle therapy for the treatment of metastatic and infectious diseases.   Our 
results show that the alpha emitting radionuclide 
225
Ac, and its radioactive daughters, can be 
sequestered within the lumen of the BAPCs and then retained for days (and through multiple cell 
divisions), just outside the nucleus of the cell. This portends well for cytocidal effects.  
The fact that BAPCs withstand rupture from the ejected high energy alpha particles and 
the resulting recoil of the daughter isotope, suggests a self-annealing property for BAPCs.  It is 
likely that BAPCs are taken up by cells through a non-selective internalization process, possibly 
proceeding via transient pore formation, analogous to that observed with some polycationic 
lipids
71
 and polymers.
72
 Should this assessment be accurate, the BAPCs would be able to find 
utility as nano-carriers in cellular systems. The poly-lysine cationic surface of the BAPCs 
provides a convenient synthetic pathway for the modification and conjugation of ligands, 
antibodies and molecular markers to achieve cellular targeting. This could greatly reduce the 
whole body load required to kill desired cells as well as reduce deleterious off-target side effects. 
The fact that the capsules also remain in circulation for an extended period most like reflects 
their small size and flexibility. The ability of the BAPCs to persist in cells through cell 
division(s) suggests a potential use as cell lineage tracers and probes. BAPCs could be 
conjugated to quantum dots in an effort to resolve some of the biocompatibility issues associated 
with the latter.
73
 The BAPCs constitute a unique and exciting new class of biomaterial, which 
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while portending promise as a convenient agent for targeted alpha particle therapy, could find 
application in many other areas as well.  
 
 3.5 Abbreviations 
 
BAPCs, Branched Amphiphilic Peptide Capsules; DMEM, Dulbecco’s minimum 
essential medium; FBS, Fetal Bovine Serum; TFE, 2,2,2 - Trifluoroethanol; DAPI, 2-(4-
amidinophenyl)-1H -indole-6-carboxamidine; CD, Circular Dichroism Spectroscopy; DLS, 
Dynamic Light Scattering or photon correlation spectroscopy; S/TEM, Scanning Transmission 
Electron Microscopy; EM, Electron Microscopy; Tcytc, 5(6)-TAMRA labeled cytochrome c; 
TRNase A, 5(6)-TAMRA labeled RNase A; EDTA, 2-({2-
[bis(carboxymethyl)amino]ethyl}(carboxymethyl)amino)acetic acid; DTPA, 2-({2-
[bis(carboxymethyl)amino]ethyl}(carboxymethyl)amino)acetic acid;  DOTA, 2-[4-nitrobenzyl]-
1, 4, 7, 10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid;  HEHA, 1,4,7,10,13,16-
hexaazacyclohexadecane- N,N',N'',N ''',N'''', N'''''–hexa-acetic acid; PEPA,  2-[4-nitrobenzyl]-
1,4,7,10,13-pentaazacyclopentadecane-N,N',N'',N ''',N''''-pentaacetic acid; TETA, 2-[4-
nitrobenzyl]-1, 4, 8, 11-tetraazacyclotetradecane N,N',N'',N'''-tetraacetic acid.    
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Chapter 4 - Thermally Induced Conformational Transitions in 
Branched Amphiphilic Peptide Capsules   
 4.1 Introduction 
 
Branched Amphiphilic Peptide Capsules (BAPCs) constitute a new class of self-assembling 
nano-delivery vehicles, made exclusively from two, 15-23 amino acid poly-cationic branched 
amphiphilic peptide sequences.
1
   The ability of the BAPCs to form bilayer delimited spheres 
capable of trapping solutes is due 
to the unique properties of their 
constituent peptides. These peptide 
sequences bis(FLIVI)-K-K4 and 
bis(FLIVIGSII)-K-K4 (Figure 4.1) 
- incorporated in equimolar proportions for BAPC formation - are designed to mimic diacyl 
phospholipids in molecular architecture, with the branch point lysine orienting the two peptide 
segments at a ~ 90˚ angles. The hydrophobic segments of these peptides are derived from the 
internal fragment of the human dihydropyridine sensitive L-type calcium channel segment 
CaIVS3.
2
 It is this characteristic of the sequence to reversibly transition from an alpha helical 
conformation in 2,2,2- Trifluoroethanol (TFE) to a beta sheet in water that enables the self-
assembly of the BAPCs when the constituent peptide mixture is hydrated from its monomeric 
state.  
In a recent publication
3
 (Chapter 3) we described the stability, cellular uptake capabilities, 
load capacity and retention in biological environments for extended periods of time. We 
observed that the BAPCs are readily taken up by cells through the endocytotic pathway, escape 
Figure 4.1 Bilayer forming peptide sequences 
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the late endosomes, and accumulate in the peri-nuclear region where they persist without 
apparent degradation for at least two weeks. This extraordinary stability of the BAPCs enabled 
us to study their tolerance to a radioactive load, cellular uptake and biodistribution. This suggests 
a potential application for BAPCs in targeted alpha particle therapy.  
The versatility of the self-assembling peptides enables us to tag individual monomers with 
ligands and molecular markers prior to assembly, making BAPCs particularly suited as 
biocompatible vehicles for the purposes of targeted drug delivery to cells. However the inability 
of the BAPCs to release their cargo makes 
these constructs in their current form 
unsuitable for the purposes of general drug 
delivery. A better comprehension of the 
parameters that contribute BAPC stability 
would enable us to develop variants that 
would be better suited for the purposes of 
efficient drug delivery into cells.  
In contrast to liposomes, where 
hydrophobic tail groups are held together 
primarily by hydrophobic interactions, 
BAPCs incorporate the additional 
components of hydrogen bonding, as well as 
inter- and intra-molecular pi-stacking (π-π) between the phenylalanine aromatic rings of peptide 
sequences. This apparently imbues the capsules with remarkable stability. In Sukthankar et al.,
4
 
(Chapter 2) we carried out investigations into some of the biophysical characteristics of the 
Figure 4.2  S/TEM Image BAPCs in the process of fusion.  
BAPCS with 30% MeHg label were incubated for 30 min at RT 
and then spotted on a negatively glow discharged Cu-C grid as 
described in section 4.2.6. No staining was employed for the 
purposes of this image 
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BAPCs; where we examined the mode of assembly, kinetics of fusion, high thermodynamic 
stability as well as our ability to re-size the BAPCs by passage through membrane extrusion 
filters with defined pore sizes. All of these experiments where carried out at 25 ˚C.  It was 
however during the process of studying the kinetics of BAPC fusion that we made the 
observation that fusion did not occur, and therefore small size was maintained, by incubating the 
BAPCs at 4 ˚C. This suggested the presence of a temperature effect, either kinetic or structural 
that needed to be factored into our understanding of BAPC behavior.  
In this study, we examined the temperature induced conformational changes in BAPCs and 
delineated the primary structural parameters within the sequences that contribute to these 
transitions. Biophysical studies were conducted to explore the assembly, encapsulation and 
fusion characteristics of bis(FLIVI)-K-K4 and bis(FLIVIGSII)-K-K4 along with two 
experimentally designed variants, at various temperatures.                     
 4.2 Materials and Methods 
 4.2.1 Peptide Synthesis  
All Peptides were synthesized using solid phase peptide chemistry on 4-(2,4-
dimethoxyphenyl-Fmoc-aminomethyl) phenoxyacetyl-norleucyl-cross-linked Ethoxylate 
Acrylate Resin
5
  (Peptides International Inc; Louisville, Kentucky) using Fmoc (N-(9-fluorenyl) 
methoxycarbonyl)/tert-butyl chemistry on an ABI Model 431 peptide synthesizer (Applied 
Biosystems; Foster City, CA) on a 0.1 mmol scale. Fmoc amino acids were obtained from 
Anaspec, Inc (Fremont, CA). The resin yielded the carboxyamide at the C-terminus upon 
cleavage. The branch point was incorporated by introducing N
α,ε
 di-Fmoc-L-lysine in the fifth 
position from the C-terminus. De-protection of the two Fmoc protecting groups led to the 
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generation of two reactive sites allowing for the generation of the bifurcated peptide branch 
point. The hydrophobic tail segments, FLIVI, FLIVIGSII, FLIVIGGII and FLIVIAAII were 
simultaneous coupled to the common hydrophilic oligo-lysine backbone by the stepwise addition 
of Fmoc amino acids to generate the respective variants.
6
  The N-termini of the peptides were 
acetylated using Acetic anhydride / N, N-Diisopropylethylamine / 1-Hydroxybenzotriazole prior 
to cleavage. The peptides were cleaved from the resin using 2,2,2-Trifluoroacetic acid 
(TFA)/H2O (98:2, v/v) for 90 min at RT.  Each cleaved peptide product was thrice washed with 
diethyl ether and re-dissolved in water prior to lyophilization.  The water used throughout this 
study is deionized, reverse osmosis treated and distilled.  The RP-HPLC purified peptides were 
dried in vacuo and characterized using a Bruker Ultraflex III matrix-assisted laser desorption 
ionization time of flight mass spectrometer (MALDI TOF/TOF) (Bruker Daltonics, Billerica, 
MA) using 2,5-dihydroxybenzoic acid matrix (Sigma-Aldrich Corp., St. Louis, MO). The dried 
peptides were stored at RT.  
 4.2.2 Synthesis of Cysteine-Hg-Me variants for Electron Microscopy Analysis 
 
  C-terminal cysteine adducted peptides were synthesized  on a 0.1mmol scale with 
standard Fmoc(N-(9-fluorenyl)methoxycarbonyl)/tert-butyl chemistry upon a  CLEAR-Amide 
Resin (Peptides International Inc; Louisville, Kentucky) support.  An additional  N-α-Fmoc-S-p-
methoxytrityl-L–cysteine (Anaspec, Inc; Fremont, CA) was coupled to the resin at C-terminus 
and the remainder of the synthesis, cleavage, post cleavage processing and characterization was 
performed as previously described (section 4.2.1), to generate bis(FLIVI)-K- K4 -C-CONH2 and 
bis(FLIVIGSII)-K- K4-C-CONH2 respectively. Both cysteine adducted peptides were solubilized 
in water and reacted with 1 equivalent of Methylmercury(II) iodide (Sigma-Aldrich Corp., St. 
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Louis, MO) at pH 9.8 for 6 h at RT
7,8
. The resulting solution was reduced using vacuum 
evaporation and subsequently lyophilized to generate the product. The percent methyl mercury 
incorporated was determined by measuring the concentration of free cysteine present after the 
coupling reaction. Unlabeled peptides of equal concentration served as the control.  Samples 
were treated with 4 mg/mL Ellman’s reagent (5, 5’-Dithiobis-(2-nitrobenzoic acid)) (Sigma-
Aldrich Corp., St. Louis, MO) in a pH of 8.2 in 0.1 M phosphate buffer. The absorbance values 
of the fully reacted sample were measured at 412 nm on a CARY 50 Bio UV/Vis 
spectrophotometer (Varian Inc., Palo Alto, CA) using a 0.3 cm path length quartz cuvette (Starna 
Cells Inc., Atascadero, CA)
9
. The concentrations of the peptides were calculated using the molar 
extinction coefficient (ε) of phenylalanine residues (two per sequence) at 257.5 nm (195 cm-1 M-
1
).
10
,
11
  
 4.2.3 BAPC formation and Encapsulation 
 
The bis(FLIVI)-K- K4 and bis(FLIVIGSII)-K- K4 peptides were dissolved individually in neat 
2,2,2-Trifluoroethanol. In this solvent the peptides are helical and monomeric thereby ensuring 
complete mixing when combined. The concentrations of all peptides were calculated using the 
molar extinction coefficient (ε) of phenylalanine residues (two per sequence) at 257.5 nm (195 
cm
-1
 M
-1
)
10,11
 on a CARY 50 Bio UV/Vis spectrophotometer (Varian Inc., Palo Alto, CA) using a 
0.3 cm path length quartz cuvette (Starna Cells Inc., Atascadero, CA). The bis(FLIVI)-K- K4 and 
bis(FLIVIGSII)-K- K4 peptide samples were mixed in equimolar ratios to generate a final 
concentration of 0.1 mM, then dried in vacuo. The dried peptide samples were then hydrated to 
form capsules at desired concentration by the drop-wise addition of water. In case of BAPC 
formation using the bis(FLIVIGGII)-K-K4 and bis(FLIVIAAII)-K-K4 , the respective peptides 
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were used in conjunction with bis(FLIVI)-K-K4 using the same mixing protocol outlined above. 
For the purposes of BAPC hydration at 4 ˚C and 37 ˚C; dried peptide samples were prepared as 
previously noted, and hydrated with water or eosin Y maintained at the indicated temperatures 
using a Heating/Cooling Fluid Circulator (IBM Corp., Armonk, New York); during the course of 
the experiment.  
 4.2.4 Sample preparation for Electron Microscopy 
 
The 30 mole% Me-Hg capsules were prepared in a manner similar to that previously detailed, by 
co-dissolving 0.7 mole equivalents of bis(FLIVI)-K- K4 and bis(FLIVIGSII)-K- K4 with 0.3 
mole equivalents of their respective cysteine containing Me-Hg labeled variants in water, to a 
final concentration containing 0.1 mM  for each of bis(FLIVI)-K- K4 and bis(FLIVIGSII)-K- K4 
peptides. The dried mixture was hydrated and allowed to stand for the indicated time intervals. 
Carbon Type A (15-25 nm) on 300-mesh support film grids with removable Formvar (Ted Pella 
Inc., Redding, CA) were immersed in chloroform to strip off the Formvar. These were 
subsequently negatively (hydrophilic) glow discharged
12
  at 5 mA for 20 s using a EMS 150 ES 
Turbo-Pumped Sputter Coater/Carbon Coater (Electron Microscopy Sciences, Hatfield, PA) - the 
carbon end of the grids being exposed to the plasma discharge making the carbon film 
hydrophilic and negatively charged, thus allowing easy spreading of aqueous suspensions. 
Capsule sample solutions (6 μL) were spotted on to grids and allowed to stand for 5 min, after 
which excess solution was wicked off the grid with a Kimwipe™ tissue (Kimberly-Clark 
Worldwide Inc., Roswell, GA) and allowed to air dry before loading it into the FEI Tecnai 
F20XT Field Emission Transmission Electron Microscope (FEI North America,  Hillsboro, 
Oregon) with a 0.18 nm STEM HAADF resolution and a 150X – 2306 x 106 X range of 
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magnification
13
. Scanning transmission electron microscopy was carried out in the annular dark 
field mode with a single tilt of 17°. For S/TEM analysis of BAPCs prepared using 
bis(FLIVIGGII)-K-K4 and bis(FLIVIAAII)-K-K4 peptides; the peptides were studied with 0.3 
mole equivalents label of bis(FLIVI)-K- K4-Cys-MeHg and 0.7 mole equivalents of bis(FLIVI)-
K- K4.     
 4.2.5 Circular Dichroism Experiments 
 
Circular Dichroism (CD) experiments were conducted to analyze conformational changes in 
secondary structures formed by the BAPCs as well as individual peptides in water or 50% TFE. 
Data was collected on a Jasco J-815 CD spectrophotometer (Jasco Analytical Instruments, 
Easton, MD) using a 0.2 mm path-length jacketed cylindrical quartz cuvette (Starna Cells Inc., 
Atascadero, CA). Spectra were scanned from 260 nm to 190 nm at scan rate of 50 nm / min with 
1 nm step intervals. Temperatures required for the experiments were maintained using a   
Heating/Cooling Fluid Circulator (IBM Corp., Armonk, New York) connected to the jacketed 
cuvette. Circular Dichrosim was measured in ‘mdeg’ with the final spectrum representing an 
average of five scans recorded. The raw data was subtracted from blank at the appropriate 
temperature and smoothed using a Savitsky-Golay filter
14
 using Spectra Analysis® software 
provided by the manufacturer (Jasco Analytical Instruments, Easton, MD).   
Peptide concentrations were determined using the absorbance of Phenylalanine as previously 
described. For experiments related to the study of capsule structure at different temperatures; 1 
mM each of the individual 15mer and 23mer peptides were used for BAPC generation; whereas 
for the measurement of individual peptides, peptide concentration was kept at 2 mM to ensure 
internal consistency of all the protein samples. The analytic parameters, and total peptide 
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concentrations for all samples measured have been kept identical across the board for the 
purposes of comparison.  
 4.2.6 Dye Encapsulation and Measurement 
 
1mM BAPC samples were prepared by the solvation of a dried monomeric mixture of the 
constituent peptides with aqueous 2.13 mM eosin Y and then allowed to stand for 30 min. 
Centrifugation was carried out at 14,000 x g in Amicon ultra- 0.5 mL 30 kDa molecular weight 
cut-off centrifugal cellulose filters (Millipore, Billerica, MA) using a Thermo Electron Legend 
14 personal micro-centrifuge (Thermo Fisher Scientific Inc., Waltham, MA).Samples were 
subjected to three centrifugation process cycles starting with a 5 min incubation with 200 mM 
Na-TFA salt, and then spin filtered. The TFA
-
 counter-ion is successfully able to strip Eosin Y 
extraneously associated with the capsule surface.
4
 For the second and third centrifugation cycles, 
the eosin encapsulating capsules were washed with water prior to centrifugation. At the 
conclusion of the third spin, the removable-filter unit was inverted and placed in a fresh tube and 
spun at 2000 x g for 5 min to recover the remaining volume containing the capsules which are 
then suspended in water.  
Fluorescence measurement of the encapsulated content was carried out by the excitation 
of eosin Y (Sigma-Aldrich Corp., St. Louis, MO) at 490 nm and scanning for observed emissions 
from 495-800 nm with a CARY Eclipse Fluorescence spectrophotometer (Varian Inc., Palo Alto, 
CA) (Scan rate: 600 nm/min; PMT detector voltage: 600 V; Excitation slit: 10 nm; Emission slit: 
10 nm) using a 0.3 cm path length quartz cuvette.    
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 4.3. Results and Discussion 
 
In a previously conducted experiment titled ‘Capsule fusion study’4 (Chapter 2); we employed 
the self-quenching fluorescence property of Eosin Y to spectroscopically study the fusion 
kinetics of our peptide capsules. 1 mM BAPCs encapsulating 2 mM eosin Y, were allowed to 
fuse with 20 mM BAPCs containing water. The fluorescence emissions were recorded as a 
function of time using excitation of eosin Y. The eosin concentration becomes diluted, as the few 
eosin containing capsules fuse with the many water containing ones. Accordingly, the 
fluorescence intensity for eosin Y continued to rise with each fusion event as a consequence of 
the reduction in the dye quenching. Finally, at about 3 h from the time of commencing the 
experiment no further increase in the fluorescence intensity of eosin Y was observed. This was 
Figure 4.3 Circular Dichosim Spectra of 1 h and 24 h BAPCs at 25 ˚C and 4 ˚C.   
1mM BAPCs were incubated for 1 h and 24 h respectively and then analyzed by CD at RT, before and after retaining 
them at 4˚C for 5 h. 
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not necessarily due to the cessation of fusion per se; but due to presence of dynamic equilibrium 
existing between the now normalized eosin concentrations amongst all BAPCs at that time point. 
However, an interesting phenomenon was observed when we tried to repeat the identical 
experiment a few hours later, using the same samples placed at 4 ˚C. On this occasion, the 1mM  
BAPCs encapsulating eosin Y kept at 4 ˚C, when mixed with 20 mM water containing BAPCs 
showed no increase in fluorescence intensity. The intensity of fluorescence remained identical to 
that of that observed for the initial time point during the 25 ˚C experiment. Furthermore, 
Figure 4.4 CD of BAPCs at 4 ˚C. 
1mM BAPCs were hydrated at RT and incubated for 30 min prior to placing them at 4 ˚C in a jacketed cuvette and 
subjected to CD analysis at maintained temperature to study changes in secondary structure over a period of time. 
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increasing the temperature of the system to up to 85 ˚C did not initiate the fusion process, nor did 
it lead to the release of the dye due to BAPC rupture - as would have been observed by a rapid 
increase in the fluorescence intensity due to the sudden dilution event. A Differential scanning 
experiment previously performed on BAPCs
1
 had identified the BAPCs as constructs capable of 
maintaining their integrity till at least 95 ˚C. Therefore, it seems reasonable to hypothesize that 
the BAPCs possibly undergo some form of a temperature based conformational alteration that 
leads to a change in their behavioral characteristics.  
                 In an effort to verify this, we conducted a preliminary experiment where 1mM 
BAPCs incubated for 1 h and 24 h were analyzed for their CD spectra before and after placing 
them at 4 ˚C for a period of 5 h. As can be seen in Figure 4.3 the CD spectrum for the 1 h 
BAPCs at 25 ˚C show a negative band at 218 nm and a positive band a 196 nm, indicative of 
beta structure
15,16
; a trait consistent with the behavioral characteristics of our constituent 
Figure 4.5 CD Spectra Scans of BAPCs at various Temperatures.  
1mM BAPCs were hydrated at 25 ˚C for 30 min and CD spectra scanned after placing them at (A) 4 ˚C (B) 10 ˚C (C) 15 ˚C (D) 
20 ˚C (E) 25 ˚C and (F) 37 ˚C respectively for a period of 24 h. Initial scans were recorded at 0 min, and then at 15 min, 30 min, 
45 min, 60 min, 75 min and 24 h. All cans were carried out at temperatures appropriate for the respective experiment. 
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peptides. However, when these capsules 
were subjected to 4 ˚C we observed a 
substantial change in the CD spectra. Apart 
from the negative band at 218 nm, there 
emerged another negative band at 200 nm 
coupled with the disappearance of the 
positive band at 196 nm. In case of the 24 h 
BAPCs at 25 ˚C, the beta character was 
retained albeit with a decrease in the value 
of the negative band and a slight shift of the 
minima from 218 nm to 217 nm. The 24 h BAPCs at 4 ˚C closely followed the spectral pattern of 
that of the 1 h BAPCs at 25 ˚C; however with decreased minima at 218 nm accompanied by the 
disappearance of the positive band at 196 nm. This clearly indicated the presence of a 
temperature based conformational variation within the BAPCs. Eosin Y encapsulation 
experiments with BAPCs conducted under this set of conditions (data not shown) showed no 
release of dye, indicating that the BAPCs retained their structural integrity during this process. 
Since some of the more drastic alterations were seen with BAPCs incubated for shorter periods 
of time we postulated that the propensity for conformational alteration is more prevalent in early 
BAPCs. Consequently, BAPCs incubated for 30 min at 25 ˚C were used for carrying out 
temperature secondary structure analysis.    
A CD experiment was conducted to observe the changes in the secondary structure of 
BAPCs over a period of time after placing them at 4 ˚C. This revealed (Figure 4.4) the almost 
instantaneous generation of the 198 / 222 nm minima band, which within 30 min gave rise to a 
Figure 4.6 Graphical Representation of Change in CD of 
BAPCs at different temperatures as a function of time. 
Absolute values at 200, 216 & 222 nm for different temperature 
scans taken as a percent of the global absolute minima values for 
the respective wavelengths. 
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spectral curve with a pronounced negative band at 198 nm coupled with a greatly diminished 
negative band at 222 nm. Thereafter, the intensity of the 198 nm negative band continued to 
increase throughout the course of the experiment until it more of less stabilized at the 20 h mark. 
It is important to note that within the first 30 min of the 4 ˚C treatment the spectral pattern had 
been defined and this did not vary throughout the remainder of the experiment. This trait 
remained consistent when we carried out a more comprehensive experiment where we assessed 
the changes in circular dichroism over a period of 24 h at 4, 10, 15, 20, 25 and 37 ˚C 
respectively. The results of that experiment are seen in Figure 4.5. As is seen, a decrease in 
temperature led to the shifting of the spectral minima bands towards lower wavelength 
suggesting perhaps a transition to a coil like intermediate. However the propensity of the minima 
bands to gravitate to a higher wavelength upon increase in temperature seemed to indicate the 
presence of a structure beyond the resolution capabilities of circular dichroism. The spectra were 
distinctive in that few or no positive bands were observed during the course of the experiments. 
Incubation at 37 ˚C generated a single negative band at 222 nm which, as seen consistently with 
all the other temperatures, continued to decrease with time until equilibrium was reached by 24 
h. Since the CD spectral patterns of temperature based conformational changes did not suggest 
any one structural motif, a 3-D graphic representation was generated to aid in visualizing the 
changes observed at the different temperatures as a function of time. The representations show 
the absolute values of the spectral data points (no positive bands were seen), and the absorbance 
values at 200 nm, 216 nm and 222 nm (these being the ternary wavelengths where a spectral 
change, if any, was always seen) as a percentage of the absolute global minima seen at those 
values for the collective temperature experiments. The changes observed at 0 and 60 min and 24 
h for all temperatures are shown in Figure 4.6. This figure illustrates that - within the range of 
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the temperatures scanned - changes observed at 4 ˚C and 37 ˚C represent distinct states, with the 
conformational spectra at the remaining temperatures being intermediary.  
To find out if BAPC assembly is feasible at 4 ˚C and 37 ˚C, we decided to conduct dye 
encapsulation experiments. As before, 1 mM of bis(FLIVI)-K- K4 and bis(FLIVIGSII)-K- K4 
were mixed in equimolar concentrations in 100% TFE, dried and then solvated with a 2 mM 
solution of Eosin Y at 4 ˚C and 37 ˚C respectively. The contents were then spin filtered and 
stripped of any external surface-bound dye and re-suspended in water (section 4.2.6) before 
measuring the extent of dye encapsulation using the fluorescence of eosin Y. BAPCs were 
maintained at the respective experimental temperatures throughout the course of the experiment. 
The fluorescence intensity values obtained from BAPC encapsulation experiments at 4 and 37 ˚C 
were comparable to those obtained at 25 ˚C (data not shown) indicating that BAPCs do assemble 
at these particular temperatures although, as characterized by the CD data, they exist in different 
conformational states. We thought that an increase in temperature would kinetically drive the 
rate of BAPC fusion.  We carried out fusion experiments to calculate the rate of fusion for 
Figure 4.7 BAPC fusion study at 4 ˚C and 37 ˚C. 
Salt washed eosin Y encapsulating BAPCs hydrated at 4 ˚C and 37 ˚C were mixed with water filled BAPCs in the ratio of 1:20 at 4 
˚C and 37 ˚C respectively. All BAPCs were prepared at their respective experimental temperatures which were maintained during 
the course of the experiment. A) BAPC fusion at 4 ˚C with each scan representing an interval of 10 min read over 8 h B) BAPC 
fusion at 37 ˚C with each scan representing an interval of 5 min over 4 h.    
 137 
BAPCs hydrated at 4 and 37 ˚C, analogous to the ones carried out for BAPC fusion at 25 ˚C 
(Chapter 2). BAPCs (1 mM ) encapsulating 2 mM Eosin Y at 4 ˚C and 37 ˚C were mixed with 
20 mM water-filled BAPCs at 4 and 37 ˚C, respectively.  Temperatures were maintained 
throughout the process of hydration, washing, assembly and fusion steps. Eosin excitation scans 
were carried out every 5 min for 37 ˚C experiments over 4 h and every 10 min for 4 ˚C for 8 h.   
Eosin Y dilution as a consequence of fusion was expected to lead to an increase in fluorescence 
intensity over time.  However, we found no significant change in the fluorescence intensity for 
either temperature (Figure. 4.7). 
In order to visually determine these processes, we carried out electron microscopy analysis of 
these samples. For the purposes of these experiments, 0.1 mM BAPCs labeled with 30% Me-Hg 
on the bis(FLIVI)-K- K4 were prepared at 4 and 37 ˚C respectively and spotted on sample grids 
Figure 4.8 Transmission Electron Microscopy Images elucidating the Temperature Dependence on BAPC Fusion 
0.1 mM BAPCs with 30% Hg label on bis(FLIVI)-K- K4 were hydrated and incubated at 4 ˚C and 37 ˚C respectively for 30 min. 
Samples were spotted on grids and stained with 2% Uranyl Acetate prior to imaging. A) BAPCs hydrated at 4 ˚C and B) BAPCs 
hydrated at 37 ˚C. Scale bar represents 100 nm.  
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as described in Section 2.4. The representative TEM images of the experiment are shown in 
Figure 4.8. We discovered that both 4 and 37 ˚C BAPCs were seen to appear as uniform 20 - 30 
nm diameter capsules at 30 min. If temperature induced kinetic factors were playing a role in 
BAPC fusion we should have seen larger BAPCs for the 37 ˚C experiment, as opposed to the 4 
˚C one. However, no such distinction was seen. On the contrary, the 4 ˚C BAPCs as a whole 
appeared to be slightly larger than those seen for the 37 ˚C experiment. Moreover, unlike BAPC 
fusion experiments carried out at 25 ˚C; no BAPCs were observed in the process of fusion.4 This 
seemed to indicate that the fusogenic properties of BAPCs at these temperatures were not 
kinetically driven; but restricted by their conformation.  
BAPCs are comprised of peptides that reversibly form beta sheets in water, and alpha helices 
in TFE.
1
 The factors that contribute towards the formation of beta sheets are not fully 
understood. Consequently, there exist no well-defined rules to predict beta-sheet formation.
17
 
Nonetheless, like any other structural conformation in proteins beta sheet formation is governed 
by the intrinsic beta sheet propensities of the amino acids as well as by side chain-side chain 
interactions across the beta strands. Since, our objective was to understand the factors 
contributing to thermally induced conformation changes; it seemed obvious to assess the effect 
Figure 4.9  Mutant, branched amphiphilic peptide sequence variants. 
G6,6’G7,7’ and A6,6’A7,7’ variants of bis(FLIVIGSII)-K-K4 peptide were designed, where the Ser-Gly residues on the 6
th and 7th 
positions of both the branches were substituted with Gly-Gly and Ala-Ala respectively, to generate stronger and weaker beta 
conformers of the parent sequence.  
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of temperature on the peptide residues that contribute to its secondary structure. Preliminary IR 
analysis conducted on BAPCs at 4 ˚C showed absorption at 1634 cm-1 suggesting the presence of 
a β-hairpin.18 Glycine is the most flexible amino acid in the peptide sequence and would 
therefore constitute a potential site to study for its contribution to beta sheet formation. 
Experiments carried out on polypeptide models have indicated that the ‘Glycine-Serine’ residues 
contribute to the stabilization of β-turn motifs.19,20 In order to study the contribution of the ‘Gly-
Ser’ residue to the conformational malleability bis(FLIVIGSII)-K-K4 peptide, we designed two 
new mutant sequences - bis(FLIVIGGII)-K-K4, a branched amphiphilic peptide that would 
exhibit a tighter beta turn, and bis(FLIVIAAII)-K-K4, a peptide that would exhibit a weaker beta 
turn (Figure 4.9).
20,21,22
  
The peptides bis(FLIVI)-K-K4, bis(FLIVIGSII)-K-K4 bis(FLIVIAAII)-K-K4 and 
bis(FLIVIGGII)-K-K4 were analyzed using Circular Dichroism, at 4, 25 and 37 ˚C to assess the  
effect of temperature on the secondary structure of these sequences as described previously. The 
spectrum in Figure 4.10A shows the least amount of thermal variability across all three 
temperatures and also the highest propensity towards a coil structure. This would be expected 
from the bis(FLIVI)-K-K4 sequence as it is composed of only 15 residues and does not contain 
the Gly-Ser residues that we believe are responsible for generating the beta conformer. The 
contribution of temperature towards a beta structure is evident in Figure 4.10B, 4.10C and 
4.10D where the increase in beta character is evident in samples measured at 37 ˚C versus 25 ˚C. 
The bis(FLIVIGGII)-K-K4 mutant (Figure 4.10D) shows the greatest degree of beta character at 
25 and 37 ˚C , due to the presence of the turn inducing Gly-Gly residues.23 The bis(FLIVIAAII)-
K-K4 mutant (Figure 4.10C) does shows beta character at  25 and 37 ˚C, but with broader 
negative minima bands. This is indicative of that fact that although the Ser-Gly residues in the 
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parent sequence do contribute to the formation of the beta conformers; there are undoubtedly 
other residual, steric and electrostatic forces within these branched sequences that enable the 
Ala-Ala mutant to form beta-like structures. The bis(FLIVIAAII)-K-K4 mutant does however 
show the least amount of secondary structure variation between 25 and 37 ˚C suggesting the 
temperature based variations within this range have partly to do with the presence of turn 
forming residues in the 6
th
 and 7
th
 positions. The transition to 4 ˚C brings about a loss of β-
structure in all studied sequences. This suggests that factors other than the turn forming residues 
contribute to this transition. For if the Ser-Gly turn residues exclusively dictated the beta 
Figure 4.10 - CD Spectra of Branched Amphiphilic Peptides at 4, 25 and 37 ˚C. 
2 mM concentrations of A) bis(FLIVI)-K-K4 B) bis(FLIVIGSII)-K-K4 C) bis(FLIVIAAI)-K-K4 D) bis(FLIVIGGII)-K-K4 in water 
at 4 ˚C, 25 ˚C and 37 ˚C 
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character, then the weaker Ala-Ala mutant should not have demonstrated a loss of beta 
conformation at 4 ˚C; and alternately the stronger Gly-Gly mutant should have retained its β-
structure at all studied temperatures. Whereas a loss of beta-character is apparent in all three 
23mer sequences (Figure 4.10B, 4.10C and 4.10D) at 4 ˚C; it is only the parent sequence - 
bis(FLIVIGSII)-K-K4 that shows a transition from a classic beta, to a coil like structure almost 
identical to that observed with bis(FLIVI)-K-K4 at the same temperature. This transition driven 
by the presence of the ‘Ser-Gly; residues at the 6,6’ and the 7,7’ positions provides for a 
common conformational denominator to both the sequences. And it is this structural 
commonality that allows for synergistic association between the bis(FLIVIGSII)-K-K4 and 
bis(FLIVI)-K-K4 sequences which enables the BAPCs to seamlessly transition from one state to 
another. This might account for why bis(FLIVIGSII)-K-K4 and bis(FLIVI)-K-K4 make 
successful sequence pairs for BAPC formation. The transformation into a conformationally 
homogeneous random coil construct at low temperatures might account for the abrogation of 
fusion at 4 ˚C implying that it is the conformational characteristics of the bis(FLIVIGSII)-K-K4 
that are the fundamental driving force behind BAPC fusion.     
 
 4.4 Abbreviations 
 
BAPCs, Branched Amphiphilic Peptide Capsules; TFE, 2,2,2 - Trifluoroethanol; CD, Circular 
Dichroism Spectroscopy; S/TEM, Scanning Transmission Electron Microscopy; EM, Electron 
Microscopy.  
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 Chapter 5 - Significance, Future Directive and Other Studies  
The material that has gone into constituting this thesis is but a cohesive fraction of the 
research that I have undertaken into designing and understanding the nature of peptide based 
biomaterials.   
BAPCs constitute a new and exciting class of nanocarriers constituted exclusively from 
peptides. The capabilities of these capsules stem from the unique properties of their constituent 
sequences that can transition from an alpha helix in trifluoroethanol to a beta sheet in water. 
BAPCs are non-immunogenic and biocompatible. They are analogous to liposomes in that they 
possess a bilayer and that they fuse and can be re-sized by membrane extrusion. Their flexibility 
and their ability to be re-sized and maintained at a desired size, makes them attractive candidates 
for drug delivery. In vitro and in vivo experiments described in this report indicate that BAPCs 
are readily taken up by cells, escape and/or evade the endocytotic pathways and accumulate in 
the peri-nuclear region of the cell for extended durations of time without apparent degradation.  
 We have demonstrated the capabilities of these constructs to encapsulate small solutes 
and proteins; and transport them into the cell. BAPCs - unlike liposomes - are remarkably stable 
and can maintain their integrity in the face of alpha particle bombardment. This portends 
potential applications in radionuclide based therapy, which is plagued by the lack of suitable 
stable carriers for encapsulating radioactive agents. However, it is this extraordinary stability of 
the BAPCs and their inability to extravasate their cargo limits them from being used as nano-
carriers for conventional drug delivery, in their current configuration. We have conducted 
biophysical investigations and identified structural parameters within the sequence that 
contribute to some of the characteristics that imbue these peptide-capsules with their remarkable 
properties.  
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 A better understanding into the nature of these BAPCs and their bilayer can enable us to 
design variants that could help us selectively de-stabilize these capsules in cells thus enhancing 
their cargo release potential. One of the unique properties of the BAPCs is their tune-ability. The 
incorporation of peptide variants into the capsular constitution could be another way to modulate 
BAPC behavior. We have designed a set of peptide sequences that have shown promise in their 
ability to form temperature sensitive capsules with varying stabilities, and further investigation is 
in progress. Work is also ongoing on the development of branched amphiphilic sequences with 
varying lengths to modulate the initial size of assembly that governs the maximum size of the 
cargo capable of encapsulation. Much needs to be understood about the nature of the BAPC 
bilayer. I have designed ‘Fluorine and 13C’ incorporating variants of the BAPC sequences to 
make them suitable for the purposes of  REDOR NMR analysis and collaborations to that effect 
are being pursued with Prof. Frances Separovic, Department of Chemistry, University of 
Melbourne.  
The mode of BAPC cellular uptake and internalization is another area worthy of 
exhaustive investigation. The availability of ε-Lysine amino groups on the surface of these 
capsules makes BAPCs ideal for the purposes of functionalization. We have till date managed to 
attach small dye molecules as well as methyl-mercury on to some of these sites and see no 
reason why molecular markers, ligands and antibodies couldn’t be attached for the purposes of 
targeted therapy. The self-assembling nature of BAPCs means that a selected mole percentage of 
sequences pre-ligated with targeting moieties could be incorporated into the capsule in a simple 
and efficient process prior to assembly. The fact that the constituent peptides can be made readily 
available in large quantities with high purity; and that BAPC assembly is spontaneous and easy, 
makes them suitable candidates for scalable therapeutic and pharmaceutical applications.  
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The peptides that make up the BAPCs also constitute a novel class of biomaterial. We 
have been able to develop a procedure to solubilize these peptides in toluene. This has widened 
the applications of these peptides by making them available to the diverse realm of non-aqueous 
organic chemistries. In collaboration with Prof. Christopher Sorensen, Department of Physics, 
Kansas State University, we have managed to coat a mono-layer of branched amphiphilic 
peptides onto gold nano-particles; in effect turning them into aqueous colloidal suspensions.  
BAPCs adumbrate great potential as singular, biologically inspired constructs with prospects for 
applications and scientific investigation. A lot remains to be asked and a lot remains to be done.     
Apart from my work on BAPCs, I have also had the pleasure of working with numerous 
other investigators in the area of organic chemistry and peptide synthesis. I owe a lot to Prof. 
Stefan Bossmann, Department of Chemistry, Kansas State University for allowing me to work in 
his lab on the generation of NIPAM-AA co-polymers and for providing me valuable insight in 
the area of organic syntheses. In collaboration with Prof. Kanost, Department of Biochemistry 
and Molecular Biophysics, Kansas State University, I have managed to develop a de novo 
procedure for total chemical synthesis of a biotinylated glycolate ester used for isolating free N-
termini proteins from serum; and developed variants thereof for the purposes of process 
efficiency. For Dr. Kristin Michel, Divison of Biology, Kansas State University; I have 
developed a gentle procedure to increase the yield efficiency of aromatic amino to nitro 
conversions of p-Phenylenediamines coupled to the C-terminus of peptides in solution, and have 
synthesized bacterial cyclic esters for Prof. Lynn Hancock, Department of Molecular 
Biosciences, University of Kansas, that have shown high activity in vitro. I hope that over time, 
some or more of these projects would yield valuable contributions to the field of scientific 
inquiry.  
